**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Updated 07/08/2022**

**ROBERT A. MONTGOMERY, M.D., D.Phil., F.A.C.S**

**H. Leon Pachter Chair and Professor of Surgery, NYU Langone Health**

**Director, NYU Langone Transplant Institute**

Office

NYU Langone Transplant Institute

550 First Avenue, HCC 12 37

New York, New York 10016

Phone: (646)-501-2418

Email: Robert.Montgomery@nyulangone.org

Married: Denyce Graves-Montgomery, Opera Singer

Children: Ella, Max, John, Elizabeth

**CURRENT AND PREVIOUS LEADERSHIP POSITIONS, EDUCATION, TRAINING, AND STEWARDSHIP**

SCOPE OF CURRENT POSITION

**H. Leon Pachter Professor and Chair of Surgery (September 2020-present)**

As the Chairman of Surgery for NYU Langone Health and the Bellevue and VA hospitals, I oversee 125 faculty members and 300 staff across 5 campuses in Manhattan, Brooklyn and Long Island. Surgery is responsible for a positive annual contribution margin of $125 million dollars. During my tenure, we have created new divisions and recruited faculty of hepatobiliary and pancreatic, inflammatory bowel, and acute care surgery. Surgery was the first department at NYU to appoint a Vice Chair of Diversity and Health Equity.

**Director, NYU Langone Transplant Institute (February 2016-present)**

As the inaugural director of the newly formed Transplant Institute I report directly to the Dean/CEO and oversee the clinical and research operations for all solid organ and bone marrow transplant programs. This involves creating a new paradigm in which the organization of the transplant enterprise is aligned with the modern clinical practice of transplantation. Namely, the Institute has a medical/surgical multidisciplinary faculty that reports to the Director and also has an academic appointment in the Departments of Surgery and Medicine. During my tenure we have had a vast expansion of transplantation services including an annual budget of $36 million dollars and the creation of lung and heart transplant programs, pediatric kidney, heart, lung programs, expansion of the allogeneic bone marrow transplant program with the recruitment of 18 new faculty members. In 2020, the heart and kidney programs were ranked #1 in the country by the SRTR scoring system.

PREVIOUS LEADERSHIP POSITIONS

Inaugural Recipient of the Margery K. and Thomas Pozefsky Professorship in Kidney Transplantation

Chief, Division of Transplantation, Department of Surgery

Director, Incompatible Kidney Transplant Program

Director, The Comprehensive Transplant Center, The Johns Hopkins Hospital

Director of The Multi-Organ Transplant Fellowship

SCOPE OF PREVIOUS LEADERSHIP POSITIONS

**Chief, Division of Transplantation (2003-January 2016):**

The Division of Transplantation in the Department of Surgery has 11 full-time faculty members and support staff with an annual budget of $6.5 million dollars. In my role as Chief, I was responsible for the fiscal performance of the section, strategic planning and vision including implementing the tripartite mission of the institution (research, patient care, teaching), directing the clinical and basic science transplant core research laboratory, overseeing 2 fellows, 8 nurse practitioners, residents and medical students rotating on the service, safety and regulatory matters, outcomes and patient satisfaction.

**Director, The Comprehensive Transplant Center (2004-January 2016):**

The Director of the Comprehensive Transplant Center (CTC) reports to a Board of Directors, which is made up of key leaders from the Hospital, University and CEO/Dean’s office. In this position, I oversaw the entire solid organ transplant enterprise (abdominal and cardiothoracic) at Johns Hopkins, which has an annual expense budget of $33.8 million dollars. The Director reports directly to the Hospital President on all clinical and operational matters involving the transplant center and is responsible for strategic planning, budgeting and financial performance, regulatory compliance, quality assurance, safety, and human resources.

**Director, Incompatible Kidney Transplant Program (2001-January 2016):**

In 2001, we brought together a diverse multidisciplinary team from the Departments of Surgery, Medicine, and Pathology to create the first program in the country dedicated to meeting the needs of renal transplant candidates with incompatible live donors through innovation and specialized care. During my tenure, we transplanted over 700 patients using desensitization and kidney paired donation modalities that our team had developed. The program served as an incubator for discovery and was been responsible for many “firsts” in this emerging field as well as 85 peer reviewed publications (5 in the New England Journal of Medicine, 2 in JAMA, 1 in The Lancet). The patients in the program brought over $220 million dollars of new revenue to the hospital.

EDUCATION

1978-1982 **St. Lawrence University,** Canton, NY.

Bachelor of Science with Honors in Biology.

Magna Cum Laude

1983-1987 **University of Rochester School of Medicine,** Rochester, NY.

Doctor of Medicine with Honor.

1989-1992 **Balliol College, University of Oxford**, Oxford, England.

Doctor of Philosophy (Molecular Immunology).

Fulbright Scholar.

POST-GRADUATE TRAINING

1987-1989 Intern and Assistant Resident in Surgery, The Johns Hopkins Hospital.

1992-1994 Resident in Surgery, The Johns Hopkins Hospital.

1994-1995 Chief Resident in Surgery, The Johns Hopkins Hospital.

1995-1997 Postdoctoral Fellow in Human Molecular Genetics, Johns Hopkins University.

1997-1999 Fellow in Transplantation Surgery, The Johns Hopkins Hospital.

ACADEMIC APPOINTMENTS

1990-1992 Clinical Lecturer in Surgery, University of Oxford.

1995-1997 Assistant in Surgery, The Johns Hopkins University.

1997-1999 Instructor in Surgery, The Johns Hopkins University.

1999-2002 Assistant Professor, The Department of Surgery, The Johns Hopkins University.

2002-2009 Associate Professor, The Department of Surgery, The Johns Hopkins University.

2008-2016 Inaugural Recipient of the Margery K. and Thomas Pozefsky Professorship in Kidney Transplantation, The Johns Hopkins University.

2009-2016 Professor of Surgery, The Department of Surgery, The Johns Hopkins University.

2016-present Professor of Surgery with Tenure, Academic Track, NYU University.

CLINICAL LEADERSHIP POSITIONS PAST and PRESENT:

H. Leon Pachter Professor and Chair of Surgery, NYU Langone Health

Director, NYU Langone Transplant Institute, NYU Langone Health

Chief, Division of Transplantation, Johns Hopkins Medicine, Department of Surgery

Director, Incompatible Kidney Transplant Program

UNOS Designated Surgical Director, Liver Transplant Program, Johns Hopkins Hospital

UNOS Designated Surgical Director, Renal Transplant Program, Johns Hopkins Hospital

UNOS Designated Surgical Director, Pancreas Transplant Program, Johns Hopkins Hospital

Director, The Comprehensive Transplant Center, The Johns Hopkins Hospital

Director of The Multi-Organ Transplant Surgery Fellowship, The Johns Hopkins Hospital

# LICENSURE AND CERTIFICATIONS:

1987-1988 New York Medical License

1995-present Maryland Medical License (D0047982)

2016-present New York Medical License (# 175588-1)

1996-present American Board of Surgery Certified

CONSULTING AND BOARD POSTIONS

Medical Advisory Board for Hansa Medical.

Lead strategist for Recombinetics Regenerative Medicine Division, Regenevida.

Lead Medical Advisor, Quhan Bio (a subsidiary of eGenesis).

University of Rochester School of Medicine and Dentistry National Council (2015-present).

STEWARDSHIP

Stewarded $6.2 million dollars in endowed and current use gifts while at Johns Hopkins University.

Endowed Professorships at Johns Hopkins:

Margery K. and Thomas Pozefsky Professorship in Kidney Transplantation.

The Bauer Foundation Transplantation Research Professorship.

LEADERSHIP TRAINING

The Johns Hopkins Leadership Development Program 2012-2013.

**CLINICAL INNOVATIONS AND FIRSTS:**

LEAD THE TEAM RESPONSIBLE FOR HOPKINS INNOVATIONS

* Demonstrated a Survival Advantage of Desensitization vs Dialysis
* First to Describe Combining Desensitization With Paired Donation
* Conceived the Idea of the Domino Paired Donation
* Performed the First Chain of Transplants Started by an Altruistic Donor
* Created the First Dedicated Incompatible Transplant Program
* Developed the Practice of Long Distance Live Donor Shipping of Kidneys
* First to Successfully Transplant Patients with Catastrophic Anti-Phospholipid Syndrome
* First to Use Complement Inhibition In Human Transplant Patients
* Performed the First Multi-Way Donor Swaps Including:
  + 2-way domino paired donation
  + 3-way paired donation
  + 3-way domino paired donation
  + 4-way paired donation
  + 4-way domino paired donation
  + 5-way domino paired donation
  + 6-way domino paired donation
  + 8-way multi-institutional domino paired donation
  + 10-way open chain

COLLABORATED IN MULTIDISCIPINARY INNOVATIONS

* Hopkins Desensitization Protocol
* First Description and Clinical Example of an Open Chain
* The Hopkins Kidney Tolerance Protocol
* Laparoscopic Donor Nephrectomy
* First NOTES Procedure for Vaginal Extraction of Donor Kidney

2010 Guinness Book of World Records: Most Kidney Transplants Performed in 1 Day

**RESEARCH ACTIVITIES:**

PATENTS

1. Transplant organ external cooling system. Inventor. U.S. Patent Appl. No. 09/788,309. US Patent No. 6,736,836 February 16, 2001.

GRANTS AND CONTRACTS:

CURRENT: Grant Support

CURRENT: Contracts

Phase Ib, open label pilot trial using Imlifidase and a tolerogenic protocol to promote immunosuppression minimization in positive crossmatch recipients of a kidney transplant.

**Role: Principal Investigator**

An open label, phase II study to investigate DSA rebound in patients with a positive crossmatch, made transplantable with imlifidase.

**Role: Sub-Investigator**

[A non-interventional extension study for patients treated in study R5459-RT-1944 with REGN5459 or REGEN5458 (BCMAxCD3 bispecific antibodies [bsAbs]) that receive a kidney transplant](http://era.med.nyu.edu/ResearchNavigator/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5b0A335C378CB26B478213F31509F4B01A%5d%5d).

**Role: Principal Investigator**

[A dose escalation and proof-of-concept study of REGN5459 or REGN5458 (BCMAxCD3 bispecific antibodies) for desensitization of chronic kidney disease patients in need of kidney transplantation that are highly-sensitized to Human Leucocyte Antigen”](http://era.med.nyu.edu/ResearchNavigator/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5b4A062BA04F9EC84AB2C8892B5C87F21A%5d%5d).

**Role: Principal Investigator**

Studying Xenografts in a recently deceased human.

**Role: Principal Investigator**

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients.

**Role: Sub-Investigator**

Prospective, observational long-term follow up study of patients treated with imlifidase (IdeS) prior to kidney transplantation.

**Role: Principal Investigator**

A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 infection.

**Role: Sub-Investigator**

A pilot study of post-transplant eplet mismatch analysis for kidney transplant recipients to inform strategic immunosuppression reduction.

**Role: Sub-Investigator**

An Open-label, randomized, controlled, Phase 2 study to evaluate the safety and efficacy of PEGCETACOPLAN in the treatment of post-transplant recurrence of C3G OR IC MPGN.

**Role: Sub-Investigator**

A Prospective, single center, pilot study of post-COVID-19 vaccination kidney allograft biomarker monitoring.

**Role: Sub-Investigator**

An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Imlifidase (IdeS) to Eliminate Donor Specific Anti-HLA Antibodies (DSAs) to Treat Active Antibody-Mediated Rejection in Kidney Transplant Patient.

**Role: Principal Investigator**

[Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients](http://era.med.nyu.edu/ResearchNavigator/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5b494E8BF92EFF8743808BD57407205B6C%5d%5d).

**Role: Sub-Investigator**

[A single-center, proof of concept study of cross-circulation for COVID-19 critical illness](http://era.med.nyu.edu/ResearchNavigator/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5b8E8FE5AF34C07649ADAA3B63F1DA33CA%5d%5d).

**Role: Principal Investigator**

A single-center pilot study evaluating a preemptive short course of glecaprevir/pibrentasvir in hepatitis C positive to negative kidney transplantation.

**Role: Sub-Investigator**

A Phase 1b/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of isatuximab (SAR650984) in patients awaiting kidney transplantation.

**Role: Sub-Investigator**

[Prospective observational study of HIV+ deceased donor transplant for HIV+ recipients.](http://era.med.nyu.edu/ResearchNavigator/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5b502217B154FC3F41B16334F264996F97%5d%5d)

**Role: Sub-Investigator**

[HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Kidney Transplants for HIV+ Recipients](http://era.med.nyu.edu/ResearchNavigator/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5bD85F3A3A472E6B4D8FD1CB4F983E347E%5d%5d).

**Role: Sub-Investigator**

A randomized, controlled, multi-center, safety and efficacy study of FCR001 cell-based therapy relative to a tacrolimus and mycophenolate-based regimen in de novo living donor renal transplant recipients, and safety in FCR001 donors (the FREEDOM-1 study).

**Role: Principal Investigator**

PREVIOUS: Grant Support

* 1. Cytokine gene expression during T-cell ontogeny

NRSA grant #5 F32 AI08481-01(02 IVP)

NIH Individual Postdoctoral Research Award.

* 1. ICAM-1 gene inactivation protects against ischemic injury

NIH R01DK/GM 59548-01A1

Score: 4%

$1,231,250.00

PI; 35% effort

2002-2007 Strategies for silencing genes that potentiate ischemia/reperfusion injury

American College of Surgeons George H.A. Clowes, JR, MD, FACS Award

$200,000.00

PI; 10% effort

* 1. Enhance the utilization of extended criteria and non-heart beating donor kidneys

using pulsatile perfusion

HRSA Extramural Grant Program

$1,137,921.00

PI; 10% effort

2009-2012 Development of a national incompatible kidney transplant registry.

NIH 1RC1DK086731-01

Score: 1%

$609,385.00

PI; 35% effort

# 2012-2016 Bone marrow transplantation and high dose post-transplant cyclophosphamide for chimerism induction and renal allograft tolerance.

# Immune Tolerance Network ACCEPTOR ITN054ST

$2,458,249.00

Co-PI; 5% effort

2013-2018 Quantifying risk and survival benefit from incompatible kidney transplantation

NIH/NIDDK: 1R01DK098431-01A1

Score: 4%

$2,488,373.00

Consultant; 10% expanded to 25% by year 5.

PREVIOUS: Contracts

An open-label concentration controlled, randomized, 6-month study of standard Dose tacrolimus + sirolimus + corticosteroids compared to reduced dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients.

**Role: Principal Investigator**

Establishment of a comprehensive transplant tissue bankFujisawa.

**Role: Principal Investigator**

Abrogation of humoral immune responses utilizing plasmapheresis/cytogam in positive crossmatch and ABO incompatible renal transplants.

**Role: Principal Investigator**

Open Label Prospective Randomized Study of Thymoglobulin versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients with a Positive Crossmatch.

**Role: Principal Investigator**

**A Randomized Double-Blind Placebo-Controlled Pilot Study to Evaluate the Safety and Effect of Cinryze™ for the Treatment of Acute Antibody-mediated Rejection in Recipients of Donor-specific Cross-match Positive Kidney Transplants.**

**Role: Principal Investigator**

**A Randomized, Open-label, Multicenter Trial To Determine Safety and Efficacy Of Eculizumab In The Prevention Of Antibody Mediated Rejection (AMR) In Living Donor Kidney Transplant Recipients Requiring Desensitization Therapy.**

**Role: National Principal Investigator**

**Eculizumab to Enable Renal Transplantation in Patients with History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome. Alexion: Investigator initiated single-center trial.**

**Role: Principal Investigator**

A phase II study to evaluate the efficacy of IdeS (IgG endopeptidase) to desensitize transplant patients with a positive crossmatch test**.**

**Role: International Principal Investigator**

A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de novo Kidney Transplant Recipients

**Role: Sub-Investigator**

A double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory antibody mediated rejection in adult renal transplant recipients

**Role: Sub-Investigator**

A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of CINRYZE® (C1 esterase inhibitor [human]) for the treatment of acute antibody-mediated rejection in kidney transplant patients

**Role: National Principal Investigator**

**RECOGNITION**

HONORS, AWARDS AND DISTINCTIONS

St. Lawrence University:

1978 Laurentian Scholar.

1980 Charles A. Dana Scholar.

1982 Phi Beta Kappa Academic Honor Society.

1982 Thomas J. Watson Fellow (1982-1983 Africa).

1999 Alumni Citation for Distinguished Achievement.

2007 Honorary Doctor of Science

University of Rochester School of Medicine:

1987 Alpha Omega Alpha Medical Honor Society.

The University of Oxford:

1. Fulbright Scholar.

1989 American College of Surgeons Scholar.

1990 Overseas Student Research Scholarship.

1991 Research Scholar of the British and American Heart Foundations.

The Johns Hopkins University School of Medicine:

1991 George D. Zuidema Research Award.

1. Anthony L. Imbembo Surgical Residents Teaching Award.

1995 American College of Surgeons Faculty Fellowship.

1. American Society of Human Genetics Postdoctoral Basic Science Award.

1999 Johns Hopkins Clinician Scientist Award.

1. William F. Rienhoff, Jr., MD Endowed Fellowship.

2000 American Society of Transplant Surgeons: Fujisawa, USA Faculty Development Award.

2002 American College of Surgeons George H.A. Clowes, JR, MD, FACS Award

2007 National Kidney Foundation of Maryland: Champion of Hope Award.

2013 Terasaki Medical Innovation Award.

2019 Greater New York Hospital Association Profile In Courage Award.

PEER AND PATIENT CLINICAL PRACTICE DISTINCTIONS

America’s Most Compassionate Doctors Award 2011, 2012, 2014

America’s Top Doctors (8 years in a row 2008-2016)

Patients’ Choice Award (2008-2016)

Baltimore/Washington Top Doctor Recognition 2015

Baltimorean of The Year 2004

**ORGANIZATIONAL ACTIVITES**

# SOCIETY MEMBERSHIPS

# 1999 Association for Academic Surgery

1999 The American Society of Transplant Surgeons

2000 The Society of University Surgeons

2003 Fellow of The American College of Surgeons

2006 International Pediatric Transplant Association

2007 The Transplantation Society

2007 Canadian Society of Transplantation

2013 American Surgical Association

2013 Halsted Society

Surgery Biology Club II

# NATIONAL and REGONAL COMMITTEES

2000 Live Donor Consensus Conference. Kansas City, MO. (Consensus statement on the live donor. JAMA 284(22): 2919-2926).

2002 Co-director: 1st Antibody Working Group. Establishing guidelines for the field of antibody-mediated transplant rejection. Houston, February 2002.

2003 Co-director: 2nd Antibody Working Group. Establishing guidelines for the field of antibody-mediated transplant rejection. Phoenix, February 2003. (Consensus opinion published in *Transplantation.* 78(2):181-5.)

2003 Project leader: NIH Consensus Conference on Humoral Rejection. Washington, April 2003. (National conference to assess antibody-mediated rejection in solid organ transplantation *Am J Transplant*. 4(7):1033-41).

1. OPTN/UNOS Histocompatibility Committee
2. Co-director: Nondirected Donation. Establishing guidelines for the evaluation and allocation of nondirected donors and organs, Seattle, October 2004
3. Director: Kidney Paired Donation Consensus Meeting. Creating a blueprint for the expansion of paired donation and the role of a national matching program. Chicago, 2005.
4. UNOS Paired Kidney Donation Committee, Chicago, 2006.

2007-2012 Board of Directors, Living Legacy Foundation OPO, Baltimore, MD.

2011-2012 Steering Committee for the Establishment of a UNOS National Kidney Paired Donation Program.

2017-present Vice President, NYKidney Consortium.

2018-present ASTS Living Donor Committee.

PROGRAM ORGANIZER

2017 International Xenotransplantation Association (IXA 2017) - Hyperimmunized / ABOi Pre-Meeting Symposium (Program Chair).

2018 TTS 2018-Kidney Track Co-Chair.

# AD HOC REVIEWER

New England Journal of Medicine

Journal of the American Medical Association

The Lancet

Transplantation

American Journal of Transplantation

Transplantation

Journal of Urology

**MENTORING** (Pre-and Post-doctoral)

2000-2004: Daniel S. Warren, PhD –Johns Hopkins University, School of

Medicine

-Postdoctoral Research Fellow

2000-2003: Christopher J. Sonnenday, MD –Johns Hopkins University,

School of Medicine

-Postdoctoral Research Fellow

-NIH Basic Scientific Training Grant for Gastrointestinal Surgeons

-Young Investigator’s Award. The 2nd International Congress on

Immunosuppression, SanDiego, CA, December 2001

2000-2002: Matthew Cooper, MD –Johns Hopkins University, School of

Medicine

-Clinical Transplant Fellow

2001-2003: Seth Karp, MD –Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

2001-2003: Ed Falta, MD –Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

2001-2002: Aerik Williams, MD –Johns Hopkins University, School of

Medicine

-Medical Student Predoctoral Fellow

-NIH PA-99-104 R01 Research Supplement

2002-2004: Alan Hawxby, MD –Johns Hopkins University, School of

Medicine

-Clinical Transplant Fellow

2003-2004: Geoff Allen –Johns Hopkins University, School of Medicine

-Medical Student Predoctoral Fellow

2003-2005: Tomasz Kozlowski, MD – Johns Hopkins University, School of

Medicine

-Clinical Transplant Fellow

2003-2004: Raghu Chivukula –Johns Hopkins University, School of Medicine

-Medical Student Predoctoral Fellow

2004-2006: Dorry L. Segev, MD –Johns Hopkins University, School of

Medicine

-Clinical Transplant Fellow

-American Society of Transplant Surgeons Scholar

2004-2006: Christopher E. Simpkins, MD –Johns Hopkins University, School of

Medicine

-Postdoctoral Research Fellow

-American College Scholar

2005-2008: Jayme E. Locke, MD -Johns Hopkins University, School of Medicine

-Postdoctoral Research Fellow

-NIH National Research Scientist Award (NRSA)

2006-2010: Dorry L. Segev, MD – Johns Hopkins University, School of Medicine

-Johns Hopkins Clinical Research Scholars Program

2006-2008: Andrew Singer, MD – Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

2007-2009: Zoe A. Stewart, MD – Johns Hopkins University, School of

Medicine

-Clinical Transplant Fellow

2008-2010: Nabil Dagher, MD – Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

2009-2011: Christopher Simpkins, MD – Johns Hopkins University, School of

Medicine

-Clinical Transplant Fellow

2010-2012: Jayme E. Locke, MD- Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

2011-2013: Susanna M. Nazarian, MD – Johns Hopkins University, School of

Medicine

-Clinical Transplant Fellow

2012-2014: Bonnie E. Lonze, MD – Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

2013-2014: Gelu Osian, MD – Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

2014-2015: Ryosuke Misawa, MD – Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

2014-2016: Charbel Chalouhy, MD – Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

2015-2016: Ashraf Reyad, MD – Johns Hopkins University, School of Medicine

-Clinical Transplant Fellow

Director of The Abdominal Transplantation Fellowship at Johns Hopkins until 1/2016

Graduate Student Thesis Committees

Daniel S. Warren

Joshua Mendell

Dorry Segev

Jacqueline Wang

Babak Orandi

Betsy King

Medical Student Teaching and Mentoring

The 6th Young European Scientist Organization. September 2011 for 1 week. Porto, Portugal.

Visiting Professor for The Alpha Omega Alpha Medical Students at the University of Rochester School of Medicine. Rochester, New York. February 27, 2014.

**JOURNAL PUBLICATIONS:**

Highest Impact Publications

**Montgomery RA.** Getting comfortable with risk. *N Engl J Med.* 2019 Oct 24;381(17):1606-1607.

**Montgomery RA**, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL.Desensitization of HLA-Incompatible Kidney Recipients and Survival. *N Engl J Med.* 2011 July 28;365(4):318-326.

Rees MA, Kopke JE, Pelletier RP, Segev DL, Rutter ME, Fabrega AJ, Rogers J, Pankewycz OG, Hiller J, Roth AE, Sandholm T, Unver MU, **Montgomery RA**. A nonsimultaneous, extended, altruistic-donor chain. *N Engl J Med.* 2009 March 12;360(11):1096-1101.

Orandi BJ, Luo X, Massie AB, Garonzik-Wang JM, Lonze BE, Ahmed R, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur, Pelletier RP, Roberts JP , Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, A. GaberAO, **Montgomery RA\***, Segev DL\* Survival Benefit in HLA-Incompatible Live Donor Kidney Transplantation. *N Engl J Med.* 2016 Mar 10;374(10):940-50.\* **Equal Contributors.**

**Montgomery RA**, Zachary AA, Ratner LE, Segev DL, Hiller JM, Houp J, Cooper M, Kavoussi L, Jarrett T, Burdick J, Maley WR, Melancon JK, Kozlowski T, Simpkins CE, Phillips M, Desai A, Collins V, Reeb B, Kraus E, Rabb H, Leffell MS, Warren DS. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. *JAMA.* 2005 Oct 5;294(13):1655-63.

Segev DL, Gentry SE, Warren DS, Reeb B, **Montgomery RA**. 2005. Kidney Paired Donation and Optimizing the Use of Live Donor Organs. *JAMA* 293(15):1883-90.

**Montgomery RA**, Gentry SE, Marks WH, Warren DS, Hiller J, Houp J, Zachary AA, Melancon JK, Maley WR, Rabb H, Simpkins C, Segev DL. Domino paired kidney donation: A strategy to make best use of live non-directed donation. *Lancet*. 2006 July 29;368(9533):419-421.

Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, McBride MA, **Montgomery RA**. Perioperative mortality and long-term survival following live kidney donation. *JAMA.* 2010 March 10;303(10):959-966.

Frischmeyer-GuerrerioPA\*, MontgomeryRA\*, WarrenDS, CookeSK, LutzJ, SonnendayCJ, GuerrerioAL, DietzHC. Perturbation of Thymocyte Development in Nonsense Mediated Decay-Deficient Mice. *PNAS* 2011 June 28;108(26):10638-10643.\* Equal Contributors.

Lonze BE, Singer AL, **Montgomery RA**. Eculizumab and renal transplantation in a patient with CAPS. *N Engl J Med*. 2010 May 6;362(18):1744-1745.

Alachkar N, Gupta G, **Montgomery RA**. [Angiotensin antibodies and focal segmental glomerulosclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/23465123) *N Engl J Med.* 2013 Mar 7;368(10):971-3.

Kucirka LM, Grams ME, Lessler J, Hall EC, James N, Massie AB, **Montgomery RA**, Segev DL. Association of race and age with survival among patients undergoing dialysis. *JAMA*. 2011 August 10;306(6):620-626.

Muzaale AD, Massie AB, Wang MC, **Montgomery RA**, McBride MA, Wainright JL, Segev DL. [Risk of end-stage renal disease following live kidney donation.](http://www.ncbi.nlm.nih.gov/pubmed/24519297) *JAMA*. 2014 Feb 12;311(6):579-86.

Ratner LE, Kavoussi LR, Sroka M, Hiller J, Weber R, Schulam PG, **Montgomery RA.** Laparoscopic assisted live donor nephrectomy: a comparison with the open approach. *Transplantation*. 1997 63(2): 229-233.

**Montgomery RA,** Zachary AA, Racusen LL, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch-positive recipients. *Transplantation* 2000. 70(6): 887-895.

**JOURNAL PUBLICATIONS (Full List): CITATIONS 27,150; h-index 86 as of 05/02/2021)**

1. **Montgomery RA.** Modernizing medicine with lessons from an ancient healing art. 1986. *The Pharos* of Alpha Omega Alpha Medical Honor Society. 49(3): 6-11. (First Prize in the AOA National Essay Contest).

2. Golueke PJ, **Montgomery RA**, Petronis JD, Perler BA, Williams GW. 1989. Lymphoscintigraphy to confirm the clinical diagnosis of lymphedema. *J. Vasc. Surg.* 10(3): 306-312.

3. **Montgomery RA,** Dallman MJ. 1991. Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction (PCR). *J. Immunol.* 147(2): 554-560.

4. Dallman MJ, **Montgomery RA**, Larsen CP, Wanders A, Wells AF. 1991. Cytokine gene expression: analysis using northern blotting, polymerase chain reaction and *in situ* hybridization. *Immunol. Reviews.* 119: 163-179.

5. **Montgomery RA**, Zabari G, Hill GS, Ratner LE. 1994. Renal transplantation in patients with sickle cell nephropathies. *Transplantation.* 58(5): 618-620.

6. Schulam PG, Kavoussi LR, Cheriff AD, Averch TD, **Montgomery RA,** Moore RG Ratner LE. 1996. Laparoscopic live donor nephrectomy: the initial 3 cases. *J. of Urology.* 155(6): 1857-1859.

7. Jin Y, Dietz HC, **Montgomery RA**, Bell WR, McIntosh I, Coller B, Bray PF. 1996. Glanzmann thrombasthenia: cooperation between sequence variants in *cis* during splice site selection. *J. Clin. Invest.* 98(8): 1745-1754.

8. Ratner LE, Kavoussi LR, Schulam PG, Bender JS, Magnuson TH, **Montgomery RA.** 1997. Comparison of laparoscopic live donor nephrectomy versus the standard open approach. *Transplantation Proceedings.* 29(1-2): 138-139.

9. Ratner LE., Kavoussi LR, Sroka M, Hiller J, Weber R, Schulam PG, **Montgomery RA** 1997. Laparoscopic-assisted live donor nephrectomy: a comparison with the open approach. *Transplantation*. 63(2): 229-233.

10. Ratner LE, Hiller J, Sroka M, Weber R, Sikorsky I, **Montgomery RA,** Kavoussi LR. 1997. Laparoscopic live donor nephrectomy removes disincentives to live donation. *Transplantation Proceedings.* 29(8): 3402-3403.

11. **Montgomery RA,** Venbrux AC, Bulkley GB. 1997. Mesenteric vascular ischemia. *Curr. Probl. Surg.* 34(12): 941-1025.

12. **Montgomery RA,** Dietz HC. 1997. Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence. *Human Molecular Genetics*. 6(4): 519-525.

13. **Montgomery RA,** Dallman MJ. 1997. Semi-quantitative polymerase chain reaction analysis of cytokine and cytokine receptor gene expression during thymic ontogeny. *Cytokine.* 9(10): 717-726.

14. Ratner LE, Kavoussi LR, Chavin KD, **Montgomery RA**. 1998. Laparoscopic live donor nephrectomy: technical considerations and vascular length (letter). *Transplantation.* 65(12): 1657-1658.

15. Ratner LE, **Montgomery RA,** Kavoussi LR. 1998. Response to two hundred consecutive living donor nephrectomies (letter). *Arch. Surg.* 133(11): 1253-1254.

16. **Montgomery RA,** Geraghty MT, Bull E, Gelb BD, Johnson M, McIntosh I, Francomano CA, Dietz HC. 1998. Multiple molecular mechanisms underlying subdiagnostic variants of the Marfan syndrome. *Am. J. Hum. Genet.* 63(6): 1703-1711.

17. Fabrizio MD, Ratner LE, **Montgomery RA,** Kavoussi LR. 1999. Laparoscopic live donor nephrectomy. *Urologic Clinics of North America.* 26(1): 247-256.

18. Tan HP, Kavoussi LR, Sosa J, **Montgomery RA**, Ratner LE. 1999. Laparoscopic live donor nephrectomy: The pro argument. *Nephrology News Issues*. 13(11) 90-95.

19. Ratner LE, **Montgomery RA**, Kavoussi LR. 1999. Solid organ transplantation. *Ann Intern Med*. 131(6): 478.

20. Ratner LE, **Montgomery RA**, Maley WR, Kavoussi LR. 1999. Laparoscopic live donor nephrectomy: the four-year Johns Hopkins University experience. *Nephrol Dial Transplant*. 14(9): 2090-2093.

21. Ratner LE, Fabrizio MD, Chavin K, **Montgomery RA**, Mandal AK, Kavoussi LR. 1999 Technical considerations in the delivery of the kidney during laparoscopic live donor nephrectomy. *J of the ACS* 189(4): 427-430.

22. Ratner LE, **Montgomery RA,** Cohen C, Maley WR, Burdick JF, Chavin KD, Kittur DS, Klein AS, Kraus ES, Kavoussi LR. 2000. Laparoscopic live donor nephrectomy: the recipient. *Transplantation.* 69(11):2319-2323.

23. Youil R, Toner T, Bull E, Bailey A, Earl CD, Dietz HC, **Montgomery RA**. 2000. Detection of mutations in the FBN1 gene using T4 endonuclease VII. *Human Mutation*. 16(1): 92-93.

24. Tan HP, Maley WR, Kavoussi LR, **Montgomery RA,** Ratner LE. 2000. Laparoscopic live: donor nephrectomy: evolution of a new standard. *Curr Opin* *Organ Transplantation* 12:312-318.

25. Ratner LE, Smith P, **Montgomery RA**, Mandal AK, Fabrizio M, Kavoussi LR. 2000. Laparoscopic live donor nephrectomy: pre-operative assessment of technical difficulty. *Clin Transplant.* 14(4): 427-432.

26. **Montgomery RA,** Zachary AA, Racusen LL, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. 2000. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch-positive recipients. *Transplantation* 70(6): 887-895.

27. Eldadah ZA, Hamosh A, Biery N, **Montgomery RA,** Duke M, Elkins R, Dietz H. 2001. Familial Tetralogy of Fallot caused by mutation in the jagged1 gene. *Human Molecular Genetics* 10(2): 163-169.

28. **Montgomery RA,** Kavoussi LR, Su LM, Sinkov V, Cohen C, Maley WR, Burdick JF, Markowitz J, Ratner LE. 2001. Improved recipient results after five years of performing the laparoscopic donor nephrectomy. *Transplantation Proceedings* 33, 1108-1110.

29. Mandal AK, Cohen C, **Montgomery RA**, Kavoussi LR, Ratner LE. 2001. Should the indications for laparoscopic live donor nephrectomy of the right kidney be the same as for the open procedure? Anomalous left renal vasculature is not a contraindication to laparoscopic left donor nephrectomy. *Transplantation* 71(5): 660-664.

30. Tan HP, Samaniego MD, **Montgomery RA**, Burdick JF, Maley WR, Kraus ES, Ratner LE. 2001. Donor horseshoe kidneys for transplantation. *Transplantation* 72(5):869-73.

31. Tan HP, Markowitz JS, **Montgomery RA.** Merritt WT, Klein AS, Thuluvath PJ, Poordad FF, Maley WR, Winters B, Akinci SB, Gaine SB. 2001. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. *Liver Transplantation* 7(8): 745-749.

32. Ratner LE, **Montgomery RA,** Kavoussi LR. 2001. Laparoscopic live

donor nephrectomy: A review of the first five years. *Urologic Clinics of North America*. 24 (4): 709-719.

33. Sonnenday CJ, Ratner LE, Zachary AA, Burdick JF, Samaniego MD, Kraus E, Warren DS, **Montgomery RA**. 2002. Preemptive therapy with plasmapheresis/intravenous immunoglobulin: successful live donor renal transplantation in patients with a positive crossmatch. *Transplant Proc.* 34:1614-1616.

34. Haas M., Ratner LE, **Montgomery RA**. 2002. C4D staining of perioperative renal transplant biopsies. *Transplantation*. 74: 711-717.

35. Molmenti EP, Pinto PA, **Montgomery RA**, Su LM, Kraus E, Cooper M, Sonnenday CJ, Klein AS, Kavoussi LR, Ratner LE. 2003. Concomitant surgery with laparoscopic live donor nephrectomy. *Am J Transplant*. 3(2):219-223.

36. **Montgomery RA**, Cooper M., Kraus E, Rabb H, Samaniego M., Simpkins CE, Sonnenday CJ, Ugarte RM, Warren DS, Zachary AA. 2003. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. *Clin Transpl*. 199-213. Review.

37. Holechek MJ, Hiller JM, Paredes M, Rickard JC, **Montgomery RA**. 2003.

Expanding the living organ donor pool: positive crossmatch and ABO incompatible renal transplantation. *Nephrol Nurs J.* 30(2):195-204.

38. Kawamoto S, **Montgomery RA**, Lawler LP, Horton KM, Fishman EK. 2003. Multidetector CT angiography for preoperative evaluation of living laparoscopic kidney donors. *AJR Am J Roentgenol.*180(6):1633-1638.

39. Pinto PA, **Montgomery RA**, Ryan B, Roberts W, Hsu T, Kavoussi P, Klein AS, Kavoussi LR, Molmenti EP. 2003. Laparoscopic procurement model for living donor liver transplantation. *Clin Transplant.* 17 Suppl 9:39-43.

40. Thomas MA, Rha KH, Ong AM, Pinto PA, **Montgomery RA**, Kavoussi LR, Jarrett TW. 2003. Optical access trocar injuries in urological laparoscopic surgery. *J Urol.* 170(1):61-63.

41. Racusen LC, Colvin R, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, **Montgomery RA**, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K. 2003. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. *Am J Transplant.* 3(6):708-714.

42. Sonnenday CJ, Cooper M, Handley C, Gage FA, Krause E, **Montgomery RA.** 2003. The hazards of basing acceptance of cadaveric renal allografts on pulsatile perfusion parameters alone. *Transplantation*. 75(12):2029-2033.

43. Kim FJ, Pinto P, Su LM, Jarrett TW, Ratner LE, **Montgomery RA**, Kavoussi LR.

2003. Ipsilateral orchialgia after laparoscopic donor nephrectomy. *J Endourol*. 17(6):405-9.

44. **Montgomery RA.** 2003. Use of plasmapheresis for pre-sensitized and crossmatch positive patients. *Transplantation and Immunology Letter*. 19(2): 6.

45. Zachary AA, **Montgomery RA**, Ratner LE, Samaniego-Picota M, Haas M,

Kopchaliiska D, Leffell MS. 2003. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients*. Transplantation*. 76(10): 1519-1525.

46. Warren DS, Zachary AA, Sonnenday CJ, King KE, Cooper M, Ratner LE, Shirey RS, Haas M, Leffell MS, **Montgomery RA**. 2004. Successful renal transplant across simultaneous ABO incompatible and positive crossmatch barriers. *Am J Transplant.* 4(4):561-8.

47. Shepherd JC, Subramanian A, **Montgomery RA**, Samaniego MD, Gong G,

Bergmann A, Blythe D, Dropulic L. 2004. West Nile virus encephalitis in a kidney transplant recipient. *Am J Transplant.* 4(5):830-3.

48. Kawamoto S, **Montgomery RA**, Lawler LP, Horton KM, Fishman EK. 2004. Multi-detector row CT evaluation of living renal donors prior to laparoscopic nephrectomy. *Radiographics*. 24(2):453-66.

49. Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, Kupiec

Weglinski J, Matas A, **Montgomery RA**, Nickerson P, Platt JL, Rabb H, Thistlethwaite R, Tyan D, Delmonico FL. 2004. National conference to assess antibody-mediated rejection in solid organ transplantation, *Am J Transplant.* 4(7):1033-41.

50. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, **Montgomery RA.** 2004. Preconditioning with plasmapheresis and CMV hyperimmune globulin and anti-CD20 monoclonal antibody allow ABO-incompatible renal transplantation without splenectomy. *Am J Transplant.* 4(8):1315-22.41.

51. Su LM, Ratner LE, **Montgomery RA**, Jarrett TW, Trock BJ, Sinkov V, Bluebond-Langner R, Kavoussi LR. 2004. Laparoscopic live donor nephrectomy: trends in donor and recipient morbidity following 381 consecutive cases. *Ann Surg.* 240(2):358-63.

52. **Montgomery RA**, Hardy MA, Jordan SC, Racusen LC, Ratner LE, Tyan DB, Zachary AA. 2004. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. *Transplantation.* 27; 78(2):181-5.

53. **Montgomery RA**. 2004. ABO Incompatible Transplantation: To B or not to B. *Am J. Transplant*. 4(7):1011-2.

54. King KE, Warren DS, Samaniego-Picota M, Campbell-Lee S, **Montgomery RA**, Baldwin WM. 2004. Antibody, complement and accommodation in ABO-incompatible transplants. *Curr Opin Immunol*. 16(5):545-9.

55. Haas M, Sonnenday CJ, Cicone JS, Rabb H, **Montgomery RA**. 2004. Isometric tubular epithelial vacuolization in renal allograft biopsy specimens of patients receiving low-dose intravenous immunoglobulin for a positive crossmatch. *Transplantation.* 78(4):549-56.

56. Sonnenday CJ, Warren DS, Cooke SK, Dietz HC, **Montgomery RA.** 2004. A novel chimeric ribozyme vector produces potent inhibition of ICAM-1 expression on ischemic vascular endothelium. *The Journal of Gene Medicine*. 6(12): 1394-402.

57. Molmenti EP, Varkarakis IM, Pinto P, Tiburi MF, Bluebond-Langner R, Komotar R, **Montgomery RA**, Jarrett T, Kavoussi LR, Ratner LE. [Renal transplantation with iliac vein transposition.](https://www.ncbi.nlm.nih.gov/pubmed/15621112) *Transplant Proc*. 2004 Nov;36(9):2643-5.

58. Nagakawa Y, Nomoto S, Kato Y, **Montgomery RA**, Williams GM, Klein AS, Sun Z. 2004. Over-expression of AIF-1 in liver allografts and peripheral blood correlates with acute rejection after transplantation in rats. *Am J Transplant*. 4(12):1949-57.

59. **Montgomery RA**, Zachary AA. 2004. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. *Pediatr Transplant*. 8(6):535-42.

60. Segev DL, Gentry SE, Warren DS, Reeb B, **Montgomery RA**. 2005. Kidney Paired Donation and Optimizing the Use of Live Donor Organs. *JAMA* 293(15):1883-90.

61. Zachary AA, **Montgomery RA**, Leffell MS. 2005. Factors associated with and

Predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. *Hum Immunol.* 66(4):364-70.

62. Leffell MS, **Montgomery RA**, Zachary AA. The changing role of antibody testing in transplantation. *Clin Transpl*. 2005:259-71.

63. Nagakawa Y, Williams GM, Zheng Q, Tsuchida A, Aoki T, **Montgomery RA**,

Klein AS, Sun Z. 2005. Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-alpha. *Hepatology* 42(1):208-15.

64. Warren DS, Simpkins CE, Cooper M, **Montgomery RA**. 2005. Modulating

alloimmune responses with plasmapheresis and IVIG. *Curr Drug Targets Cardiovasc Haematol Disord.* 5(3):215-22.

65. Gentry SE, Segev DL, **Montgomery RA**. 2005. A comparison of populations served by kidney paired donation and list paired donation. *Am J Transplant*. 5(8):1914-21.

66. Kaplan I, Houp JA, **Montgomery RA**, Leffell MS, Hart JM, Zachary AA. A computer match program for paired and unconventional kidney exchanges. *Am J Transplant.* 2005 Sep;5(9):2306-8.

67. Segev DL, Gentry SE, Melancon JK, **Montgomery RA**. Characterization of waiting times in a simulation of kidney paired donation. *Am J Transplant.* 2005 Oct;5(10):2448-55.

68. Segev DL, Simpkins CE, Warren DS, King KE, Shirey RS, Maley WR, Melancon JK, Cooper M, Kozlowski T, **Montgomery RA**. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. *Am J Transplant.* 2005 Oct;5(10):2570-5.

69. **Montgomery RA**, Zachary AA, Ratner LE, Segev DL, Hiller JM, Houp J, Cooper M, Kavoussi L, Jarrett T, Burdick J, Maley WR, Melancon JK, Kozlowski T, Simpkins CE, Phillips M, Desai A, Collins V, Reeb B, Kraus E, Rabb H, Leffell MS, Warren DS. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. *JAMA.* 2005 Oct 5;294(13):1655-63.

70. Ugarte R, Kraus E, **Montgomery RA**, Burdick JF, Ratner L, Haas M, Hawxby AM, Karp SJ. Excellent outcomes after transplantation of deceased donor kidneys with high terminal creatinine and mild pathologic lesions. *Transplantation.* 2005 Sep 27;80(6):794-800.

71. Segev DL, Gentry SE, **Montgomery RA**. Relative roles for list paired exchange, live donor paired exchange and desensitization. *Am J Transplant.* 2006 Feb;6(2):437.

72. Stewart ZA, Kozlowski T, Segev DL, **Montgomery RA**, Klein AS. Successful transplantation of cadaveric polycystic liver: case report and review of the literature.

*Transplantation.* 2006 Jan 27;81(2):284-6.

73. Tan HP, Shapiro R, **Montgomery RA**, Ratner LE. Proposed live donor nephrectomy complication classification scheme. *Transplantation*. 2006 April 28;81(8):1221-1223.

74. **Montgomery RA**, Simpkins CE, Segev DL. New options for patients with donor incompatibilities. *Transplantation*. 2006 July 27;82(2):164-165.

75. **Montgomery RA**, Gentry SE, Marks WH, Warren DS, Hiller J, Houp J, Zachary AA, Melancon JK, Maley WR, Rabb H, Simpkins C, Segev DL. Domino paired kidney donation: A strategy to make best use of live non-directed donation. *Lancet*. 2006 July 29;368(9533):419-421.

76. Locke JE, Zachary AA, Mohammed BS, Warren DS, **Montgomery RA**. [Rescue splenectomy for severe acute antibody-mediated rejection.](https://www.ncbi.nlm.nih.gov/pubmed/18365416) *Clin Transpl*. 2006:518-20.

# 77. Haas M, Rahman MH, Racusen LC, Kraus ES, Bagnasco SM, Segev DL, Simpkins CE, Warren DS, King KE, Zachary AA, **Montgomery RA**. C4d and C3d staining in biopsies of ABO- and HLA- incompatible renal allografts: Correlation with histologic findings. *Am J Transplant*. 2006 Aug;6(8): 1829-1840.

78. Lee KW, Simpkins CE, **Montgomery RA**, Locke JE, Segev DL, Maley WR. Factors affecting graft survival after liver transplantation from donation after cardiac death donors. *Transplantation*. 2006 Dec 27;82(12): 1683-1688.

79. Simpkins CE, **Montgomery RA**, Hawxby AM, Locke JE, Gentry SE, Warren DS, Segev DL. Cold ischemia time and allograft outcomes in live donor renal transplantation: Is live donor organ transport feasible? *Am J Transplant*. 2007 Jan;7(1): 99-107.

80. Haas M, **Montgomery RA**, Segev DL, Rahman MH, Racusen LC, Bagnasco SM, Simpkins CE, Warren DS, Lepley D, Zachary AA, Kraus ES. Subclinical acute antibody-mediated rejection in positive crossmatch renal allograft. *Am J Transplant*. 2007 March;3(7): 576-585.

81. Locke JE, Zachary AA, Haas M, Melancon JK, Warren DS, Simpkins CE, Segev, **Montgomery RA**. The Utility of Splenectomy as Rescue Treatment for Severe Acute Antibody Mediated Rejection. *Am J Transplant*. 2007 April; 7(4):842-846.

82. Locke JE, Segev DL, Warren DS, Dominici F, Simpkins CE, **Montgomery RA.** Outcomes of kidneys from donors after cardiac death: Implications for Allocation and Preservation. *Am J Transplant*. 2007 July; 7(7):1797-1807.

# 83. Bagnasco SM, Tsai W, Rahman MH, Kraus ES, Barisoni L, Vega R, Racusen LC, Haas M, Mohammed BS, Zachary AA, **Montgomery RA**. CD20-Positive Infiltrates in Renal Allograft Biopsies With Acute Cellular Rejection Are Not Associated With Worse Graft Survival. *Am J Transplant*. 2007 August; 7(8):1968-1973.

# 84. Jordan SC, Locke JE, **Montgomery RA**. Desensitization Protocols for crossing Human Leukocyte Antigen and ABO Incompatible Barriers. *Current Opinion in Organ Transplantation.* 2007 August; 12(4):371-378.

85. Woodle S, Goldfarb D, Segev DL, Waterman AD, Gentry S, Aeder M, **Montgomery RA**, Miao Y, Lewis RM, Shapiro R. Kidney Paired Donation: State of the Science and Practice. *Current Opinion in Organ Transplantation*. 2007 August; 12(4):384-389.

86. Zachary AA, **Montgomery RA**, Jordan SC, Reinsmoen NL, Claas FH, Reed EF.

[14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/17445194) *Tissue Antigens.* 2007 Apr;69 Suppl 1:160-73.

87. Segev DL, Nguyen GC, Locke JE, Simpkins CE, **Montgomery RA**, Maley WR, Thuluvath PJ. Twenty Years of Liver Transplantation for Budd-Chiari Syndrome: A National Registry Analysis. *Liver Transplantation*. 2007 September; 13(9): 1285-1294.

88. Gentry SE, Segev DL, Simmerling M, **Montgomery RA**. Expanding Kidney Paired Donation Through Participation by Compatible Pairs. *Am J Transplant*. 2007 Oct; 7 (10):2361-2370.

89. Segev DL, Gentry SE, **Montgomery RA**. Association between waiting times for kidney transplantation and rates of Live Donation. *Am J Transplant*. 2007 Oct; 7 (10):2406-2413.

90. Segev DL, Maley WR, Simpkins CE, Locke JE, Nguyen GC, **Montgomery RA,** Thuluvath PJ. Minimizing risk associated with elderly liver donors by matching to preferred recipients. *Hepatology.* 2007 December; 46 (6):1907-1918

91. **Montgomery RA**, Locke JE. ABO-Incompatible Transplantation: Less May be More.

*Transplantation*. 2007 December; 84 (12suppl): S8-9.

92. Haas M, Segev DL, Racusen LC, Bagnasco SM, Melancon JK, Tan M, Kraus ES, Rabb H, Ugarte RM, Burdick JF, **Montgomery RA**. Arteriosclerosis In Kidneys From Healthy Live Donors: Comparison Of Wedge And Needle Core Perioperative Biopsies. *Arch Pathol Lab Med*. 2008 January; 132(1): 37-42.

93. Segev DL, Simpkins CE, Thompson RE, Locke JE, Warren DS, **Montgomery RA**. Obesity Impacts Access to Kidney Transplantation. *J Am Soc Nephrol*. 2008 February; 19(2):349-355.

94. Gentry SE, Segev DL, **Montgomery RA**. Working Together Toward A National Kidney Paired Donation Program. *Am J Transplant*. 2008 February; 8(2):464.

95. Sun Z, Zhang X, Ito K, Li Y, **Montgomery RA**, Tachibana S, Williams GM. Amelioration of Oxidative mitochondrial DNA Damage and Deletion after Renal Ischemic Injury by the K-ATP Channel Opener Diazoxide. *Am J Physio Renal Physiol*. 2008 March; 294(3): F491-498.

96. Segev DL, Kucirka LM, Nguyen GC, Cameron AM, Locke JE, Simpkins CE, Thuluvath PJ, **Montgomery RA**, Maley WR. Effect modification in liver allografts with prolonged cold ischemic time. *Am J Transplant*. 2008 March; 8(3):658-666.

97. Segev DL, Gentry SE, **Montgomery RA**. Response to “Waiting Time and Use of Living Donors.” *Am J Transplant*. 2008 March; 8(3):722.

98. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, **Montgomery RA**, Cameron AM, Maley WR. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. *Liver Transpl*. 2008 April; 14(4):512-25.

99. Locke JE, Warren DS, Singer AL, Segev DL, Simpkins CE, Maley WR, **Montgomery RA**, Danovitch G, Cameron AM. Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts. *Transplantation*. 2008 April 15; 85(7):935-942.

100. Segev DL, **Montgomery RA**. Regional and racial disparities in the use of live non-directed kidney donors. *Am J Transplant*. 2008 May; 8(5):1051-5.

101. Lee KW, Cameron AM, Maley WR, Segev DL, **Montgomery RA**. Factors affecting graft survival after adult/child split-liver transplantation: Analysis of the UNOS/OPTN data base.

*Am J Transplant*. 2008 June; 8(6):1186-1196.

102. Zachary AA, **Montgomery RA**, Leffell MS. Defining unacceptable HLA antigens. *Current Opinion in Organ Transplantation*. 2008 August; 13(4): 405-410.

103. Segev DL, Kucirka LM, Gentry SE, **Montgomery RA**. Utilization and outcomes of kidney paired donation in the United States. *Transplantation*. 2008 August 27;86 (4):502-510.

104. Locke JE, Sun Z, Warren DS, Sheets TP, Holzer H, Shamblott MJ, **Montgomery RA**, Cameron AM. Generation of humanized animal livers using stem cell transplant. *Annals of Surgery 2008*; September; 248 (3):487-493.

105. Haas M, Segev DL, Racusen LC, Bagnasco SM, Locke JE, Warren DS, Simpkins CE, Lepley D, King KE, Kraus ES, **Montgomery RA**. C4d Deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. *J Am Soc Nephrol* 2009 Jan;20(1):197-204.

106. **Montgomery RA**, Katznelson S, Bry WI, Zachary AA, Houp J, Hiller JM, Shridharani S, John D, Singer AL, Segev DL. Successful Three-Way Kidney Paired Donation with Cross-Country Live Donor Allograft Transport. *Am J Transplant* 2008 October; 8 (10):2163-2168.

107. Allen G, Simpkins CE, Segev DL, Warren DS, King K, Taube J, Locke JE, Baldwin W, Haas M, Chivukula R, **Montgomery RA**. Rapid accommodation of an A1 renal allograft after preconditioning for ABO-incompatible transplantation. *Contrib Nephrol*. 2008 October; (162):35-36.

108. Locke JE, Warren DS, Dominici F, Cameron AM, Leffell MS, McRann DA, Melancon, JK, Segev DL, Simpkins CE, Singer AN, Zachary AA, **Montgomery RA**. Donor ethnicity influences outcomes following deceased-donor kidney transplantation in black recipients. *J Am Soc Nephrol* 2008 October; 19 (10):2011-2019.

109. Segev DL, Thompson R, Locke JE, Simpkins CE, Thuluvath PJ, **Montgomery RA**, Maley WR. Prolonged waiting times for liver transplantation in obese patients. *Annals of Surgery* 2008 November; 248 (5):863-870.

110. Tobian AA, Shirey RS, **Montgomery RA**, Ness PM, King KE. [The critical role of plasmapheresis in ABO-incompatible renal transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/18657072) *Transfusion.* 2008 Nov;48(11):2453-60.

111. Locke JE, **Montgomery RA**, Warren DS, Subramanian A, Segev DL. Renal transplantation in HIV-positive recipients: Long-term outcomes and risk factors for graft loss. *Archives of Surgery* 2009 January; 144(1):83-86.

112. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, **Montgomery RA**. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. *Am J Transplant*. 2009 January; 9(1):231-235.

113. Stewart ZA, Cameron AM, Singer AL, Dagher NN, **Montgomery RA**, Segev DL. Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival in pancreas transplantation. *Am J Transplant*. 2009 January; 9 (1):217-221.

114. Haas M, Segev DL, Racusen LC, Bagnasco SM, Locke JE, Warren DS, Simpkins CE, Lepley D, King KE, Kraus ES, **Montgomery RA**. C4d deposition without rejection correlates with reduces early scarring in ABO-incompatible renal allografts. *J Am Soc Nephrol*. 2009 January; 20(1):197-204.

115. Huang E, Samaniego-Picota M, McCune T, Melancon JK, **Montgomery RA**, Ugarte R, Kraus E, Womer K, Rabb H, Watnick T. DNA testing for live kidney donors at risk for autosomal dominant polycystic kidney disease. *Transplantation.* 2009 January; 15;87(1):133-137.

116. Stewart ZA, Cameron AM, Singer AL, **Montgomery RA**, Segev DL. Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death. *Am J Transplant*. 2009 February; 9;(2):286-293.

117. Kucirka LM, Namuyinga R, Hanrahan C, **Montgomery RA**, Segev DL. Formal policies and special informed consent are associated with higher provider utilization of CDC high-risk donor organs. *Am J Transplant*. 2009 March;9(3):629-635.

118. Lonze BE, Warren DS, Stewart ZA, Dagher NN, Singer AL, Shah AS, **Montgomery RA**, Segev DL. Kidney transplantation in previous heart or lung recipients. *Am J Transplant.* 2009 March;9(3):578-585.

119. Kucirka LM, Alexander C, Namuyinga R, Hanrahan C, **Montgomery RA**, Segev DL. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. *Am J Transplant*. 2009 March;9(3):620-628.

120. Rees MA, Kopke JE, Pelletier RP, Segev DL, Rutter ME, Fabrega AJ, Rogers J, Pankewycz OG, Hiller J, Roth AE, Sandholm T, Unver MU, **Montgomery RA**. A nonsimultaneous, extended, altruistic-donor chain. *N Engl Journal Med.* 2009 March 12;360(11):1096-1101.

121. Segev DL, Kucirka LM, Oberai PC, Parekh RS, Boulware LE, Powe NR, **Montgomery RA**. Age and comorbidities are effect modifiers of gender disparities in renal transplantation. *J Am Soc Nephrol*. 2009 March;20(3):621-628.

122. Bagnasco SM, Mohammed BS, Mani H, Gandolfo MT, Haas M, Racusen LC, **Montgomery RA**, Kraus E. Oxalate deposits in biopsies from native and transplanted kidneys, and impact on graft function. *Nephrol Dial Transplant*. 2009 April;24;(4):1319-1325.

123. **Montgomery RA**, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, Cooper M, Simpkins CE, Singer AL. Stewart ZA, Melancon JK, Ratner L, Zachary AA, Haas M. ABO incompatible renal transplantation: a paradigm ready for broad implementation. *Transplantation.* 2009 April:27;(8):1246-1255.

124. Stewart ZA, Lonze BE, Warren DS, Dagher NN, Singer AL, **Montgomery RA,** Segev DL. Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants. *Am J Transplant.* 2009 May;9(5):1048-1054.

125. Kucirka LM, Namuyinga R, Hanrahan C, **Montgomery RA**, Segev DL. Provider utilization of high-risk donor organs and nucleic acid testing: results of two national surveys. *Am J Transplant.* 2009 May;9(5):1197-1204.

126. Kopchaliiska D, Zachary AA, **Montgomery RA**, Leffell MS. Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients. *Transplantation*. 2009 May 15:87(9):1394-1401.

127. Gentry SE, **Montgomery RA**, Swihart BJ, Segev DL. The roles of dominos and nonsimultaneous chains in kidney paired donation. *Am J Transplant*. 2009 June;9(6):1330-1336.

128. Tobian AA, Shirey RS, **Montgomery RA**, Tisch DJ, Ness PM, King KE. Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. *Transfusion*. 2009 June;49(6):1248-1254.

129. Massie AB, Zeger SL, **Montgomery RA**, Segev DL. The effects of DonorNet 2007 on kidney distribution equity and efficiency. *Am J Transplant*. 2009 July;9(7):1150-1557.

130. Kraus ES, Parekh RS, Oberai P, Lepley D, Segev DL, Bagnasco S, Collins V, Leffell M, Lucas D, Rabb H, Racusen LC, singer AL, Stewart ZA, Warren DS, Zachary AA, Haas M, **Montgomery RA**. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. *Am J Transplant*. 2009 August;9(8):1826-1834.

131. Stewart ZA, Locke JE, **Montgomery RA**, Singer AL, Cameron AM, Segev DL. ABO-incompatible deceased donor liver transplantation in the United States: a national registry analysis. *Liver Transpl*. 2009 August;15(8):883-893.

132. Locke JE, Zachary AA, Warren DS, Segev DL, Houp JA, **Montgomery RA**, Leffell MS. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. *Am J Transplant.* 2009 Sept;9(9):2136-2139.

133. Okabayashi T, Maeda H, Sun ZL, **Montgomery RA**, Nishimori I, Hanazaki K. Perioperative insulin therapy using a closed-loop artificial endocrine pancreas after hepatic resection. *World J Gastroenterol*. 2009 Sept 7;15(33):4116-4121.

134. Stewart ZA, Locke JE, Segev DL, Dagher NN, Singer AL, **Montgomery RA**, Cameron AM. Increased risk of graft loss from hepatic artery thrombosis after liver transplantation with older donors. *Liver Transpl.* 2009 Dec;15(12):1688-1695.

135. Melancon JK, Kucirka LM, Boulware LE, Powe NR, Locke JE, **Montgomery RA**, Segev DL. Impact of Medicare coverage on disparities in access to simultaneous Pancreas and Kidney Transplantation. *Am J Transplant.* 2009 Dec:9(12):2785-2791.

136. Lonze BE, Dagher NN, Simpkins CE, Singer AL, Segev DL, Zachary AA, **Montgomery RA.** [The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.](https://www.ncbi.nlm.nih.gov/pubmed/20524301) *Clin Transpl.* 2009:377-84.

137. Shirey RS, Cai W, **Montgomery RA**, Chhibber V, Ness PM, King KE. Streamlining ABO antibody titrations for monitoring ABO-incompatible kidney transplants. *Transfusion*. 2010 Mar;50(3):631-4.

138. **Montgomery RA**. 2010. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. *Am J Transplant*. 2010 March;10(3):449-457.

139. Zachary AA, **Montgomery RA**, Locke JE, Leffell MS. Proinflammatory events and HLA antibodies. *Am J Transplant.* 2010 Apr;10(4):956

140. Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, McBride MA, **Montgomery RA**. Perioperative mortality and long-term survival following live kidney donation. *JAMA.* 2010 March 10;303(10):959-966.

141. Grams ME, Womer KL, Ugarte RM, Desai NM, **Montgomery RA**, Segev DL. Listing for expanded criteria donor kidneys in older adults and those with predicted benefit. *Am J Transplant.* 2010 April;10(4):802-809.

142. Segev DL, **Montgomery RA**. The application of paired donation to live donor liver transplantation. *Liver Transpl*. 2010 April;16(4):423-425.

143. Kucirka LM, Singer AL, Ros RL, **Montgomery RA**, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. *Am J Transplant.* 2010 May;10(5):1238-1246.

144. Tobian AA, Shirey RS, **Montgomery RA**, Cai W, Haas M, Ness PM, King KE. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. *Am J Transplant*. 2010 May;10(5):1247-1253.

145. Lonze BE, Singer AL, **Montgomery RA**. Eculizumab and renal transplantation in a patient with CAPS. *N Engl J Med*. 2010 May 6;362(18):1744-1745.

146. Allaf ME, Singer AL, She W, Green I, Womer K, Segev DL, **Montgomery RA**. Laparoscopic live donor nephrectomy with vaginal extraction: initial report. *Am J Transplant*. 2010 June;10(6):1473-1477.

147. Warren DS, **Montgomery RA**. Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange. *Immunol Res*. 2010 July;47(1-3) L 257-264.

148. Massie AB, Desai NM, **Montgomery RA**, Singer AL, Segev DL. Improving distribution efficiency of hard-to-place deceased donor kidneys: Predicting probability of discard or delay. *Am J Transplant*. 2010 July;10(7):1613-1620.

149. Lonze BE, Dagher NN, Simpkins CE, Locke JE, Singer AL, Segev DL, Zachary AA, **Montgomery RA**. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. *Am J Transplant*. 2010 Sept;10(9):2154-2160.

150. Mark AL, Sun Z, Warren DS, Lonze DB, Knabel MK, Williams GM, Locke JE, **Montgomery RA**, Cameron AM. Stem cell mobilization is life saving in an animal model of acute liver failure. *Ann Surg*. 2010 Oct;252(4):591-596.

151. Massie AB, Stewart DE, Dagher NN, **Montgomery RA**, Desai NM, Segev DL. Center-level patterns of indicated willingness to and actual acceptance of marginal kidneys. *Am J Transplant*. 2010 Nov;10(11):2472-2480.

152. Gentry SE, **Montgomery RA**, Segev DL. Kidney paired donation: fundamentals, limitations and expansions. *Am J Kidney Dis*. 2011 Jan;57(1):144-151.

153. Kucirka LM, Ros, RL, Subramanian AK, **Montgomery RA**, Segev DL. Provider response to a rare but highly publicized transmission of HIV through solid organ transplantation. *Arch Surg.* 2011 Jan;146(1):41-5.

154. Segev DL, Veale JL, Berger JC, Hiller JM, Hanto RL, Leeser DB, Geffner SR, Shenoy S, Bry WI, Katznelson S, Melcher ML, Rees MA, Samara EN, Israni AK, Cooper M, Montgomery RJ, Malinzak L, Whiting J, Baran D, Tchervenkov JI, Roberts JP, Rogers J, Axelrod DA, Simpkins CE, **Montgomery RA.** Transporting live donor kidneys for kidney paired donation: initial national results. *Am J Transplant.* 2011 Feb;11(2):356-360.

155. Dagher NN, Lonze BE, Singer AL, Simpkins CE, Desai NM, **Montgomery RA**, Segev DL. Outcomes and discard of kidneys from pediatric donors after cardiac death. *Transplantation.* 2011 April 15;91(7):765-771.

156. Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, **Montgomery RA**, Ross RL, Segev DL. Risk of window period Hepatitis-C infection in high infectious risk Donors: systematic review and meta-analysis. *Am J Transplant*. 2011 June;11(6):1188-1200.

157. Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, **Montgomery RA**, Ros RL, Segev DL. Risk of window period HIV infection in high infectious risk donors: systemic review and meta-analysis. *Am J Transplant*. 2011 June;11(6):1176-1187

158. Boyarsky BJ, Hall EC, Singer AL, **Montgomery RA**, Gebo KA, Segev DL. Estimating the potential pool of HIV-infected deceased organ donors in the United States. *Am J Transplant.* 2011 June;11(6):1209-17.

159. **Montgomery RA.** Living donor exchange programs: theory and practice. *Br Med Bull.* 2011;98:21-30.

160. **Montgomery RA**, Lonze BE, Jackson AM. [Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients.](http://www.ncbi.nlm.nih.gov/pubmed/21666478) *Curr Opin Organ Transplant.* 2011 Aug;16(4):439-43.

161. Frischmeyer-GuerrerioPA\*, MontgomeryRA\*, WarrenDS, CookeSK, LutzJ, SonnendayCJ, GuerrerioAL, DietzHC. Perturbation of thymocyte development in nonsense mediated decay-deficient mice. *Proc Natl Acad Sci U S A*. 2011 Jun 28;108(26):10638-43. \* Equal Contributors.

162. Garonzik Wang JM, **Montgomery RA**, Kucirka LM, Berger JC, Warren DS, Segev DL.

Incompatible live-donor kidney transplantation in the United States: results of a national survey. *Clin J Am Soc Nephrol*. 2011 August;6(8):2041-2046.

163. **Montgomery RA**, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL. Desensitization of HLA-incompatible kidney recipients and survival. *N Engl J Med.* 2011 July 28;365(4):318-326.

164. Kucirka LM, Grams ME, Lessler J, Hall EC, James N, Massie AB, **Montgomery RA,** Segev DL. [Association of race and age with survival among patients undergoing dialysis.](http://www.ncbi.nlm.nih.gov/pubmed/21828325) *JAMA*. 2011 Aug 10;306(6):620-626.

165. Okabayashi T, Cameron AM, Hisada M, **Montgomery RA**, Williams GM, Sun Z. Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. *Am J Transplantation*. 2011 October 11;(10):2046-2056.

166. **Montgomery RA**, Cozzi E, West LJ, Warren DS. Humoral immunity and antibody-mediated rejection in solid organ transplantation. *Semin Immunol*. 2011 Aug;23(4):224-34.

167. Deshpande NA, James NT, Kucirka LM, Boyarsky BJ, Garonzik-Wang JM, **Montgomery RA,** Segev DL. Pregnancy outcomes in kidney transplant recipients: a systemic review and meta-analysis. *Am J Transplant.* 2011 Nov;11(11):2388-404.

168. Van Arendonk KJ, James NT, Locke JE, **Montgomery RA**, Colombani PM, Segev DL. Late graft loss among pediatric recipients of DCD kidneys. *Clin J Am Soc Nephrol.* 2011 Nov;6(11):2705-11.

169. Lonze BE, Dagher NN, Liu M, Kucirka LM, Simpkins CE, Locke JE, Desai NM, Cameron AM, **Montgomery RA**, Segev DL, Singer AL. Outcomes of renal transplants from centers for disease control and prevention high-risk donors with prospective recipient viral testing: a single-center experience. *Arch Surg.* 2011 Nov;146(11):1261-6

170. Hall EC, Massie AB, James NT, Wang JM, **Montgomery RA**, Berger JC, Segev DL. [Effect of eliminating priority points for hla-B matching on racial disparities in kidney transplant rates.](http://www.ncbi.nlm.nih.gov/pubmed/21802805) *Am J Kidney Dis.* 2011 Nov;58(5):813-816.

171. Berger JC, Muzaale AD, James N, Hoque M, Wang JM, **Montgomery RA**, Massie AB, Hall EC, Segev DL. [Living kidney donors ages 70 and older: recipient and donor outcomes.](http://www.ncbi.nlm.nih.gov/pubmed/22034505) *Clin J Am Soc Nephrol.* 2011 Dec;6(12):2887-93.

172. Ros RL, Kucirka LM, Govindan P, Sarathy H, **Montgomery RA**, Segev DL. Patient attitudes toward CDC high infectious risk donor kidney transplantation: inferences from focus groups. *Clin Transplant.* 2012 Mar-April;26(2):247-253.

173. Boyarsky BJ, Hall EC, Deshpande NA, Ros RL, **Montgomery RA,** Steinwachs DM, Segev DL. Potential limitations of presumed consent legislation. *Transplantation.* 2012 January 27;93(2):136-140.

174. Garonzik-Wang JM, James NT, Weatherspoon KC, Deshpande NA, Berger JA, Hall EC, **Montgomery RA**, Segev DL. The aggressive phenotype: center-level patterns in utilization of suboptimal kidneys. *Am J Transplant.* 2012 February;12(2):400-408.

175. Muzaale AD, Dagher NN, **Montgomery RA**, Taranto SE, McBride MA, Segev DL. Estimates of Early Death, Acute Liver Failure, and Long-term Mortality Among Live Liver Donors. *Gastroenterology.* 2012 February;142(2):273-280.

176. Grams ME, Kucirka LM, Hanrahan CF, **Montgomery RA**, Massie AB, Segev DL. Candidacy for Kidney Transplantation of Older Adults. *J Am Geriatric Soc*. 2012 January;60;(1):1-7.

177. Montgomery JR, Berger JC, Warren DS, James NT, **Montgomery RA**, Segev DL. Outcomes of ABO-Incompatible Kidney Transplantation in the United States. *Transplantation*. 2012 March 27;93(6):603-609.

178. Jackson AM, Kuperman MB, **Montgomery RA**. Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. *Am J Transplant*. 2012 June;12(6):1643-1649.

179. Garonzik-Wang JM, Govindan P, Grinnan JW, Liu M, Ali HM, Chakraborty A, Jain V, Ros RL, James NT, Kucirka LM, Hall EC, Berger JC, **Montgomery RA**, Desai NM, Dagher NN, Sonnenday CJ, Englesbe MJ, Makary MA, Walston JD, Segev DL. Frality and delayed graft function in kidney transplant recipients. *Arch Surg*. 2012 February;147(2): 190-193.

180. Hall EC, James NT, Garonzik-Wang JM, Berger JC, **Montgomery RA**, Dagher NN, Desai NM, Segev DL. Center-level factors and racial disparities in living donor kidney transplantation. *Am J Kidney dis*. 2012 June;59(6):849-857.

181. Segev DL, Powe NR, Troll MU, Wang NY, **Montgomery RA**, Boulware LE. Willingness of the United States general public participate in kidney paired donation. *Clin* *Transplant*. 2012 Sep-Oct;26(5):714-21.

182. Sharif A, Zachary AA, Hiller J, Segev D, Alachkar N, Kraus ES, Desai NM, Dagher NN, Singer AL, **Montgomery RA**. Rescue kidney paired donation as emergency salvage for failed desensitization. *Transplantation*. 2012 April 15;93(7):27-29.

183. Garonzik-Wang JM, Berger JC, Ros RL, Kucirka LM, Deshpande NA, Boyarsky BJ, **Montgomery RA**, Hall EC, James NT, Segev DL. Live donor champion: Finding live kidney donors by separating the advocate from the patient. *Transplantation*. 2012 June 15;93(11):1147-1150.

184. Lonze BE, Holzer HT, Knabel MK, Locke JE, DiCamillo GA, Karhadkar SS, **Montgomery RA**, Sun Z, Warren DS, Cameron AM. In vitro and ex vivo delivery of short hairpin RNAs for control of hepatitis C viral transcript expression. *Arch Surg*. 2012 April;147(4):384-387.

185. Gentry SE, **Montgomery RA**, Segev DL. Controversies in kidney paired donation. *Adv Chronic Kidney Dis*. 2012 July;19(4):257-261.

186. Alachkar N, Lonze BE, Zachary AA, Holechek MJ, Schillinger K, Cameron AM, Desai NM, Dagher NN, Segev DL, **Montgomery RA**, Singer AL. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. *Transplantation*. 2012 July 27;94(2):165-171.

187. **Montgomery RA**, Zachary AA. Transplantation: All for one and one for all-alloimmunization and polyreactivity. *Nat Rev Nephrol*. 2012 July 10;8(8):442-3.

188. **Montgomery RA**, Warren DS, Segev DL, Zachary AA. HLA incompatible renal transplantation. *Curr Opin Organ Transplant*. 2012 August;17(4):386-392.

189. Alachkar N, Bagnasco SM, **Montgomery RA**. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. *Transplant Int*. 2012 August;25(8):93-95.

190. Jackson AM, Leffell MS, **Montgomery RA**, Zachary AA. A GPS for finding the route to transplantation for the sensitized patient. *Curr Opin Organ Transplant.* 2012 August;17(4):433-439.

191. Hisada M, Ota Y, Zhang X, Cameron AM, Gao B, **Montgomery RA**, Williams GM, Sun Z. [Successful transplantation of reduced-sized rat alcoholic Fatty livers made possible by mobilization of host stem cells.](http://www.ncbi.nlm.nih.gov/pubmed/22994609) *Am J Transplant.* 2012 Dec;12(12):3246-56.

192. Chu LC, Sheth S, Segev DL, **Montgomery RA**, Fishman EK. [Role of MDCT angiography in selection and presurgical planning of potential renal donors.](http://www.ncbi.nlm.nih.gov/pubmed/23096176) *AJR Am J Roentgenol.* 2012 Nov;199(5):1035-41.

193. Alachkar N, Gupta G, **Montgomery RA**. [Angiotensin antibodies and focal segmental glomerulosclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/23465123) *N Engl J Med*. 2013 Mar 7;368(10):971-3.

194. Massie AB, Gentry SE, **Montgomery RA**, Bingaman AA, Segev DL. [Center-Level Utilization of Kidney Paired Donation.](http://www.ncbi.nlm.nih.gov/pubmed/23463990) *Am J Transplant*. 2013 May;13(5):1317-1322.

195. Garonzik-Wang JM, James NT, Arendonk KJ, Gupta N, Orandi BJ, Hall EC, Massie AB, **Montgomery RA**, Dagher NN, Singer AL, Cameron AM, Segev DL. [The Aggressive Phenotype Revisited: Utilization of Higher-Risk Liver Allografts.](http://www.ncbi.nlm.nih.gov/pubmed/23414232) *Am J Transplant*. 2013 Apr;13(4):936-42.

196. Alachkar N, Gupta G, **Montgomery RA**. [Angiotensin antibodies and focal segmental glomerulosclerosis.](http://www.ncbi.nlm.nih.gov/pubmed/23465123) *N Engl J Med*. 2013 Mar 7;368(10):971-3.

197. Zachary AA, Lucas DP, **Montgomery RA**, Leffell MS. Rituximab Prevents An Anamnestic Response in Patients With Cryptic Sensitization to HLA. *Transplantation*. 2013 Mar 15;95(5):701-4.

198. Singer AL, Alachkar N, **Montgomery RA**, Zachary AA. Reply to “Defining the benefits od desensitization therapy”. *Transplantation*. 2013 Mar 27;95(6):e33

199. Van Arendonk KJ, Garonzik Wang JM, Deshpande NA, James NT, Smith JM, **Montgomery RA**, Colombani PM, Segev DL. [Practice Patterns and Outcomes in Retransplantation Among Pediatric Kidney Transplant Recipients.](http://www.ncbi.nlm.nih.gov/pubmed/23549198) *Transplantation*. 2013 June 15;95(11):1360-1368.

200. Chow EK, Massie AB, Muzaale AD, Singer AL, Kucirka LM, **Montgomery RA**, Lehmann HP, Segev DL. [Identifying Appropriate Recipients for CDC Infectious Risk Donor Kidneys.](http://www.ncbi.nlm.nih.gov/pubmed/23557212) A*m J Transplant*. 2013 May;13(5):1227-34.

201. **Montgomery RA**, Leffell MS, Zachary AA. Transplantation of the sensitized patient: Histocompatibility testing. *Methods Mol Biol*. 2013; 1034:117-125.

202. Cameron AM, Massie AB, Alexander CE, Stewart B, **Montgomery RA**, Benavides NR, Fleming GD, Segev DL. Social media and organ donor registration: the facebook effect. *Am J Transplant*. 2013 August;13(8):2059-2065.

203. Hall EC, Engels EA, **Montgomery RA**, Segev DL. Cancer Risk after ABO-Incompatible Living-Donor Kidney Transplantation. *Transplantation.* 2013 Sept 15;96(5):476-479.

204. Leto Barone AA, Sun Z, **Montgomery RA**, Lee WP, Brandacher G. Impact of donor-specific antibodies in reconstructive transplantation. *Expert Rev Clin Immunol.* 2013 Sep;9(9):835-44.

205. Iyer HS, Jackson AM, Zachary AA, **Montgomery RA.** [Transplanting the highly sensitized patient: trials and tribulations.](http://www.ncbi.nlm.nih.gov/pubmed/24076558) *Curr Opin Nephrol Hypertens.* 2013 Nov;22(6):681-8.

206. Maeda H, Ota Y, Wang Y, Ramachandran K, **Montgomery RA**, Williams GM, Sun Z. Contribution of extrahepatic small cells resembling small hepatocyte-like progenitor cells to liver mass maintenance in transplantation model of retrorsine-pretreated liver. *Springerplus*. 2013 Sep 8;2:446.

207. Garonzik-Wang JM, Sullivan B, Hiller JM, Cass V, Tchervenkow J, Feldman L, Baran D, Chaudhury P, Cantarovich M, Segev DL, **Montgomery RA**. International kidney paired donation. *Transplantation.* 2013 Oct 15;96(7):e55-6.

208. Locke JE, James NT, Mannon RB, Mehta SG, Pappas PG, Baddley JW, Desai NM, **Montgomery RA**, Segev DL. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. *Transplantation*. 2014 Feb 27;97(4):446-50.

209. Bagnasco SM, Zachary AA, Racusen LC, Arend LJ, Carter-Monroe N, Alachkar N, Nazarian SM, Lonze BE, **Montgomery RA**, Kraus ES. [Time Course of Pathologic Changes in Kidney Allografts of Positive Crossmatch HLA-Incompatible Transplant Recipients.](http://www.ncbi.nlm.nih.gov/pubmed/24173106)

*Transplantation*. 2014 Feb 27;97(4):440-5.

210. Lonze BE, Zachary AA, Magro CM, Desai NM, Orandi BJ, Dagher NN, Singer AL, Carter-Monroe N, Nazarian SM, Segev DL, Streiff MB, **Montgomery RA**. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enable successful renal transplantation.  *Am J Transplant*. 2014 Feb;14(2):459-65.

211. Muzaale AD, Massie AB, Wang MC, **Montgomery RA**, McBride MA, Wainright JL, Segev DL. [Risk of end-stage renal disease following live kidney donation.](http://www.ncbi.nlm.nih.gov/pubmed/24519297) *JAMA*. 2014 Feb 12;311(6):579-86.

212. Sharif A, Kraus ES, Zachary AA, Lonze BE, Nazarian SM, Segev DL, Alachkar N, Arend LJ, Bagnasco SM, Racusen LC, **Montgomery RA**. Histologic Phenotype on 1-year posttransplant biopsy and allograft survival in HLA-incompatible kidney transplants. *Transplantation*. 2014 March 15;97(5):541-547.

213. Lin Q, Wesson RN, Maeda H, Wang Y, Cui Z, Liu JO, Cameron AM, Gao B, **Montgomery RA**, Williams GM, Sun Z. Pharmacological Mobilization of Endogenous Stem Cells Significantly Promotes Skin Regeneration after Full Thickness Excision: The Synergistic Activity of AMD3100 and Tacrolimus. *J Invest Dermatol*. 2014 Sep;134(9):2458-68.

214. Philogene MC, Sikorski P, **Montgomery RA**, Leffell MS, Zachary AA. Differential effect of bortezomib on HLA class I and class II antibody. *Transplantation.* 2014 Sep 27;98(6):660-5.

215. **Montgomery RA.** One kidney for life. *Am J Transplant*. 2014 July;14(7):1473-1474.

216. Matar D, Naqvi F, Racusen LC, Carter-Monroe N, **Montgomery RA**, Alachkar N. Atypical Hemolytic Uremic Syndrome Recurrence After Kidney Transplantation. *Transplantation*. 2014 Dec 15;98(11):1205-12.

217. Maeda H, Shigoka M, Wang Y, Fu Y, Wesson RN, Lin Q, **Montgomery RA**, Enzan H, Sun Z. [Disappearance of GFP-positive hepatocytes transplanted into the liver of syngeneic wild-type rats pretreated with retrorsine.](https://www.ncbi.nlm.nih.gov/pubmed/24796859) *PLoS One.* 2014 May 5;9(5): e95880

218. Gupta G, Abu Jawdeh BG, Racusen LC, Bhasin B, Arend LJ, Trollinger B, Kraus E, Rabb H, Zachary AA, **Montgomery RA**, Alachkar N. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies*. Transplantation*. 2014 June 27;97(12):1240-1246.

219. Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, **Montgomery RA**. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection following HLA-incompatible kidney transplantation. *Transplantation.* 2014. Oct 27;98(8):857-63.  
  
220. Orandi BJ, Garonzik-Wang JM, Massie AB, Zachary AA, Montgomery JR, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson P, Wellen J, Bozorgzadeh A, Gaber AO, **Montgomery RA**, Segev DL. Quantifying the risk of incompatible kidney transplantation: A multi-center study. *Am J Transplant.* 2014 July;14(7):1573-1580.

221. Boyarsky BJ, Massie AB, Alejo JL, Van Arendonk KJ, Wildonger S, Garonzik-Wang JM, **Montgomery RA**, Deshpande NA, Muzaale AD, Segev DL. Experiences Obtaining Insurance After Live Kidney Donation. *Am J Transplant*. 2014 Sep;14(9):2168-72.

222. Fu Y, Sun Z, Fuchs EJ, Wang Y, Shen ZY, Maeda H, Lin Q, Warren DS, Williams DS, **Montgomery RA**. Successful transplantation of kidney allografts in sensitized rats after syngeneic hematopoietic stem cell transplantation and fludarabine. *Am J Transplant.* 2014 Oct;14(10):2375-83.

223. **Montgomery RA**. Less sensitization but not necessarily more tolerance with better matching. *Am J Transplant.* 2014 Nov;14(11):2668

224. Berli JU, Montgomery JR, Segev DL, Ratner LE, Maley WR, Cooper M, Melancon JK, Burdick J, Desai NM, Dagher NN, Lonze BE, Nazarian SM, **Montgomery RA**. Surgical Management of Early and Late Ureteral Complications after Renal Transplantation: Techniques and Outcomes. *Clin Transplant.* 2014 Oct 13.

225**.** Bagnasco SM, Gottipati S, Kraus E, Alachkar N, **Montgomery RA**, Racusen LC, Arend LJ. Sarcoidosis in native and transplanted kidneys: incidence, pathologic findings, and clinical course. *PLoS One*. 2014 Oct 20;9(10):e110778.

226. Orandi BJ, James NT, Hall EC, Van Arendonk KJ, Garonzik-Wang JM, Gupta N, **Montgomery RA**, Desai NM, Segev DL. Center-Level Variation in the Development of Delayed Graft Function After Deceased Donor Kidney Transplantation. *Transplantation.* 2015 May;99(5):997-1002.

227. Jackson AM, Sigdel TK, Delville M, Hsieh SC, Dai H, Bagnasco S, **Montgomery RA**, Sarwal MM. Endothelial Cell Antibodies Associated with Novel Targets and Increased Rejection. *J Am Soc Nephrol.* 2015 May; 26(5):1161-71

228. Orandi BJ, Chow EH, Hsu A, Gupta N, Van Arendonk KJ, Garonzik-Wang JM, Montgomery JR, Wickliffe C, Lonze BE, Bagnasco SM, Alachkar N, Kraus ES, Jackson AM, **Montgomery RA**, Segev DL. [Quantifying renal allograft loss following early antibody-mediated rejection.](http://www.ncbi.nlm.nih.gov/pubmed/25611786) *Am J Transplant.* 2015 Feb;15(2):489-98.

229. Knabel MK, Ramachandran K, Karhadkar S, Hwang HW, Creamer TJ, Chivukula RR, Sheikh F, Clark KR, Torbenson M, **Montgomery RA**, Cameron AM, Mendell JT, Warren DS. [Systemic Delivery of scAAV8-Encoded MiR-29a Ameliorates Hepatic Fibrosis in Carbon Tetrachloride-Treated Mice.](http://www.ncbi.nlm.nih.gov/pubmed/25923107) *PLoS One*. 2015 Apr 29;10(4):e0124411.

230. Muzaale AD, Massie AB, Kucirka LM, Luo X, Kumar K, Brown RS, Anjum S, **Montgomery RA**, Lentine KL, Segev DL. [Outcomes of Live Kidney Donors Who Develop End-Stage Renal Disease.](http://www.ncbi.nlm.nih.gov/pubmed/26457599) *Transplantation.* 2016 Jun;100(6):1306-12. PMID: 26457599.

231. Orandi BJ, Alachkar N, Kraus ES, Naqvi F, Lonze BE, Lees L, Van Arendonk KJ, Wickliffe C, Bagnasco SM, Zachary AA, Segev DL, **Montgomery RA**. [Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation.](http://www.ncbi.nlm.nih.gov/pubmed/26317487) *Am J Transplant.* 2016 January 16(1):213-220.

232. Orandi BJ, Luo X, Massie AB, Garonzik-Wang JM, Lonze BE, Ahmed R, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, A. Gaber AO, **Montgomery RA\***, Segev DL\* Survival Benefit in HLA-Incompatible Live Donor Kidney Transplantation. *N Engl J Med.* 2016 Mar 10;374(10):940-50.\* **Equal Contributors.**

233. Hu X, Okabayashi T, Cameron AM, Wang Y, Hisada M, Li J, Raccusen LC, Zheng Q, **Montgomery RA**, Williams GM, Sun Z. [Chimeric Allografts Induced by Short-Term Treatment with Stem Cell Mobilizing Agents Result in Long-term Kidney Transplant Survival without Immunosuppression: I Study in Rats.](http://www.ncbi.nlm.nih.gov/pubmed/26749344) *Am J Transplant.* 2016 Jul;16(7):2055-65.

234. Cameron AM, Wesson R, Ahmadi A, Singer AL, Hu X, Okabayashi T, Wang Y, Shigoka M, Fu Y, Gao W, Raccusen LC, **Montgomery RA**, Williams GM, Sun Z. [Chimeric Allografts Induced by Short-Term Treatment with Stem Cell Mobilizing Agents Result in Long-term Kidney Transplant Survival without Immunosuppression: II Study in Miniature Swine.](http://www.ncbi.nlm.nih.gov/pubmed/26748958) *Am J Transplant.* 2016 Jul;16(7):2066-76.

235. Alasfar S, Carter-Monroe N, Rosenberg AZ, **Montgomery RA**, Alachkar N. [Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification.](http://www.ncbi.nlm.nih.gov/pubmed/26754737) *BMC Nephrol.* 2016 Jan 11;17(1):7.

236. Jackson AM, Kraus ES, Orandi BJ, Segev DL, **Montgomery RA**, Zachary AA. [A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/25054778) *Kidney Int.* 2015 Feb;87(2):409-16.

237. **Montgomery RA**. Therapeutics for ABMR: A Slippery Slope Into Confusion. *Am J Transplant.* 2016 May;16(5):1350-1.

238. King KE, **Montgomery RA**. [Therapeutic plasma exchange for kidney transplantation: the problem of antibody-mediated rejection.](http://www.ncbi.nlm.nih.gov/pubmed/26840785) *Transfusion.* 2015 Apr;55(4):696-9.

239. Sue PK, Pisanic N, Heaney CD, Forman M, Valsamakis A, Jackson AM, Ticehurst JR, **Montgomery RA**, Schwarz KB, Nelson KE, Karnsakul W. [Hepatitis E Virus Infection Among Solid Organ Transplant Recipients at a North American Transplant Center.](http://www.ncbi.nlm.nih.gov/pubmed/27014710) *Open Forum Infect Dis*. 2016 Jan 18;3(1):ofw006.

240. Fahmy LM, Massie AB, Muzaale AD, Bagnasco SM, Orandi BJ, Alejo JL, Boyarsky BJ, Anjum SK, **Montgomery RA**, Dagher NN, Segev DL. [Long-term Renal Function in Living Kidney Donors Who Had Histological Abnormalities at Donation.](http://www.ncbi.nlm.nih.gov/pubmed/27152920) *Transplantation*. 2016 Jun;100(6):1294-8.

241. **Montgomery RA**, Orandi BJ, Racusen L, Jackson AM, Garonzik-Wang JM, Shah T, Woodle ES, Sommerer C, Fitts D, Rockich K, Zhang P, Uknis ME. [Plasma-Derived C1 Esterase Inhibitor for Acute Antibody Mediated Rejection Following Kidney Transplantation: Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study.](http://www.ncbi.nlm.nih.gov/pubmed/27184779) *Am J Transplant*. 2016 Dec;16(12):3468-3478.

242. Orandi BJ, Lonze BE, Jackson A, Terezakis S, Kraus ES, Alachkar N, Bagnasco SM, Segev DL, Orens JB, **Montgomery RA**. [Splenic irradiation for the treatment of severe antibody-mediated rejection.](http://www.ncbi.nlm.nih.gov/pubmed/27214874) *Am J Transplant*. 2016 Oct;16(10):3041-3045.

243. Orandi BJ, **Montgomery RA**, Segev DL.Kidney Transplants from HLA-Incompatible Live Donors and Survival (letter). *N Engl J Med.* 2016 Jul 21;375(3):288-9.

244. Philogene MC, Bagnasco S, Kraus ES, **Montgomery RA**, Dragun D, Leffell MS, Zachary AA, Jackson AM. Anti-Angiotensin II Type I Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies. *Transplantation*. 2017 Mar;101(3):608-615.

245. Soares KC, Arend LJ, Lonze BE, Desai NM, Alachkar N, Naqvi F, **Montgomery RA**.

[Successful Renal Transplantation of Deceased Donor Kidneys With 100% Glomerular Fibrin Thrombi and Acute Renal Failure Due To Disseminated Intravascular Coagulation.](http://www.ncbi.nlm.nih.gov/pubmed/27490412) *Transplantation*. 2017 Jun;101(6):1134-1138.

246. McAdams-DeMarco MA, King EA, Luo X, Haugen C, DiBrito S, Shaffer A, Kucirka LM, Desai NM, Dagher NN, Lonze BE, **Montgomery RA**, Walston J, Segev DL. [Frailty, Length of Stay, and Mortality in Kidney Transplant Recipients: A National Registry and Prospective Cohort Study.](https://www.ncbi.nlm.nih.gov/pubmed/27655240) *Ann Surg.* Dec;266(6):1084-1090.

247. McAdams-DeMarco MA, Ying H, Olorundare I, King EA, Haugen C, Buta B, Gross AL, Kalyani R, Desai NM, Dagher NN, Lonze BE, **Montgomery RA**, Bandeen-Roche K, Walston JD, Segev DL. [Individual Frailty Components and Mortality In Kidney Transplant Recipients.](https://www.ncbi.nlm.nih.gov/pubmed/27779573)

*Transplantation*. 2017 Sep;101(9):2126-2132.

248. Nijim S, Vujjini V, Alasfar S, Luo X, Orandi B, Delp C, Desai NM, **Montgomery RA**, Lonze BE, Alachkar N. [Recurrent IgA Nephropathy After Kidney Transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/27788802) *Transplant Proc.* 2016 Oct;48(8):2689-2694.

249. Avery RK, Lonze BE, Kraus ES, Marr KA, **Montgomery RA**. [Severe chronic norovirus diarrheal disease in transplant recipients: Clinical features of an under-recognized syndrome.](https://www.ncbi.nlm.nih.gov/pubmed/28176463)

*Transpl Infect Dis.* 2017 Apr;19(2).

250. Lonze BE, Bae S, Kraus ES, Holechek MJ, King KE, Alachkar N, Naqvi FF, Dagher NN, Sharif A, Desai NM, Segev DL, **Montgomery RA**. [Outcomes and risk stratification for late antibody-mediated rejection in recipients of ABO-incompatible kidney transplants: a retrospective study.](https://www.ncbi.nlm.nih.gov/pubmed/28403566) *Transpl Int.* 2017 Sep;30(9):874-883.

251. Axelrod D, Lentine KL, Schnitzler MA, Luo X, Xiao H, Orandi BJ, Massie A, Garonzik-Wang J, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Osama Gaber A, **Montgomery RA**, Segev DL. [The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis.](https://www.ncbi.nlm.nih.gov/pubmed/28613436) *Am J Transplant.* 2017 Dec;17(12):3123-3130.

252. Orandi BJ, Luo X, King EA, Garonzik-Wang JM, Bae S, **Montgomery RA**, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Osama Gaber A, Segev DL. [Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study.](https://www.ncbi.nlm.nih.gov/pubmed/28834181) *Am J Transplant.* 2017 Mar;18(3):650-658.

253. Lonze BE, Dagher NN, Alachkar N, Jackson AM, **Montgomery RA**. Non-Traditional Sites for Vascular Anastomoses to Enable Kidney Transplantation in Patients with Major Systemic Venous Thromboses. *Clin Transplant*. 2017 Dec;31(12).

254. Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, **Montgomery RA**, Zeevi A, Halloran PF, Loupy A. [Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.](https://www.ncbi.nlm.nih.gov/pubmed/29042454) *J Am Soc Nephrol.* 2018 Feb;29(2):620-635.

256. Alasfar S, Matar D, **Montgomery RA**, Desai N, Lonze B, Vujjini V, Estrella MM, Manllo Dieck J, Khneizer G, Sever S, Reiser J, Alachkar N.. [Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/29189487) *Transplantation.* 2018 Mar;102(3):e115-e120.

257. Tatapudi VS, **Montgomery RA.** [Pharmacologic Complement Inhibition in Clinical Transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/29214126) *Curr Transplant Rep.* 2017;4(2):91-100.

258. **Montgomery RA**, Lonze BE, Tatapudi VS. [IgG Degrading Enzyme of Streptococcus Pyogenes: An Exciting New Development in Desensitization Therapy.](https://www.ncbi.nlm.nih.gov/pubmed/29271867) *Transplantation*. 2018 Jan;102(1):2-4.

259. **Montgomery RA**, Loupy A, Segev DL. [Antibody-mediated rejection: New approaches in prevention and management.](https://www.ncbi.nlm.nih.gov/pubmed/29292861) *Am J Transplant.* 2018 Jan;18 Suppl 3:3-17.

260. WangHD, MillerDT, Fidder SAJ, FurtmüllerGJ, LopezJ, QuanA, BudihardjoJ, LoughDM, RaimondiG, LeeWPA, **Montgomery RA**, SunZ, BrandacherG. Desensitization and prevention of antibody-mediated rejection in vascularized composite allotransplantation by syngeneic hematopoietic stem cell transplantation. *Transplantation.* 2018 Apr;102(4):593-600.

261. Philogene MC, Zhou S, Lonze BE, Bagnasco S, Alasfar S, **Montgomery RA**, Kraus E, Jackson AM, Leffell MS, Zachary AA. [Pre-transplant screening for non-HLA antibodies: Who should be Tested?](https://www.ncbi.nlm.nih.gov/pubmed/29428484) *Hum Immunol*. 2018 Apr;79(4):195-202.

262. Tatapudi VS, Lonze BE, Wu M, **Montgomery RA**. [Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome.](https://www.ncbi.nlm.nih.gov/pubmed/29594146) *Case Rep Nephrol Dial.* 2018 Jan 19;8(1):10-19.

263. Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Murad MH, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, Süsal C, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, **Montgomery RA**, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A. [Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/29799874) *PLoS Med.* 2018 July 27;15(7). doi: 10.1371 PMID: 30052664.

264. Pinelli DF, Zachary AA, Friedewald JJ, Gjertson DW, Evans MA, Chatroop EN, Leffell MS, Vo AA, Jordan SC, **Montgomery RA**, Tambur AR. [Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.](https://www.ncbi.nlm.nih.gov/pubmed/29981209) *Am J Transplant.* 2019 Feb;19(2):381-390.

265. **Montgomery RA**, Tatapudi VS, Leffell MS, Zachary AA. [HLA in transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/29985463) *Nat Rev Nephrol*. 2018 Sep;14(9):558-570.

266. Lonze BE, Tatapudi VS, Weldon EP, Min ES, Ali NM, Deterville CL, Gelb BE, Benstein JA, Dagher NN, Wu M, **Montgomery RA**. [IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody.](https://www.ncbi.nlm.nih.gov/pubmed/30004918) *Ann Surg*. 2018 Sep;268(3):488-496.

267. **Montgomery RA**, Tatapudi VS, Leffell MS, Zachary AA. HLA in Transplantation. *Nat Rev Nephrol.* 2018 Sep;14(9):558-570.

268. Tatapudi VS, Min ES, Gelb BE, Dagher NN, **Montgomery RA**, Lonze BE. Repeat A2 Into B Kidney Transplantation After Failed Prior A2 Into B Transplant: A Case Report. *Transplant Proc*. 2018 Dec;50(10):3913-3916.

269. Marks WH, Mamode N, **Montgomery RA**, Stegall MD, Ratner LE, Cornell LD, Rowshani AT, Colvin RB, Dain B, Boice JA, Glotz D. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. *Am J Transplant*. 2019 Oct;19(10):2876-2888. PMID: 30887675.

270. Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M, Divard G, Jackson AM, Viglietti D, Giral M, Kamar N, Thaunat O, Morelon E, Delahousse M, Kuypers D, Hertig A, Rondeau E, Bally E, Eskandary F, Bohmig G, Gupta G, Glotz D, Legendre C, **Montgomery** **RA**, Stegall MD, Empana JP, Jouven X, Segev DL, Lefaucheur C. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. *BMJ* 2019 Sep 17; 366: l4923.

271. Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, **Montgomery RA**, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. ['Stealth' corporate innovation: an emerging threat for therapeutic drug development.](https://www.ncbi.nlm.nih.gov/pubmed/31562490) *Nat Immunol*. 2019 Nov;20(11):1409-1413.

272. Tatapudi VS, **Montgomery RA.** [Therapeutic Modulation of the Complement System in Kidney Transplantation: Clinical Indications and Emerging Drug Leads.](https://www.ncbi.nlm.nih.gov/pubmed/31632397)  *Front Immunol.* 2019 Oct 1;10:2306.

273. **Montgomery RA.** Getting comfortable with risk. *N Engl J Med.* 2019 Oct 24;381(17):1606-1607.

274. Schinstock CA, Smith BH, **Montgomery RA,** Jordan SC, Bentall AJ, Mai M, Khamash HA, Stegall MD. [Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization?](https://www.ncbi.nlm.nih.gov/pubmed/31769104) *Clin Transplant*. 2019 Dec;33(12). doi: 10.1111 PMID: 31769104.

275. Loupy A, Bouquegneau A, Stegall MD, **Montgomery RA**. Clinical outcomes after ABO-incompatible renal transplantation. *Lancet*. 2019 Nov 30;394(10213):1988-1989.

276. Karpel HC, Ali NM, Lawson N, Tatapudi VS, Friedlander R, Philogene MC, **Montgomery RA**, Lonze BE.Karpel HC. [Successful A2 to B Deceased Donor Kidney Transplant after Desensitization for High-Strength Non-HLA Antibody Made Possible by Utilizing a Hepatitis C Positive Donor.](https://pubmed.ncbi.nlm.nih.gov/32231847/) *Case Rep Transplant*. 2020 Mar 13;2020:3591274.

277. Jackson KR, Long J, Motter J, Bowring MG, Chen J, Waldram MM, Orandi BJ, **Montgomery RA**, Stegall MD, Jordan SC, Benedetti E, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Verbesey JE, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Wellen J, Bozorgzadeh A, Gaber AO, Heher E, Weng FL, Djamali A, Helderman JH, Concepcion BP, Brayman KL, Oberholzer J, Kozlowski T, Covarrubias K, Desai N, Massie AB, Segev DL, Garonzik-Wang J.Jackson KR*.* [Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes.](https://pubmed.ncbi.nlm.nih.gov/32235255/) *Transplantation*. 2021 Feb 1;105(2):436-442. doi: 10.1097 PMID: 32235255

278. Sharif A, **Montgomery RA.** [Regulating the risk-reward trade-off in transplantation.](https://pubmed.ncbi.nlm.nih.gov/32243681/)

*Am J Transplant.* 2020 Aug:20(8):2282-2283. PMID: 32243681

279. Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, Lefaucheur C, **Montgomery RA**, Nickerson P, Tullius SG, Ahn C, Askar M, Crespo M, Chadban SJ, Feng S, Jordan SC, Man K, Mengel M, Morris RE, O'Doherty I, Ozdemir BH, Seron D, Tambur AR, Tanabe K, Taupin JL, O'Connell PJ.Schinstock CA. [Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group.](https://pubmed.ncbi.nlm.nih.gov/31895348/) *Transplantation.* 2020 May;104(5):911-922 PMID: 31895348

280. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell LD, Clahsen-van Groningen MC, Demetris AJ, Dragun D, Duong van Huyen JP, Farris AB, Fogo AB, Gibson IW, Glotz D, Gueguen J, Kikic Z, Kozakowski N, Kraus E, Lefaucheur C, Liapis H, Mannon RB, **Montgomery RA**, Nankivell BJ, Nickeleit V, Nickerson P, Rabant M, Racusen L, Randhawa P, Robin B, Rosales IA, Sapir-Pichhadze R, Schinstock CA, Seron D, Singh HK, Smith RN, Stegall MD, Zeevi A, Solez K, Colvin RB, Mengel M.Loupy A, [The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.](https://pubmed.ncbi.nlm.nih.gov/32463180/)  *Am J Transplant.* 2020 Sep;20(9):2318-2331 doi: 10.1111/ajt.15898. PMID: 32463180

281. Mehta SA, Leonard J, Labella P, Cartiera K, Soomro I, Neumann H, **Montgomery RA**, Ali NM, Mehta SA. [Outpatient management of kidney transplant recipients with suspected COVID-19-Single-center experience during the New York City surge.](https://pubmed.ncbi.nlm.nih.gov/32578324/) *Transpl Infect Dis*. 2020 Dec;22(6). doi: 10.1111/tid.13383. PMID: 32578324

282. Kon ZN, Smith DE, Chang SH, Goldenberg RM, Angel LF, Carillo JA, Geraci TC, Cerfolio RJ, **Montgomery RA**, Moazami N, Galloway AC, Kon ZN. Extracorporeal Membrane Oxygenation Support in Severe COVID-19. *Ann Thorac Surg.* 2021 Feb;111(2):537-543.17:S0003-4975(20)31152-8. doi: 10.1016 PMID: 32687823

283. Chang SH, Angel L, Smith DE, Carillo J, Rudym D, Lesko M, Sureau K, **Montgomery RA**, Moazami N, Kon ZN. Extracorporeal Membrane Oxygenation Support in Severe COVID-19. *Ann Thorac Surg*. 2020 Jul 17:S0003-4975(20)31157-7. doi: 10.1016 Online ahead of print. PMID: 32687830

284. Jordan SC, Legendre C, Desai NM, Lorant T, Bengtsson M, Lonze BE, Vo AA, Runström A, Laxmyr L, Sjöholm K, Schiött Å, Sonesson E, Wood K, Winstedt L, Kjellman C, **Montgomery RA.** Imlifidase desensitization in crossmatch-positive, highly-sensitized kidney transplant recipients: Results of an international phase 2 trial (Highdes). *Transplantation*. 2020 Oct 21. doi: 10.1097 Online ahead of print. PMID: 33093408

# 285. Lewis TC, Adhikari S, Tatapudi V, Holub M, Kunichoff D, Troxel AB, **Montgomery RA**, Sterman DH. A Propensity-Matched Cohort Study of Tocilizumab in Patients with Coronavirus Disease 2019 *Crit Care Explor.* 2020 Nov 16:2(11) doi: 10.1097 PMID: 33225307.

286. Massie AB, Orandi BJ, Waldram MM, Luo X, Nguyen AQ, **Montgomery RA**, Lentine KL, Segev DL. Impact of ABO-Incompatible Living Donor Kidney Transplantation on Patient Survival. *Am J Kidney Dis*. 2020 Nov:75(5):616-623. doi:10.1053 PMID: 32668318.

287. Raynaud M, Aubert O, Reese PP, Bouatou Y, Naesens M, Kamar N, Bailly É, Giral M, Ladrière M, Le Quintrec M, Delahousse M, Juric I, Basic-Jukic N, Gupta G, Akalin E, Yoo D, Chin CS, Proust-Lima C, Böhmig G, Oberbauer R, Stegall MD, Bentall AJ, Jordan SC, Huang E, Glotz D, Legendre C, **Montgomery RA**, Segev DL, Empana JP, Grams ME, Coresh J, Jouven X, Lefaucheur C, Loupy A. Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. *Kidney Int.* 2021 Jan;99(1):186-197. doi: 10.1016 PMID: 32781106

288. Chang SH, Angel L, Smith DE, Carillo J, Rudym D, Lesko M, Sureau K, **Montgomery RA**, Moazami N, Kon ZN. A Simple Prioritization Change to Lung Transplant Allocation May Result in Improved Outcomes. *Ann Thorac Surg*. 2021 Feb;111(2):427-435. doi: 10.1016 PMID: 32687830.

289. Jackson KR, Long J, Motter J, Bowring MG, Chen J, Waldram MM, Orandi BJ, **Montgomery RA**, Stegall MD, Jordan SC, Benedetti E, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Verbesey JE, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Wellen J, Bozorgzadeh A, Gaber AO, Heher E, Weng FL, Djamali A, Helderman JH, Concepcion CP, Brayman KL, Oberholzer J, Kozlowski T, Covarrubias K, Desai N, Massie AB, Segev DL, Garonzik-Wang J. Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. *Transplantation*. 2021 Feb 1;105(2):436-442. PMID: 32235255.

# 290. Keating BJ, Mukhtar EH, Elftmann ED, Eweje FR, Gao H, Ibrahim LI, Kathawate RG, Lee AC, Li EH, Moore KA, Nair N, Chaluvadi V, Reason J, Zanoni F, Honkala AT, Al-Ali AK, Alrubaish FA, Ahmad Al-Mozaini M, Al-Muhanna FA, Al-Romaih K, Goldfarb SB, Kellogg R, Kiryluk K, Kizilbash SJ, Kohut TJ, Kumar J, O'Connor MJ, Rand EB, Redfield RR, Rolnik B, Rossano J, Sanchez PG, Alavi A, Bahmani A, Bogu GK, Brooks AW, Metwally AA, Mishra T, Marks SD, **Montgomery RA**, Fishman JA, Amaral S, Jacobson PA, Wang M, Snyder MP. Early Detection of SARS-CoV-2 and other Infections in Solid Organ Transplant Recipients and Household Members using Wearable Devices *Transpl Int.* 2021 Mar 18. Online ahead of print PMID: 33735480

# 291. Avery RK, Motter JD, Jackson KR, **Montgomery RA**, Massie AB, Kraus ES, Marr KA, Lonze BE, Alachkar N, Holechek MJ, Ostrander D, Desai N, Waldram MM, Shoham S, Steinke SM, Subramanian A, Hiller JM, Langlee J, Young S, Segev DL, Garonzik Wang JM. Quantifying infection risks in incompatible living donor kidney transplant recipients. *Am J Transplant.* 2021 Apr;21(4):1564-1575 PMID: 32949093

292. Motter JD, Jackson KR, Long JJ, Waldram MM, Orandi BJ, **Montgomery RA**, Stegall MD, Jordan SC, Benedetti E, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Verbesey JE, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Wellen JR, Bozorgzadeh A, Gaber AO, Heher EC, Weng FL, Djamali A, Helderman JH, Concepcion BP, Brayman KL, Oberholzer J, Kozlowski T, Covarrubias K, Massie AB, Segev DL, Garonzik-Wang JM.

Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation. *Am J Transplant*. 2021 Apr;21(4):1612-1621. PMID: 33370502.

293. Cosimi AB, Ascher NL, Emond JC, Kaufman DB, Madsen JC, Miller J, Monaco AP, **Montgomery RA**, Newell KA, Sánchez-Fueyo A, Sarwal MM, Scandling JD, Strober S, Todo S, Weir MR, Sachs DH. The Importance of Bringing Transplantation Tolerance to the Clinic. *Transplantation*. 2021 May 1:105(5):935-940 PMID: 33901128.

294. Lonze DE, Baptiste G, Ali NM, Dagher NN, Gelb BE, Mattoo A, Soomro I, Tatapudi VS, **Montgomery RA**, Stewart ZA. Pancreas transplantation from hepatitis C viremic donors to uninfected recipients. *Am J Transplant.* 2021 May:21(5):1931-1936 PMID: 33346951.

295. Ali NM, Alnazari N, Mehta SA, Boyarsky B, Avery RK, Segev DL, **Montgomery RA**, Stewart ZA. Development of COVID-19 Infection in Transplant Recipients after SARS-CoV-2 Vaccination. *Transplantation.* 2021 Sept 1:105(9):104-106. PMID: 34049360.

296. Woodle ES, Gebel HM, **Montgomery RA**, Maltzman JS. SARS-CoV-2 Vaccination, Immune Responses, and Antibody Testing in Immunosuppressed Populations: Tip of the Iceberg. *Transplantation.* 2021 Sept 1:105(9):1911-1913. PMID: 34144554.

297. Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, **Montgomery RA**, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. *Transplant Direct.* 2021 Sept 7:7(10):762. PMID: 34514117.

298. Smith DE, Kon ZN, Carillo JA, Chen S, Gidea CG, Piper GL, Reyentovich A, **Montgomery RA**, Galloway AC, Moazami N. Early experience with donation after circulatory death heart transplantation using normothermic regional perfusion in the United States. *J Thorac Cardiovasc Surg.* 2021 Sept 14: S0022-5229. PMID: 34728084.

299. Stern J, Alnazari N, Tatapudi VS, Ali NM, Stewart ZA, **Montgomery RA**, Lonze BE. Impact of the 2014 kidney allocation system changes on trends in A2/A2B into B kidney transplantation and organ procurement organization reporting of donor subtyping. *Clin Transplant.* 2021 Sept: 35(9): e14393. PMID: 34165821.

300. Kjellman C, Maldonado AQ, Sjoholm K, Lonze BE, **Montgomery RA**, Runström A, Lorant T, Desai NM, Legendre C, Lundgren T, von Zur Muhlen B, Vo AA, Olsson H, Jordan SC. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. *Am J Transplant*. 2021 Dec:21(12):3907-3918. PMID: 34236770.

301. Raynaud M, Aubert O, Divard G, Reese PP, Kamar N, Yoo D, Chin CS, Bailly E, Buchler M, Ladriere M, Le Quintrec M, Delahousse M, Juric I, Basic-Jukic N, Cresp M, Silva HT Jr, Linharres K, Ribeiro de Castro MC, Soler Pujol G, Empana JP, Ulloa C, Akalin E, Bohmig G, Huang E, Stegall MD, Bentall AJ, **Montgomery RA,** Jordan SC, Oberbauer R, Segev DL, Friedewald JJ, Jouven X, Legendre C, Lefaucheur C, Loupy A. Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. *Lancet Digit Health.* 2021 Dec:3(12):795-805. PMIS: 34756569.

302. Wasuwanich P, Sirisreetreerux P, Ingviya T, Kraus ES, Brennan DC, Sue PK, Jackson AM, Oshima K, Philosophe B, **Montgomery RA**, Karnasakul W. Hepatitis E virus infection and rejection in kidney transplant recipients. *Transpl Immunol*. 2022 Feb;(70):101517. PMID: 34923120.

303. Parent B, Caplan A, Moazami N, **Montgomery RA**. Regarding normothermic regional perfusion: Arguing by insistence is not a strong argument. *Am J Transplant.* 2022 Jun;22(6):17729-1730. PMID: 35352473.

304. Mehta SA, Reyentovich A, **Montgomery RA**, Segev DL, Gebel HM, Bray RA, Samanovic MI, Cornelius AR, Mulligan MJ, Herati RS. Immunogenicity after heterologous third dose COVID-19 vaccination in a heart transplant recipient. *Clin Transplant.* 2022 Apr;36(4):14605. PMID: 35107835.

305. Parent B, Caplan A, Moazami N, **Montgomery RA**. Response to American College of Physician’s statement on the ethics of transplant after normothermic regional perfusion. *Am J Transplant.* 2022 May;22(5):1307-1310. PMID: 35072337.

306. Lonze BE, Spiegler P, Wesson RN, Alachkar N, Petkova E, Weldon EP, Dieter RA, Li Y, Quinn M, Mattoo A, Soomro I, Cohen SM, Leung S, Deterville CL, Landrum BM, Ali NM, Cohen DJ, Singer AL, Sen A, Chong E, Hochman JS, Troxel AB, **Montgomery RA**. A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia with Hyperinflammation. *Crit Care Med.* 2022 May 18. Online ahead of print. PMID: 35583232.

307. **Montgomery RA**, Stern JM, Lonze BE, Tatapudi VS, Mangiola M, Wu M, Weldon EP, Lawson N, Deterville CL, Dieter RA, Sullivan B, Boulton G, Parent B, Piper G, Sommer P, Cawthon S, Duggan E, Ayares D, Dandro A, Fazio-Kroll A, Kokkinaki M, Burdorf L, Lorber M, Boeke JD, Pass H, Keating B, Griesemer A, Ali NM, Mehta SA, Stewart ZA. Results of Two Cases of Pig-to-Human Kidney Xenotransplantation. *N Engl J Med*. 2022 May 19;386(20):1889-1898. PMID: 35584

# INVITED BOOK CHAPTERS:

1. **Montgomery RA,** Ratner LE. 2001. Laparoscopic assisted live donor

Nephrectomy. In *Kidney Transplantation: Principles and Practice* (fifth edition). W. B. Saunders Company: 106-112.

2. **Montgomery RA.** 2001. Effective rescue treatment of acute humoral rejection.

In *Techniques for Reducing Panel-Reactive Antibodies in Solid Organ Transplantation*. Virginia Commonwealth University Press. 3-4.

3**. Montgomery RA**, Simpkins CE, Warren DS. Overcoming MHC incompatibility. *In Living Donor Kidney Transplantation*. Taylor and Francis. 131-142.

4. Simpkins CE, Su LM, **Montgomery RA.** 2006. Laparoscopic Nephrectomy. *Advanced Therapy in Minimally Invasive Surgery.* BC Decker. Chapter 36: 291-301.

5. **Montgomery RA**, Melancon JK, Warren DS. 2008. Options Available to Recipients with Incompatible Donors. *Living Donor Organ Transplantation*. McGraw Hill Medical. 347-355.

6. Simpkins CE, **Montgomery RA**. 2008. Kidney Transplantation: Principles and Practice. *Laparoscopic Live Donor Nephrectomy.* Saunders Elsevier. Chapter 8B 117-125.

7. **Montgomery RA.** 2015. Kidney and Pancreas Transplantation. HLA and ABO desensitization. Jaypee Publishers. Chapter 22; 107-110.

8. Sandal S and **Montgomery RA.** 2016. Renal Transplantation Across HLA and ABO Barriers. Kidney Transplantation, Bioengineering and Regeneration. Elsevier, First Edition. Chapter 26.

9. **Montgomery RA.** 2020. Management of Anti-HLA Antibodies and Acute Antibody-Mediated Rejection. Springer Nature Switzerland AG, D.K.C Cooper, G. Byrne (eds.) *Clinical Xenotransplantation*. Chapter 10.

# PRESENTATIONS AND ABSTRACTS (Platform Oral Presentations Only)

1. **Montgomery, R.A.** and M.J. Dallman. Cytokine gene expression during T-cell ontogeny. (Workshop presentation at the Oxford 1991 Meeting on Graft Infiltration: Cellular and Molecular Mechanisms. Oxford, England, September 1991).

2. Schulam, P.G., **R.A. Montgomery,** L.E. Ratner, R.G. Moore and L.R. Kavoussi. Laparoscopic live donor nephrectomy. (Platform presentation at the World Congress of Endourology and ESWL. Tel Aviv, Israel, 1996).

3. Ratner, L.E., L.R. Kavoussi, P.G. Schulam and **R.A. Montgomery**. Laparoscopic live donor nephrectomy: a comparison with the open approach. (Platform presentation at the American Society of Transplant Surgeons Meeting, Dallas, TX, May 1996).

4. Ratner, L.E., L.R. Kavoussi, P.G. Schulam, J.S. Bender, T.H. Magnuson and **R.A. Montgomery.** Comparison of laparoscopic live donor nephrectomy versus the standard open approach. *Transplantation Proceedings.* 29: 138-139. (Platform presentation at the XVI International Transplantation Society Meeting, Barcelona, Spain, August 1996).

5. Jin, Y., H.C. Dietz, **R.A. Montgomery,** W.R. Bell, I. McIntosh, B. Coller and P.F. Gray. Glanzmann thrombasthenia: cooperation between sequence variants in *cis* during splice site selection. (Platform presentation at the American Society of Hematology Meeting, Orlando, FL, December 1996).

6. **Montgomery, R.A.** and H.C. Dietz. 1996. U1 snRNA as a vehicle for the delivery of antisense targeting sequences. *Am. J. Hum. Genet.*  59(4): A10. (Platform presentation and **winner of the Postdoctoral Basic Science Award: 1996 Awards Competition**, the American Society of Human Genetics 46th Annual Meeting, San Francisco, CA, October 1996).

7. Ratner, L.E., **R.A. Montgomery**, E.S. Kraus and L.R. Kavoussi. Laparoscopic live donor nephrectomy: lessons learned in a two-year experience (Platform presentation at the American Society of Transplant Surgeons Meeting, Chicago, IL., May 1997).

8. Ratner, L.E., **R.A. Montgomery**, J.A. Cadeddu, W.R. Maley and L.R. Kavoussi. Laparoscopic Live Donor Nephrectomy (Platform presentation at the American Urological Society Meeting, New Orleans, LA, April 1997).

9. Ratner, L.E., J. Hiller, M. Sroka, R. Weber, I. Sikorsky, **R.A. Montgomery** and L.R. Kavoussi. Laparoscopic live donor nephrectomy removes disincentives to live donation. *Transplantation Proceedings.* 29: 3402-3403. (Platform presentation a the 4th Annual International Congress of the Society for Organ Sharing, Washington, DC, July 1997).

10. Ratner, L.E., J.A. Sosa, **R.A. Montgomery**, L.R. Kavoussi and N.R. Powe. Assessing disincentives to live kidney donation. (Platform presentation at the Conference on Increasing Donation and Transplantation: The Challenge of Evaluation, Department of Health and Human Services, Arlington, VA, April 1998).

11. Sosa, J.A., T.A. Albini, N.R. Powe, **R.A. Montgomery**, L.R. Kavoussi and L.E. Ratner. Laparoscopic vs open live donor nephrectomy: a multivariate patient outcomes analysis. *Transplantation.* 65(12): S85. (Platform presentation at the American Society of Transplant Physicians Meeting, Chicago, IL, May 1998).

12. Chavin, K.D., R. Rai, G. Zeldin, **R.A. Montgomery**, C. Cohen, D. Cohen, W.R. Maley, J.F. Burdick, A.S. Klein, D.S. Kittur, L.E. Ratner, D.P. Slakey, E.S. Kraus and R. Abdi. Helicobacter pylori - Is it important in the multiorgan transplant population. *Transplantation*. 65(12): S154 (Platform presentation at the American Society of Transplant Physicians Meeting, Chicago, IL, May 1998).

13. Ratner, L.E., **R.A. Montgomery,** C. Cohen, W.R. Maley, J.F. Burdick, K.D. Chavin, D.S. Kittur, A.S. Klein, E.S. Kraus and L.R. Kavoussi. Laparoscopic live donor nephrectomy: the recipient. *Transplantation.* 65(12): S109 (Platform presentation at the American Society of Transplant Physicians Meeting, Chicago, IL, May 1998).

14. Ratner, L.E., **R.A. Montgomery**, W.R. Maley and L.R. Kavoussi. Laparoscopic

live donor nephrectomy: review of the Johns Hopkins’ experience. (Platform presentation at the Simposio Transplante Renal De Donante Vivo, Barcelona, Spain, September 1998).

15. Leffell, S., L.E. Ratner, **R.A. Montgomery**, B. Fivush, A. Neu, P. Colombani, B.

Wise, D. Lucas, N. Delaney and A. Zachary. Abrogation of humoral rejection by removal of HLA-specific antibody. (Platform presentation at the Clinical Histocompatibility Workshop, Palm Beach, Florida, March 1999).

16. Zachary, A., L.E. Ratner, **R.A. Montgomery**, B. Fivush, A. Neu, P. Colombani, B. Wise, D. Lucas, N. Delaney and S. Leffell. Changes in alloantibody specificity following plasmapheresis and IVIg. (Platform presentation at the Clinical Histocompatibility Workshop, Palm Beach, Florida, March 1999).

17. Youil, R., T. Toner, E. Bull, A. Bailey, C.D. Earl, H.C. Dietz and **R.A. Montgomery**. Detection of mutations in the FBN1 gene using T4 endonuclease VII. (Platform presentation at the Mutation Detection 1999 V International Symposium on Mutations in the Human Genome, Italy, May 1999).

18. Ratner, L.E., **R.A. Montgomery**, A.K. Mandal, M. Fabrizio and L.R. Kavoussi. Laparoscopic live donor nephrectomy: pre-operative assessment of technical difficulty. (Platform presentation at South-Eastern Organ Procurement Foundation Scientific Sessions, Memphis, September 1999).

19. Ratner, L.E., **R.A. Montgomery**, K. King, B. Fivush, P. Colombani,, L.C. Racusen, D. Lucas and A.A. Zachary. Successful treatment of antibody-mediated renal allograft rejection with plasmapheresis and intravenous immune globulin (PP/IVIG). (Platform presentation at the Minneapolis Transplant Congress, Minneapolis, October, 1999).

20. **Montgomery, R.A.,** A. Zachary, L. Racusen, M. Lefelle, K. King, J.F. Burdick, W.R. Maley, J. Markowitz, C. Cohen and L.E. Ratner. Plasmapheresis (PP) and intravenous immune globulin (IVIG) provides effective rescue therapy for refractory humoral rejection in renal allografts. (Platform presentation at the Annual Meeting of the American Society of Transplantation, Chicago, May 2000).

21. Ratner, L.E., S. Humphries, D. Edwin, J. Markowitz, **R.A. Montgomery,** W. Maley, J. Burdick. Are altruistic strangers an untapped source of organs for transplantation? (Platform presentation at the Annual Meeting of the American Society of Transplantation, Chicago, May 2000).

22. Ratner, L.E. K. King, A. Zachary, C. Cohen, W. Maley, J. Burdick, J. Markowitz, M. Lefell and **R.A. Montgomery**. Successful abrogation of a positive crossmatch with plasmapheresis and intravenous immune globulin in live donor renal transplantation. (Platform presentation at the Annual Meeting of the American Society of Transplantation, Chicago, May 2000).

23. Geetha, D., Y. Talusan, L. Racusen, L. Ratner, J. Burdick, **R.A. Montgomery,** W. Maley, E. Kraus and J. Markowitz: Human polyoma virus infection causing renal allograft dysfunction: A consequence of potent immunosuppression. (Platform presentation at the Annual Meeting of the American Society of Transplantation, Chicago May 2000).

24. **Montgomery, R.A.,** L.R. Kavoussi, C. Cohen, W.R. Maley, J.F. Burdick, J. Markowitz, and L.E. Ratner. Improved recipient results after 5 years of performing the laparoscopic donor nephrectomy. (Platform presentation at the International Transplantation Society Meeting, Italy, August 2000).

25. Ratner, L.E. L.R. Kavoussi, P.M. Colombani, **R.A. Montgomery**, A.M. Neu, and B. Fivush. Recipient outcomes in children receiving kidneys from live donors undergoing laparoscopic live donor nephrectomy. (Platform presentation at the First IPTA Meeting on Pediatric Transplantation, Italy, August 2000)

26. Judge, D., S. Martin, N. Williams, **R.A. Montgomery,** H. Dietz, and S. Chatterjee. Neutral sphingomyelinase-deficient cells are resistant to apoptosis caused by pro-inflammatory cytokines. (Platform presentation at the American Society of Human Genetics 73rd Annual Meeting, Philadelphia, October 2000).

27. Sonnenday, C., S. Cooke, D. Warren, H. Dietz, L.R Ratner, and **R.A.**

**Montgomery**. An *in situ* expressed chimeric antisense vector inhibits ICAM-1 expression on vascular endothelium. (Platform presentation at the Society of University of Surgeons 62nd Annual Meeting, Resident’s Section Chicago, February 2001).

28. Sonnenday, C., S. Cooke, D. Warren, H. Dietz, and **R.A. Montgomery**. U1

snRNA/ribozyme chimeric vectors as a novel vehicle for the delivery of *in situ* expressed regulatory molecules. (Vector targeting strategies for gene therapy, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, March, 2001).

29. Samaniego, M., H. Tan, K. King, **R.A. Montgomery,** M. Hass, L. Ratner, and A. Zachary. Anti-CD20 monoclonal antibody rescue therapy for refractory antibody-mediated rejection. (Platform presentation at the Transplant 2001 The American Society of Transplantation Meeting, Chicago, May 2001).

30. Ratner, L.E., K. King, H.P. Tan, A. Zachary, M.D. Samaniego, E.S. Kraus, M. Cooper, and **R.A. Montgomery.**  Plasmapheresis (PP) and intravenous immune globulin(IG) for the treatment and prevention of antibody-mediated rejection in renal transplantation. (Platform presentation at the Transplant 2001 The American Society of Transplantation Meeting, Chicago, May 2001).

31. Ratner, L.E., V. Sinkov, **R.A. Montgomery,** K. Fox-Talbot, H. Tan, M. Cooper, and L. Kavoussi. Laparoscopic live donor nephrectomy: Global-status at the millennium. (Platform presentation at the Transplant 2001 The American Society of Transplantation Meeting, Chicago, May 2001).

32. Rudick, J., J. Eustace, J.S. Markowitz, H.P. Tan, L. Lees, **R.A. Montgomery,** L.E. Ratner, and M. Samaniego. Thymoglobulin is as effective as OK-T3 monoclonal antibody in the treatment of histologically severe acute rejection in kidney allograft recipients. (Platform presentation at the Transplant 2001 The American Society of Transplantation Meeting, Chicago, May 2001).

33. Sonnenday, C., S. Cooke, D. Warren, H. Dietz, L.R Ratner, and **R.A.**

**Montgomery**. A novel strategy for interrogating the function of individual genes in the ischemia/reperfusion injury (IRI) pathway. (Platform presentation at the International Conference on Transplantation, Nagoya, Japan, July 2001).

34. **Montgomery, R.A**, P.A. Frishmeyer\*, S.K. Cooke, D.S. Warren, C.J. Sonnenday, H.C. Dietz. Pertubation of thymic development in nonsense-mediated decay-deficient mice. (Platform presentation and **winner of Doctoral Student Basic Science Research Award-2001 Awards Competition**, The American Society of Human Genetics 51st Annual Meeting, San Diego, CA, October 2001) \*equal contributor and presenter.

35. Sonnenday, C. J., L.E. Ratner, J.F. Burdick, M.D. Samaniego, E. Kraus, D.S.

Warren, and **R.A. Montgomery**. Pre-emptive therapy with Plasmapheresis/intravenous immune globulin(PP/IVIG) allows successful live donor renal transplantation in patients with a positive crossmatch. (Platform presentation and **winner of The Young Investigator’s Award** at The 2nd International Congress on Immunosuppression, San Diego, CA, December, 2001).

36. Racusen LC, **Montgomery RA**, Samaniego M, Sonneday C, Zachary A, Kraus E, Haas M. Biopsy (BX) findings in sensitized patients receiving renal transplant (TX) after pre-emptive Plasmapheresis/IVIG. (Platform presentation at The American Congress of Transplantation Meeting, Washington, April 2002).

37. **Montgomery, R.A**., M.D. Samaniego, A.A. Zachary, C. Sonnenday, D. Warren,

E. P. Molmenti and L.R Ratner. Differing patterns of antibody suppression and re-emergence between ABO and positive crossmatch kidney transplants. (Platform presentation at The American Congress of Transplantation Meeting, Washington, April 2002).

38. Samaniego, M.D., A.A. Zachary, D. Lucas, H. Haas, K. King, L.R. Ratner, and

**R.A. Montgomery.** Early Allograft Outcomes in Patients with Antibody- Mediated Rejection Treated with Rituximab: A single Center Experience. (Platform presentation at The American Congress of Transplantation Meeting, Washington, April 2002).

39. Sonnenday, C.J., E. Kraus, F.A. Gage, L.E. Ratner, J.F. Burdick, and **R.A.**

**Montgomery**. Cadaveric kidneys from extended criteria donors treated with pulsatile perfusion have durable long-term function comparable to kidneys from ideal donors. (**Henry Christian Award Winner**, American Federation for Medical Research Clinical Research Meeting, April 2002 and poster presentation at the American Transplant Congress, April 2002).

40. Jacobbi, L.M., S.T. Bartlett, **R.A. Montgomery**, and F. Gage. Machine

Preservation Can Maximize the Current Organ Pool and Significantly Increase the Number of Kidneys Available for Transplantation (Platform presentation at XIX International Congress of the Transplantation Society, August 2002).

41. **Montgomery, R.A**., C.J Sonnenday, E. Kraus, F.A. Gage, and J.F. Burdick.

Pulsatile perfusion protects extended criteria cadaveric kidneys from graft loss. (Platform presentation at XIX International Congress of the Transplantation Society, August 2002).

42. Sonnenday, C.J., M. Cooper, C. Handley, F.A Gage, E. Krause, and **R.A.**

**Montgomery.** The hazards of basing acceptance of cadaveric renal allografts on pulsatile perfusion parameters alone. (Platform presentation at XIX International Congress of the Transplantation Society, August 2002).

43. **Montgomery, R.A**., C.J. Sonnenday, M.D. Samaniego, A.A. Zachary, D.S.

Warren and L.E. Ratner. Antibody suppression and re-emergence in positive crossmatch and ABO incompatible kidney transplant recipients. (Platform presentation at XIX International Congress of the Transplantation Society, August 2002).

44. Sonnenday C.J., L.E Ratner,M.D. Samaniego, A.A. Zachary, K.E. King, L.C.

Racusen, D.S. Warren, and **R.A. Montgomery.** Durable Graft Function and Donor –Specific Antibody Suppression Following live donor renal transplantation in patients Treated with pre-emptive plasmapheresis/intravenous immunoglobulin. (Platform presentation at XIX International Congress of the Transplantation Society, August 2002).

45. **Montgomery, R.A.,** C.J. Sonnenday, E. Kraus, F.A. Gage, and J.F. Burdick. Pulsatile perfusion protects extended criteria cadaveric kidneys from graft loss. (Platform presentation at XIX International Congress of the Transplantation Society, August 2002).

46. Sonnenday, C.J., M. Cooper, E. Kraus, F. Gage, C. Hadley and **R.A. Montgomery.** The hazards of basing acceptance of cadaveric renal allografts on pulsatile perfusion parameters alone. (Platform presentation at XIX International Congress of Transplantation Society, August 2002).

47. Sonnenday, C.J., J. Graziani, A.A. Zachary, K.E. King, M. Haas, M. Saminiego and **R.A. Montgomery.** Characterization of acute rejection episodes following pre-emptive plasmapheresis/CMVIg to abrogate a positive crossmatch and allow live donor renal transplantation. (Platform presentation at The American Congress of Transplantation Meeting, Washington, May, 2003).

48. Sonnenday, C.J., D.S. Warren, A.A. Zachary, K. King, M. Cooper, M. Haas and **R.A. Montgomery.** Renal transplantation in patients who have both a positive crossmatch and ABO incompatibility with their live donor. (Platform presentation at The American Congress of Transplantation Meeting, Washington, May, 2003).

49. Jacobbi, L.M., F. Gage, **R.A. Montgomery** and C.J. Sonnenday. Machine preservation improves functional outcomes in cadaveric renal transplantation. (Platform presentation at The American Congress of Transplantation Meeting, Washington, May, 2003).

50. **Montgomery, R.A.,** C.E. Simpkins, A.A. Zachary, L. Lees, D.S. Warren, M. Cooper and M. Samaniego. Anti-CD 20 rescue therapy for kidneys undergoing antibody-mediated rejection. (Platform presentation at The American Congress of Transplantation Meeting, Boston, MA, May, 2004).

51. Ugarte, R.M., L. Racusen, M. Haas, M.S. Leffell, A. Zachary, M. Samaniego-Picota, E. Molmenti, M. Cooper, **R.A. Montgomery,** H. Rabb and E.S. Kraus. Thymoglobulin versus no induction in adult primary deceased-donor renal transplant recipients on maintenance tacrolimus, mycophenolate mofetil, and prednisone: a single-center longitudinal study. (Platform presentation at The American Congress of Transplantation Meeting, Boston, MA, May, 2004).

52. Leffell, M.S., D. Kopchaliiska, **R.A. Montgomery** and A.A. Zachary. Frequencies of alloreactive B lymphocytes in renal transplant patients with historic and current sensitization to HLA antigens. (Plateform presentation at The American Congress of Transplantation Meeting, Boston, MA, May, 2004).

53. Simpkins, C.E., A.A. Zachary, M. Cooper, D.S. Warren, L.E. Ratner and **R.A. Montgomery.** Improved results with selective use of splenectomy and anti-CD 20 for positive crossmatch transplants. (Platform presentation at The American Congress of Transplantation Meeting, Boston, MA, May, 2004).

54. Cooper M., D.S. Warren, C.E. Simpkins, D. Segev, J. Hiller, J. Rickard, H. Rabb, A.A. Zachary, J. Graziani, V. Collins and **R.A. Montgomery.**  Conventional and unconventional paired kidney exchanges. (Platform presentation at XX International Congress of the Transplantation Society, Vienna, Austria, September, 2004).

55. Simpkins, C.E., D.S. Warren, C.J. Sonnenday, A.A. Zachary, M. Cooper, L. Lees, L.E. Ratner and **R.A. Montgomery.** Improved results with selective use of splenectomy and anti-CD 20 for positive crossmatch transplants. (Platform presentation at XX International Congress of the Transplantation Society, Vienna, Austria, September, 2004).

56. **Montgomery, R.A.,** C.E. Simpkins, D.S. Warren, A.A. Zachary, M. Cooper, K. King, L. Lees, M. Haas, V. Collins, M. Samaniego. Anti-CD 20 rescue therapy for acute antibody-mediated rejection in kidney transplant recipients. (Platform presentation at XX International Congress of the Transplantation Society, Vienna, Austria, September, 2004).

57. Warren, D.S., C.E. Simpkins, C.J. Sonnenday, Y. Yan, S.K. Cooke, A. Williams and **R. A. Montgomery.** In vivo RNA interference: reducing ischemia/reperfusion injury in allotransplantation. (**Combined Clinical and Basic Science Plenary Presentation** for at The American Congress of Transplantation Meeting, Seattle, Washington, May, 2005).

58. Zachary, A.A., **R.A. Montgomery,** C.E. Simpkins, D.S. Warren and M.S. Leffell. Impact of persistent, low levels of donor-specific antibody on renal transplants. (Platform presentation at The American Congress of Transplantation Meeting, Seattle, Washington, May, 2005).

59. **Montgomery, R.A.,** M. Cooper, A.A. Zachary, M.S. Leffell, J.M. Hiller and D.S. Warren. Excellent graft outcomes achieved with paired kidney exchange. (Platform presentation at The American Congress of Transplantation Meeting, Seattle, Washington, May, 2005).

60. Warren, D.S., C.E. Simpkins, K.E. King, A.A. Zachary, C.J. Sonnenday, M. Cooper, J.K. Melancon, D. Segev, T. Kozlowski, H. Rabb, R.S. Shirey and **R.A. Montgomery.** Excellent results achieved for ABOI renal allografts with or without splenectomy. (Platform presentation at The American Congress of Transplantation Meeting, Seattle, Washington, May, 2005).

61. Segev, D.L., S.E. Gentry, D.S. Warren, B. Reeb, C.E. Simpkins and **R.A. Montgomery.** Paired kidney exchange – the need for mathematically verifiable optimization. (Platform presentation at The American Congress of Transplantation Meeting, Seattle, Washington, May, 2005).

62. Sun, Z., Q. Zheng, Y. Nagakawa, G.M. Williams, **R.A. Montgomery,** A.M. Diehl and A.S. Klein. Repopulation of liver allografts by recipient-derived progenitor cells via mixed cell fusion and transdifferentiation: a new insight of tolerance and regeneration. (Platform presentation at The American Congress of Transplantation Meeting, Seattle, Washington, May, 2005).

63. Ugarte, R., T. Mehta, A. Hawxby, S. Karp, **R.A. Montgomery,** M. Cooper, H. Rabb, L. Racusen, M. Haas, A.A. Zachary, M. Leffell and E. Kraus. Donor acute tubular necrosis predicts early acute rejection in deceased-donor renal transplants: a single-center longitudinal study. (Platform presentation at The American Congress of Transplantation Meeting, Seattle, Washington, May, 2005).

64. Zachary AA, Simpkins CE, Warren DS, Leffell MD, **Montgomery RA**. Desensitization, persistent antibody, and graft function in renal transplantation. (Platform presentation at The 35th Annual Scientific Meeting of the Australasian Society for Immunology and 14th International HLA & Immunogenetics Workshop, Melbourne, Australia, December 2005).

65. Locke JE, Simpkins CE, Gentry SE, Warren DS, **Montgomery RA**. Changing trends in the impact of HLA mismatch on outcomes of live donor kidney transplants. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

66. Segev DL, Simpkins CE, Locke JE, Warren DS, **Montgomery RA**. The burden of obesity on waiting for deceased donor kidneys. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

67. Zachary AA, Kopchaliiski D, **Montgomery RA**, Melancon JK, Leffell MS. Predicting post-transplant de novo production of HLA-specific antibody. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

68. Simpkins CE, **Montgomery RA**, Gentry SE, Locke JE, Warren DS, Segev DL. The effect of cold ischemic time on live donor renal transplantation: is organ transport feasible for live donors? (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

69. Lee KW, Simpkins CE, **Montgomery RA**, Locke JE, Segev DL, Maley, WR. Factors affecting survival following liver transplantation from non-heart beating donors. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

70. Melancon JK, Simpkins CE, Locke JE, **Montgomery RA**, Segev DL. Racial and financial disparities in multiple listings from renal transplantation. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

71. Segev DL, Simpkins CE, Locke JE, Thuluvath PJ, **Montgomery RA**, Maley WR. The effect of obesity on liver transplant waiting times in the era of meld. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

72. Locke JE, Zachary AA, Warren DS, Houp JG, **Montgomery RA**, Leffell MS. The impact of proinflammatory events on antibody levels in sensitized patients. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

73. Segev DL, Maley WR, Simpkins CE, Locke JE, **Montgomery RA**, Thuluvath PJ. Liver transplantation from elderly donors (over 70) in the era of meld. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

74. Zachary AA, Lucas DP, **Montgomery RA**, Warren DS, Simpkins CE, Leffell MS. Mechanisms of desensitization: the role of plasmapheresis. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

75. Locke JE, Simpkins CE, **Montgomery RA**, Segev DL. Do ECD criteria apply to kidneys donated after cardiac death? (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

76. Locke JE, Simpkins CE, **Montgomery RA**, Segev DL. Long-term outcomes from kidneys donated after cardiac death. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

77. Kraus ES, Lepley D, Segev DL, Bagnasco S, Haas M, Racusen L, Warren DS, Simpkins CE, Leffell MS, Zachary AA, Ugarte R, Rabb H, **Montgomery RA**. The utility of protocol biopsies in incompatible kidney transplant recipients. (Platform presentation at The First Joint International Transplant Meeting, Boston, Massachusetts, July 2006).

78. Simpkins CE, Warren DS, Sun Z, Allen G, Sonnenday C, Cooke S, Chivukula R, Baldwin W, Wasowska B, **Montgomery RA**. Characterization of two small animal models for the evaluation of antibody-mediated rejection therapies in transplantation. (Platform presentation at the American College of Surgeons 92nd Annual Clinical Congress. Working Together Toward Humanitarian Ideals, Chicago, IL, October, 2006).

79. Segev DL, Simpkins CE, Warren DS, King KE, Shirey RS, Maley WR, Melancon JK, Locke JE, **Montgomery RA**. Excellent graft function 1 year or longer following high-titer ABO incompatible renal transplantation without anti-CD20 or splenectomy. (Platform presentation at the Canadian Society of Transplantation. Banff, Alberta Canada, March 2007).

80. Locke JE, **Montgomery RA**, Warren DS, Simpkins CE, Segev DL. Should all kidneys donated after cardiac death be considered marginal? (Platform presentation and **winner of the Best Resident Paper** at the Canadian Society of Transplantation. Banff, Alberta Canada, March 2007).

81. Segev DL, Maley WR, Simpkins CD, Locke JE, **Montgomery RA**, Thuluvath PJ. Liver allografts from elderly donors – how old is too old? (Platform presentation at the Canadian Society of Transplantation. Banff, Alberta Canada, March 2007).

82. Segev DL, Locke JE, Simpkins CE, King KE, Shirey RS, Tan M, Melancon JK, Warren DS, **Montgomery RA**. A single-center evolution of ABO incompatible renal transplantation: less is more. (Platform presentation at the American Transplant Congress Meeting, San Francisco, California, May 2007).

83. Locke JE, **Montgomery RA**, Warren DS, Simpkins CE, Segev DL. The effect of center volume on the long-term graft survival of pulsatile perfusion preserved kidneys. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California. May 2007).

84. Kopchaliiska D, Zachary AA, **Montgomery RA**, Leffell MS. Characterization of HLA specific B Cell populations after B lymphocyte depletion. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California. May 2007).

85. Kraus E, Lepley D, Segev D, Leffell M, Lucas D, Haas M, Racusen L, Bagnasco S, Collins V, Simpkins C, Warren D, **Montgomery R**. Donor specific antibody (DSA) and C4d+ in surveillance biopsies following positive cross match live donor kidney transplantation. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California. May 2007).

86. Liu X, Locke J, Warren D, Zhang X, Tachibana S, **Montgomery RA**, Williams GM, Sun Z. Cyclosporine A, and not prednisone reduces CD4+CD25+Foxp3+T cells after liver transplantation in rats. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California. May 2007).

87. Lee KW, **Montgomery RA**, Cameron AM, Segev DL, Simpkins CE, Locke JE, Maley WR. Factors affecting survival following split liver transplantation in children: analysis of UNOS/OPTN database. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California. May 2007).

88. Segev DL, Locke JE, Simpkins CE, Warren DS, **Montgomery RA**. Regional and racial disparities in use of the live non-directed donors. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California. May 2007).

89. Simpkins CE, Locke JE, **Montgomery RA**, Warren DS, Reeb BE, Segev DL. Impact of socioeconomic status on graft survival following preemptive live donor renal transplantation. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California, May 2007).

90. Locke JE, **Montgomery RA**, Warren DS, Simpkins CE, Segev DL. Risk factors predictive of renal allograft loss among HIV positive recipients. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California, May 2007).

91. Lee KW, **Montgomery RA**, Cameron AM, Segev DL, Simpkins CE, Locke JE, Maley WR. Factors affecting survival following split liver transplantation in adulthood: analysis of UNOS/OPTN database. (Platform presentation at the American Transplant Congress Meeting San Francisco, California. May 2007).

92. Sonnenday CJ, Warren DS, Locke JE, Collins V, Simpkins CE, Kraus ES, Haas M, Rabb H, **Montgomery RA**. Routine pulsatile perfusion does not improve early outcomes from ECD kidneys: results of a prospective trial. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California. May 2007).

93. Passaretti CL, Lee VE, Simpkins CE, Leffell MS, Zachary AA, Dropulic LK, **Montgomery RA**, Subramanian AK. Spectrum of infectious complications following ABO or HLA incompatible kidney transplants. (Platform presentation at the American Transplant Congress Meeting. San Francisco, California May 2007).

94. Segev DL, Locke JE, Simpkins CE, Warren DS, **Montgomery RA**. Kidneys transplanted after many refusals: who uses them and how do they do? (Platform presentation at the American Transplant Congress Meeting. San Francisco, California May 2007).

95. Segev DL, Kucirka LM, Oberai P, Parekh R, **Montgomery RA**. Gender disparities in access to transplantation for elderly patients. (Platform presentation at the American Society of Transplant Surgeons 8th Annual State of the Art Winter Symposium: The High Risk Recipient. Marco Island, Florida January 2008).

96. Locke JE, Warren DS, Singer AL, Segev DL, Simpkins CE, Maley WR, **Montgomery RA**, Danovitch G, Cameron AM. Declining outcomes in simultaneous liver kidney transplantation in the MELD era: ineffective utilization of renal allografts. (Platform presentation at the American Society of Transplant Surgeons 8th Annual State of the Art Winter Symposium The High Risk Recipient. Marco Island, Florida January 2008).

97. Segev DL, Kucirka LM, **Montgomery RA**. Expanded criteria donors and elderly patients: allocation and outcomes. (Platform presentation at the American Society of Transplant Surgeons 8th Annual State of the Art Winter Symposium The High Risk Recipient. Marco Island, Florida January 2008).

98. Segev DL, Kucirka LM, **Montgomery RA**. Obesity, access to transplantation, and survival benefit. (Platform presentation at the American Transplant Congress, Toronto, Canada May 2008).

99. Kucirka LM, **Montgomery RA**, Segev DL. Gender disparities in access to transplantation are worsened by age and comorbidities. (Platform presentation at the American Transplant Congress, Toronto, Canada May 2008).

100. Segev DL, **Montgomery RA**. The effect of DonorNet on allocation efficiency of exported organs. (Platform presentation at the American Transplant Congress, Toronto, Canada May 2008).

101. Rees, MA, Kopke JE, Hil G, Reitsma W, Pankewycz OG, Miller AL, Hawxby AM, **Montgomery RA**, Abraham D, Sandholm T, Roth AR, Somnez T, Unver MU. The never-ending altruistic donor. (Platform presentation at the American Transplant Congress, Toronto, Canada May 2008).

102. Locke J, Warren D, Dominici F, Cameron A, Leffell M, Zachary A, Melancon J, Segev D, Singer A, **Montgomery RA**. The influence of donor and recipient ethnicity on outcomes following donation after cardiac death kidney transplantation. (Platform presentation at the XXII International Congress of The Transplantation Society, Sydney, Australia. August, 2008).

# 103. Singer A, Locke J, Haas M, Stewart Z, King K, Melancon JK, Segev D, Warren D, **Montgomery RA**. Elimination of splenectomy and anti-CD20 therapy does not result in increased chronic allograft nephropathy: A single center experience in ABO-incompatible renal transplantation. (Platform presentation at the XXII International Congress of The Transplantation Society, Sydney, Australia. August, 2008).

104. Stewart ZA, Cameron AM, Dagher NN, Singer AL, **Montgomery RA**, Segev DL. Use of Histidine-Tryptophan-Ketoglutarate for Pancreas Allograft Preservation is not cost effective resource utilization. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

105. Lonze BE, Melancon JK, Zhang, X, Singer AL, Cameron AM, Segev DL, **Montgomery RA**, Warren DS, Williams GM, Sun Z. Mitochondrial Membrane Potential as a predictor of post-transplant renal graft function. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

106. Stewart ZA, Lonze BE, Warren DS, Dagher NN, Singer AL, **Montgomery RA**, Segev DL. Histidine-Tryptophan-Ketoglutarate (HTK) is Associated with reduced graft survival of deceased donor kidney transplants. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

107. Locke JE, Simpkins CE, Leffell MS, Andrea AA, Collins V, Warren DS, Segev DL, Singer AL, Haas, M, **Montgomery RA**. Induction Immunosuppression in Crossmatch positive renal transplant recipients: Results of a randomized controlled clinical trial. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

108. Zachary AA, Lucas DP, **Montgomery RA**, Leffell MS. Effect of desensitization on complement activation by HLA-Specific Antibodies. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

109. Kucirka LM, Hanrahan CF, Namuyinga R, **Montgomery RA**, Segev DL. OPO Viral Nucleic Acid testing (NAT) and provider utilization of high-risk donor organs: results of Two National Surveys. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

110. Stewart ZA, Cameron AM, Dagher NN, Singer AL, **Montgomery RA**, Segev DL. Use of Histidine-Tryptophan-Ketoglutarate for Liver Allograft preservation reduces graft survival and is not cost-effective resource utilization. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

111. Segev DL, Powe NR, Troll MU, Wang NY, **Montgomery RA**, Boulware E. Factors influencing willingness of the general population to participate in kidney paired donation. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

112. Rees M, Segev DL, Chan L, Mulgaonkar S, Pankewycz O, Bowers V, VanBuren C, Pelletier R, Nibhunupudy B, Fabrega A, Rogers J, **Montgomery RA**. Experience with over 50 Altruistic and “Bridge” Donors involved in never-ending Altruistic Donor Chains and Kidney Paired Donation. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

113. Kucirka LM, Hanrahan CF, Namuyinga R, **Montgomery RA**, Segev DL. Special informed consent and hospital policies are associated with increased utilization of high risk donor organs. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

114. Hanrahan CF, Kucirka LM, **Montgomery RA**, Segev DL. Racial Disparities in Access to kidney transplantation differ by appropriateness for transplantation. (Platform presentation at the American Transplant Congress, Boston, MA May 2009).

115. Kucirka LM, Govindan P, **Montgomery RA,** Segev DL. Disparities in allocation of HCV+ Kidneys. (Platform presentation at the American Society of Transplant Surgeons 10th Annual State of the Art Winter Symposium “The Cutting Edge of Transplant Surgery” Fort Lauderdale, FL January 2010).

116. Segev DL, Muzaale A, Caffo B, **Montgomery RA**. Short-Term Survival in a 15-Year Cohort of All Live Kidney Donors in the United States. (Platform presentation at the American Society of Transplant Surgeons 10th Annual State of the Art Winter Symposium “The Cutting Edge of Transplant Surgery” Fort Lauderdale, FL January 2010).

117. Dagher N, Singer A, Desai N, **Montgomery RA**, Segev DL. Outcomes and Discard of Kidneys from Pediatric Donors After Cardiac Death. (Platform presentation at the American Society of Transplant Surgeons 10th Annual State of the Art Winter Symposium “The Cutting Edge of Transplant Surgery” Fort Lauderdale, FL January 2010).

118. Massie AB, Desai NM, **Montgomery RA**, Signer AL, Segev DL. Improving Allocation Efficiency of Hard-to-Place Deceased Donor Kidneys: Predicting Probability of Discard or Delay. (Platform presentation at the American Transplant Congress, San Diego, California May 2010).

119. Grams ME, Womer KL, Ugarte RM, Desai NM, **Montgomery RA**, Segev DL. Listing for Expanded Criteria Donor Kidneys in Older Adults and Those with Predicted Benefit. . (Platform presentation at the American Transplant Congress, San Diego, California May 2010).

120. Segev DL, Veale J, Leeser D, Hiller J, Bry W, Melcher M, Malinzak L, Katznelson S, Tchervenkov J, Kapur S, Hanto R, Roberts J, Rees M, **Montgomery R**. Transporting Kidneys for Live Donor Kidney Transplant: National Results. (Platform presentation at the American Transplant Congress, San Diego, California May 2010).

121. Jackson AM, Houp JA, **Montgomery RA**, Leffell MS, Zachary AA. Paired Kidney Donation (PKD): The Impact on sensitized Patients. (Platform presentation at the American Transplant Congress, San Diego, California May 2010).

122. Segev DL, Garonzik-Wang J, Kucirka L, Berger J, **Montgomery RA**. Incompatible Live Donor Kidney Transplantation in the United States: Results of a National Survey. (Platform presentation at the American Transplant Congress, San Diego, California May 2010).

123. Dagher NN, Lone BE, Kucirka LM, Simpkins CE, Kremer EE, Desai NM, Cameron AM, Segev DL, **Montgomery RA**, Singer AL. Renal Transplants from CDC High-Risk Donors: What’s the Risk and for Whom Is It Justified? (Platform presentation at the American Transplant Congress, San Diego, California May 2010).

124. Segev D, Muzaale A, Caffo B, Mehta S, Singer A, McBride M, **Montgomery RA**. Short-Term and Long-Term Survival in a 15-Year Cohort of All Live Kidney Donors in the United States. (Platform presentation at the American Transplant Congress, San Diego, California May 2010).

125. Hisada M, Williams GM, Zhang X, Okabayashi T, Cameron AM, **Montgomery RA**, Sun Z. Improved Survival with Transplantation of Reduced Size Alcoholic Fatty Liver Grafts Compared to Whole Grafts Via Mobilization of Recipient Bone Marrow Stem Cells in Rats. (Platform presentation at the American Transplant Congress, San Diego, California May 2010).

126. Lonze BE, Dagher NN, Simpkins CE, Segev DL, Singer AL, Cohney S, Alachkar N, **Montgomery RA**. Eculizumab Prevents Recurrence of Antiphospholipid Antibody Syndrome (APS) in Renal Allografts. (Platform presentation at the XXIII International Congress of The Transplantation Society, Vancouver, BC, Canada. August 2010).

127. Lonze BE, Segev DL, Dagher NN, Simpkins CE, Locke JE, Kucirka LM, Singer AL, Zachary AA, **Montgomery RA**. Outcomes of Patients Desensitized for a Positive Crossmatch Compared to Patients Who Are Not Offered This Option. (Platform presentation at the XXIII International Congress of The Transplantation Society, Vancouver, BC, Canada. August 2010).

128. Lonze BE, Dagher NN, Simpkins CE, Locke Je, Segev DL, Singer AL, Hiller J, Collins V, **Montgomery RA**. 100 Kidney Transplants Performed Via Kidney Paired Donation at The Johns Hopkins Hospital. (Platform presentation at the XXIII International Congress of The Transplantation Society, Vancouver, BC, Canada. August 2010).

129. Locke JE, Lonze B, Singer AL, Cameron AM, Warren DS, **Montgomery RA**, Segev DL. Risk Factors Predictive of Live Allograft Loss among HIV Positive Recipients. (Platform presentation at the American Transplant Congress, San Diego, California May 2010).

130. Kucirka LM, **Montgomery RA**, Ellison R, Wolf J, Segev DL. Risk of Window Period HIV and HCV Infection in DCD High Risk Donors: A Systematic Review and Meta-Analysis. (Platform presentation at the American Society of Transplant Surgeons 11th Annual State of the Art Winter Symposium “Transplantation at the Crossroads”. Hollywood, FL. January 2011).

131. Muzaale AD, Dagher NN, **Montgomery RA**, Segev DL. Acute Liver Failure, Early Death and Long-Term Mortality in 3800 Living Liver Donors. (Platform presentation at the American Society of Transplant Surgeons 11th Annual State of the Art Winter Symposium “Transplantation at the Crossroads”. Hollywood, FL. January 2011).

132. Muzaale AD, Berger J, **Montgomery RA**, Segev DL. The Decline in Live Kidney Donor Transplantation in the United States: A Multivariate Analysis. (Platform presentation at the American Society of Transplant Surgeons 11th Annual State of the Art Winter Symposium “Transplantation at the Crossroads”. Hollywood, FL. January 2011).

133. Van Arendonk KJ, James NT, Locke JE, Colombani PM, **Montgomery RA**, Segev DL. Deceased Late Graft Survival in Pediatric Recipients of DCD Kidneys. (Platform presentation at the American Society of Transplant Surgeons 11th Annual State of the Art Winter Symposium “Transplantation at the Crossroads”. Hollywood, FL. January 2011).

134. Massie AB, **Montgomery RA**, Segev DL. Does the Kidney Donor Index Need Non-Donor Factors? (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

135. Garonzik Wang JM, James NT, Witherspoon KC, Berger JA, Hall EC, **Montgomery RA**, Segev DL. The Aggressive Phenotype: Center-Level Patterns in the Utilization of Sub-Optimal Kidneys. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

136. Chow E, Muzaale A, Singer AL, Kucirka L, **Montgomery RA**, Segev DL. A Novel Tool for Identifying Appropriate Patients for CDC High Infectious Risk Donor Kidneys. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

137. Garonzik Wang J, James N, Van Arendonk K, Deshpande N, Hall E, Berger J, **Montgomery RA**, Segev DL. Third and Fourth Kidney Transplant Recipients: Who Are They and Was It Worth the Last Transplant? (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

138. Boyarsky BJ, Hall EC, Deshpande NA, **Montgomery RA**, Segev DL. Limited Impact of Presumed Consent Legislation on Deceased Donation Rates. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

139. Muzaale AD, Dagher NN, **Montgomery RA**, Segev DL. Acute Liver Failure, Early Death and Long-Term Mortality in Living Liver Donors. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

140. Segev DL, Berger J, Montgomery JR, Simpkins C, King K, **Montgomery RA**. Outcomes of 95 Consecutive ABO Incompatible Kidney Transplants Are Equivalent to Matched Controls. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

141. Muzaale AD, Berger JC, **Montgomery RA**, Segev DL. The Decline of Live Kidney Donor Transplantation in the United States: A Multivariate Analysis. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

142. Massie AB, Bingaman A, **Montgomery RA**, Segev DL. Center-Level Variation in Utilization (and Underutilization) of Kidney Paired Donation. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

143. Segev DL, Garonzik Wang J, Gloor J, Stegall M, Kapur S, Dunn T, Pelletier R, Singh P, Posner M, Shapiro R, El-Amm JM, Light J, Marsh C, Melancon JK, Lipkowitz G, Wellen J, Oberholzer J, **Montgomery RA**. Risks of HLA Incompatible Kidney Transplants by Antibody Strength: Initial Results from a National Study of 603 Patients. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

144. Locke JE, Singer AL, Desai N, **Montgomery RA**, Segev DL. Equivalent Outcomes for NIH Study Protocol and Non-Protocol HIV- Infected Kidney Transplant Recipients. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

145. Bone CW, Kucirka L, Ros L, **Montgomery RA**, Segev DL. Risk Perception and Patient Willingness To Accept High Infectious Risk Donor Kidneys. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

146. Kucirka L, Ros RL, Bone C, **Montgomery RA**, Segev DL. Discrepancies between Patient, Provider and Evidence-Based Risk Estimates Regarding High Infectious Risk Donor Organs. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

147. Van Arendonk KJ, James NT, Locke JE, **Montgomery RA**, Colombani PM, Segev DL.

Late Graft Loss among Pediatric Recipients of DCD Kidneys. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

148. Massie AB, Hall EC, **Montgomery RA**, Segev DL. African-American Patients Are Not at Increased Risk of Graft Failure among Older Patients or Diabetic Patients. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

149. Kucirka L, Weatherspoon K, Van Arendonk K, Montgomery JR, Deshpande N, Law A, Bone C, **Montgomery RA**, Segev DL. Potential New High Infectious Risk Donor Categories: Results of a Systematic Review and Meta-Analysis. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

150. Deshpande NA, Kucirka LM, Boyarsky BJ, Garonzik Wang JM, **Montgomery RA**, Segev DL. Pregnancy Outcomes in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis. (Platform presentation at the American Transplant Congress, Philadelphia, PA. May 2011).

151. Garonzik Wang JM, James NT, VanArendonk KJ, Gupta N, Hall EC, **Montgomery RA**, Segev DL. The Liver Aggressive Phenotype: Center-Level Patterns in the Utilization of Suboptimal Liver Allografts. (Platform presentation at the American Society of Transplant Surgeons 12th Annual State of the Art Winter Symposium, Miami, FL. January 2012).

152. VanArendonk KJ, James NT, Garonzik Wang JM, **Montgomery RA,** Colombani PM, Segev DL. Age at Graft Loss after Pediatric Kidney Transplantation. (Platform presentation at the American Society of Transplant Surgeons 12th Annual State of the Art Winter Symposium, Miami, FL. January 2012).

153. VanArendonk KJ, James NT, Garonzik Wang JM, **Montgomery RA**, Colombani PA, Segev DL. Order of Donor Type in Pediatric Kidney Transplantation. (Platform presentation at the American Society of Transplant Surgeons 12th Annual State of the Art Winter Symposium, Miami, FL. January 2012).

154. Boyarsky BJ, VanArendonk K, Deshpande NA, James NT, **Montgomery RA**, Segev DL. Race Is Associated with New Onset Hypertension and Diabetes after Living Kidney Donation. (Platform presentation at the American Society of Transplant Surgeons 12th Annual State of the Art Winter Symposium, Miami, FL. January 2012).

155. Boyarsky BJ, VanArendonk K, Deshpande NA, James NT, **Montgomery RA**, Segev DL. Difficulty Obtaining Insurance after Living Kidney Donation. (Platform presentation at the American Transplant Congress, Boston, MA. June 2012).

156. Boyarsky BJ, VanArendonk K, Deshpande NA, James NT, **Montgomery RA**, Segev DL. Race is Associated with New Onset Hypertension and Diabetes after Living Kidney Donation. (Platform presentation at the American Transplant Congress, Boston, MA. June 2012).

157. VanArendonk KJ, James NT, Boyarsky BJ, Garonzik Wang J, **Montgomery RA**, Colombani PM, Segev DL. Age at Graft Loss after Pediatric Kidney Transplantation: Understanding the High-Risk Period. (Platform presentation at the American Transplant Congress, Boston, MA. June 2012).

158. Gupta G, Abu Jawdeh BG, Bhasin B, Trollinger B, **Montgomery RA**, Womer K, Kraus E, Rabb H, Alachkar N. Outcome of Late Antibody Mediated Rejection in Renal Allografts after Conventional and Novel Therapies. (Platform presentation at the 24th International Congress of The Transplantation Society, Berlin, Germany. July 2012).

159. Sharif A, Lonze B, Hiller J, Zachary AA, Leffell MS, Alachkar N, Kraus E, Dagher N, Desai N, Segev D, **Montgomery RA**. Outcomes from Combining Kidney Paired Donation and Desensitization: An Approach to Kidney Transplantation for the Most Highly Sensitized Patients. (Platform presentation at the 24th International Congress of The Transplantation Society, Berlin, Germany. July 2012).

160. Sharif A, Alachkar N, Bagnasco S, Arend L, Racusen L, **Montgomery RA**, Kraus E. One-Year Biopsy Data of Antibody-Incompatible Kidney Transplantation and Correlation with Medium-To-Long Term Risk of Allograft Loss – a Prospective Analysis. (Platform presentation at the 24th International Congress of The Transplantation Society, Berlin, Germany. July 2012).

161. Sharif A, Alachkar N, Kraus E, Bagnasco S, Arend L, Zachary AA, Racusen L, Segev D, **Montgomery RA**. Kidney Transplantation Across Simultaneous ABO/HLA-Incompatible Immunological Barriers Is Similar to Either ABO- or HLA- Incompatible Transplantation for Safety and Efficacy. (Platform presentation at the 24th International Congress of The Transplantation Society, Berlin, Germany. July 2012).

162. Lonze BE, Zachary A, Alachkar N, Kraus ES, Locke JE, Nazarian SM, Orandi BJ, Garonzik Wang JM, Warren DS, Dagher NN, Singer AL, Desai NM, Segev DL, **Montgomery** **RA.** Outcomes of 262 Consecutive HLA-Incompatible Renal Transplants. (Platform presentation at the 24th International Congress of The Transplantation Society, Berlin, Germany. July 2012).

163. Lucas DP, Leffell MS, **Montgomery RA**, Zachary A. Rituximab Prevents Recurrence of HLA Antibody in Sensitized Patients. (Platform presentation at the 24th International Congress of The Transplantation Society, Berlin, Germany. July 2012).

164. Garonzik Wang JM, James NT, Van Arendonk KJ, Gupta N, Hall EC, **Montgomery RA**, Segev DL. The Liver Aggressive Phenotype: Center-Level Patterns in the Utilization of Suboptimal Liver Allografts. (Platform presentation at the American Society of Transplant Surgeons 12th Annual State of the Art Winter Symposium, Miami, Florida. January 2013).

165. Van Arendonk KJ, James NT, Garonzik Wang JM, **Montgomery RA**, Colombani PM, Segev DL. Age at Graft Loss after Pediatric Kidney Transplantation. (Platform presentation at the American Society of Transplant Surgeons 12th Annual State of the Art Winter Symposium, Miami, Florida. January 2013).

166. Van Arendonk KJ, James NT, Garonzik Wang JM, **Montgomery RA**, Colombani PA, Segev DL. Order of Donor Type in Pediatric Kidney Transplantation. (Platform presentation at the American Society of Transplant Surgeons 12th Annual State of the Art Winter Symposium, Miami, Florida. January 2013).

167. Boyarsky BJ, Van Arendonk K, Deshpande NA, James NT, **Montgomery RA**, Segev DL. Race Is Associated with New Onset Hypertension and Diabetes after Living Kidney Donation. (Platform presentation at the American Society of Transplant Surgeons 12th Annual State of the Art Winter Symposium, Miami, Florida. January 2013).

168. Locke J, James N, Mehta S, Pappas P, Mannon R, Desai N, **Montgomery RA**, Segev DL. Immunosuppression Regimen and the Risk of Acute Rejection in HIV-Infected Kidney Transplant Recipients. (Platform presentation at the American Society of Transplant Surgeons 13th Annual State of the Art Winter Symposium, Miami, Florida. January 2013).

169. Orandi BJ, VanArendonk KJ, James NT, Montgomery JR, Wickliffe C, Krause ES, Racusen LC, **Montgomery RA**, Segev DL. Early Antibody-Mediated Rejection Portends Worse Long-Term Renal allograft and Patient Survival. (Platform presentation at the American Society of Transplant Surgeons 13th Annual State of the Art Winter Symposium, Miami, Florida. January 2013).

170. Locke J, James N, Mehta S, Pappas P, Mannon R, Desai N, **Montgomery RA**, Segev DL. Immunosuppression Regimen and the Risk of Acute Rejection in HIV-Infected Kidney Transplant Recipients. (Platform presentation at the American Transplant Congress, Seattle, Washington, May 2013).

171. Jackson A, Sigdel T, Bagnasco S, **Montgomery RA**, Sarwal M. Endothelial Cell Reactive Antibodies: Antigenic Targets and Mechanism of Action. (Platform presentation at the American Transplant Congress, Seattle, Washington, May 2013).

172. Muzaale A, Massie A, Wang MC, **Montgomery RA**, McBride M, Wainright J, Segev DL. Risk of End Stage Renal Disease Attributable to Live Kidney Donation. (Platform presentation at the American Society of Transplant Surgeons 14th Annual State of the Art Winter Symposium, Miami Beach, Florida, January 2014).

173. Orandi B, Garonzik-Wang J, Montgomery J, Massie A, Van Arendonk K, Stegall M, Jordan S, Oberholzer J, Dunn T, Ratner L, Kapur S, Pelletier R, Roberts J, Melcher M, Singh P, Sudan D, Posner M, El-Amm J, Shapiro R, Cooper M, Lipkowitz G, Rees M, Marsh C, **Montgomery RA**, Segev DL. Quantifying the Risk of Incompatible Kidney Transplantation: A Multi-Center Study. (Platform presentation at the American Society of Transplant Surgeons 14th Annual State of the Art Winter Symposium, Miami Beach, Florida, January 2014).

174. Orandi BJ, Garonzik-Wang JM, Van Arendonk KJ, King EA, Gupta N, **Montgomery RA**, Segev DL. Sequelae of Concurrent Antibody- and Cell-Mediated Rejection Following Kidney Transplantation. (Platform presentation at the 9th Annual Academic Surgical Congress, San Diego, CA, February 2014).

175. Fahmy L, Massie A, Orandi B, Bagnasco S, Alejo J, Boyarsky B, Anjum S, **Montgomery R,** Dagher N, Segev D. Association Between Histological abnormalities in Time-Zero renal Biopsies and Post-donation eGFR in Live Donors. (Platform presentation at American Transplant Congress. Philadelphia, PA, May 2015).

176. Avery R, Tsai H-L, Huang C-Y, Shoham S, Ostrander D, Lu N, **Montgomery R**, Marr K.     Risk Factors for Infections After Transplant in a Prospective Cohort Study Including Incompatible Kidney Transplant Recipients.  (Platform presentation at American Transplant Congress. Philadelphia, PA, May 2015).

177. Orandi BJ, King E, Lou X, Bae S, Lonze B, **Montgomery RA**, Segev DL. Hospital Readmissions Following Incompatible Live Donor Kidney Transplantation: A Multicenter Study. (Platform presentation American Transplant Congress. Boston, MA, May 2016).

178. Jordan SC, Legendre C, Desai N, Lorant T, Bengtsson M, Laxmyr L, Lonze B, Vi, A, Wood KJ, Kjellman C, **Montgomery RA**. Safety and Efficacy of Imlifidase in Highly sensitized Kidney Transplant Patients: Results from a Phase 2 Study. (Platform presentation American Transplant Congress. Boston, MA. June 2, 2019).

179. Avery R, **Montgomery RA**, Motter J, Massie A, Kraus E, Marr K, Lonze B, Alachkar N, Jackson K, Holechek M, Ostrander D, Desai N, Waldram M, Shoham S, Mehta S, Hiller J, Langlee J, Young S, Segev D, Garonzik Wang J. Quantifying Differential infection Risks in HLA and/or ABO Incompatible Kidney Transplant Recipients. (Platform presentation American Transplant Congress. Boston, MA. June 4, 2019).

# VIDEO PRESENTATIONS

1. Schulam, P.G., J.T. Bishoff, R.G. Moore, T.D. Averch, **R.A. Montgomery,** L.E. Ratner and L.R. Kavoussi. Laparoscopic live donor nephrectomy: the initial clinical experience. (Video section, American Urological Association. Orlando, FL, May 1996).

2. **Montgomery, R.A.,** J.A. Cadadu, L.R. Kavoussi and L.E. Ratner. Live donor

nephrectomy: the laparoscopic technique. (Motion picture section, The American College of Surgeons Meeting. Chicago, IL, October 1997).

3. **Montgomery, R.A.**, J.A. Cadadu, L.R. Kavoussi and L.E. Ratner. Laparoscopic

live donor nephrectomy: refined surgical technique 1998 update. (Video section, American Urological Association. May 1998).

4. **Montgomery, R.A,** J.A. Cadadu, L.R. Kavoussi and L.E. Ratner. Live donor nephrectomy: the updated laparoscopic technique. (Motion Picture Section, The American College of Surgeons Meeting. Orlando, FL, October 1998).

5. **Montgomery, R.A.** Live laparoscopic donor nephrectomy with vaginal kidney extraction. (American Society of Transplant Surgeons 10th Annual State of the Art Winter Symposium “The Cutting Edge of Transplant Surgery” Fort Lauderdale, FL January 2010).

CME COURSES

Incompatible Kidney Transplantation: High PRA, positive crossmatch, paired

kidney exchange, and ABO incompatible transplants. Johns Hopkins University, May 2003 (Director CME)

# SHORT COURSES

1. The 37th Annual Short Course in Medical and Experimental Mammalian Genetics. Bar Harbor, Maine, July 19-July 30, 1996.

2. Laparoscopic Live Donor Nephrectomy Course. Johns Hopkins University, November 1996. (Instructor).

3. Laparoscopic Live Donor Nephrectomy Course. Johns Hopkins University,

March 1997. (Instructor).

INVITED LECTURES

1. Cytokine semi-quantitative PCR on fine needle aspirates from human renal allografts. Molecular Approaches to Nephrology Meeting. Bari, Italy, April 1992.

2. Cytokines in graft rejection. European College of Transplantation. Oxford, England, May 1992.

3. Renal transplantation in patients with sickle cell nephropathies. Oxford Transplantation Center Grand Rounds. Oxford, England, December 1993.

4. Laparoscopic live donor nephrectomy: an initial experience. 21st Anniversary Meeting of Transplantation in Oxford. Oxford, England, March 1996.

5. Marfan syndrome: Molecular genetics and gene therapy. Johns Hopkins Cardiac Surgery Grand Rounds. Baltimore, MD, November 1997.

6. Laparoscopic donor nephrectomy: does it impact long-term graft outcome? Southeastern Organ Procurement Foundation. Baltimore, MD, June 1998.

7. Laparoscopic live donor nephrectomy. Clinical lecture upon election as Professor of Transplantation. University of Oxford, Oxford Transplant Center. Oxford, England, July 1998.

8. Gene therapy for Marfan syndrome. Basic science lecture upon election as Professor of Transplantation. University of Oxford, Institute of Molecular Medicine. Oxford, England, July 1998.

9. Laparoscopic kidney donation. Challenges for Transplantation into the Next Century. Baltimore, MD, October 1998.

10. Laparoscopic donor nephrectomy. Visiting Professor. Maadi Hospital. Cairo,

Egypt, December 1998.

11. Gene therapy strategies utilizing *In situ* expressed conformationally improved antisense oligonucleotides. “Strategies for Inactivation of Mutant Genes.” Banbury Conference, Banbury Center, Cold Spring Harbor Laboratory, May 1999.

12. Update on immunosuppression and gene therapy strategies for renal transplantation. Johns Hopkins Urology Grand Rounds. Baltimore, MD, May 1999.

13. Plasmapheresis and Cytogam provide effective treatment for refractory acute humoral rejection and prevent hyperacute rejection in crossmatch positive renal transplant recipients. Teleconference for the Central Region Transplant Advisory Panel. Wisconsin, September 1999.

14. Immunosuppressives: Now and the future. Society of Critical Care Medicine. 2000 29th Educational & Scientific Symposium. Orlando, FL., February 2000.

15. Plasmapheresis and Cytogam provide effective rescue treatment for refractory

acute humoral rejection. Advisory Panel Discussion: Techniques for Reducing PRA’s in Solid Organ Transplantation. Scottsdale, Az., February 2001.

16. Treatment for antibody-mediated rejection: Plasmapheresis/IVIG and Anti-

CD20. The Sixth Banff Conference. Banff, Canada, April 2001.

17. Enhancing the utilization of extended criteria donors: Dual organ transplantation

and pulsatile perfusion. The Sixth Banff Conference. Banff, Canada, April, 2001.

18. Preemptive therapy for transplantation across immunological barriers. The Sixth

Banff Conference. Banff, Canada, April, 2001.

19. A novel strategy for interrogating the function of individual genes in the

ischemia/reperfusion injury (IRI) pathway. Tokyo, Japan, July 2001.

20. The treatment of human disease with gene and cell therapy. University of

Southern California Grand Rounds. Los Angeles, November 2001.

21. Live demonstration of the laparoscopic donor nephrectomy operation. Sir Ganga Ram Hospital. 7th Congress of the Asian Society of Transplantation. New Delhi, India. March 2002.

22. Invited Lectures at Hospitals and Universities on Positive crossmatch and ABO incompatible transplantation:

2001: Emory University, Maadi Hospital (Cairo, Egypt).

2002: Harvard University/Mass General Hospital, Harvard University/Beth Isreal Deaconess Medical Center, The University of Minnesota, The University of Buffalo, McGill University, University of Toronto, Samsung Medical Center (Seoul Korea), University of Iowa, University of Nebraska, Washington Hospitals, University of Utah, Seattle Hospitals, New York Hospitals.

2003: University of Wisconsin, Medical College of Wisconsin, Houston Hospitals, Ohio State, UCLA, University of Portland, San Antonio.

23. Increasing Living Kidney Donation: Controversies and New Approaches, Annual Canadian Society of Transplantation Meeting, Banff, CA. 2003.

24. Blood Group and Crossmatch Incompatible Kidney Transplantation. “Exploring the Crisis In Transplantation: Perspectives On Living Kidney Donation” Kidney & Urology Foundation of America, Inc. New York, NY. June 2004.

25. Trends and Innovations in Living Donor Transplantation. “A Capital Quest for the Cure”. 15th Annual Conference on PKD. Washington, DC, June 2004.

26. Highly Sensitized (Positive Crossmatch) Program at the Johns Hopkins Comprehensive Transplant Center. “Quandaries in allocation – Have We Improved Access?” Investigator/Advisory meeting. Reflections on the Scientific Advancements of Transplantation in the Tacrolimus Era. Chicago, Illinois. July 2004.

27 Determining Medical Suitability of the Expanded Criteria Donor. NATCO

Miami Beach, FL., January 2005.

28. The Armamentarium Against Acute Humoral Rejection, Including the Role of Rituximab, IVIg, Plasmapheresis, Etc. “Non-Traditional Rejection: Too Little Art or Too Little Science”. American Society of Transplant Surgeons. Miami Beach, FL., January 2005.

29. Experience Transplanting at Risk Kidney Patients: High Levels of Sensitization. “Assessment and Management of Immunologic Risk in Transplantation – a CCDT Consensus Forum”. Canadian Council for Donation and Transplantation. Montreal, Canada. January 2005.

30. ABO Incompatible and High Risk Renal Transplantation. The University of Tennessee-Grand Rounds. Visiting Professor. Chattanooga, TN., February 2005.

31. Johns Hopkins: A Single Center’s Experience with Live Donor Paired Kidney Exchanges. Live Donor Paired Kidney Donation Consensus Meeting. Chicago, IL. March 2005.

32. ABO Incompatible and Positive Crossmatch Renal Transplantation. The University of Alberta. Visiting Professor. Alberta, Canada. March 2005.

33. Positive Crossmatch and ABO Incompatible Kidney Transplantation. Oklahoma University Hospital-Grand Rounds. Visiting Professor. Oklahoma City, OK. March 2005.

34. Transplantation of the Highly Sensitized Recipients. International Society for Heart & Lung Transplantation (ISHLT). Philadelphia, PA. April 2005.

35. Highly Sensitized (Positive Crossmatch) Transplantation. Keynote Address: 2005 Roche Asia Transplant & Immunology Forum; The Korean Society for Transplantation. Jeju-Do, Korea. April 2005.

36. The Diagnosis and Treatment of Humoral Rejection. “Kidney Transplantation into Sensitized Recipients”. American Transplant Congress 2005. Seattle, WA. May 2005.

37. Expanding Donor Criteria for Pancreas Transplantation. Scientific Program: American Transplant Congress 2005. Seattle, WA. May 2005.

38. Donor Swap Kidney Transplantation. The Johns Hopkins Department of Surgery Biennial Program. Baltimore, MD. June 2005.

39. Incompatible Transplantation. 8th Annual Nephrology Symposium; Kaiser Permanente. Anaheim, CA. July 2005.

40. Strategies for Patients with Incompatible Donors: Kidney Transplantation for Highly Sensitized and ABO Incompatible Patients. 8th Annual Nephrology Symposium; Kaiser Permanente. Anaheim, CA. July 2005.

41. Sensitized Patient Renal Transplantation. University of Miami School of Medicine-Grand Rounds. Visiting Professor. Miami, FL., August 2005.

42. Sensitized Patient Renal Transplantation. Florida Hospital-Visiting Professor. “Translife Kidney Program”. Orlando, FL., August 2005.

43. Beyond B-cell Ablative Therapy: Successful ABO Incompatible Transplantation Without Splenectomy or Anti-CD20. 2nd International Symposium on ABO Incompatibility in Transplantation. Gothenburg, Sweden. September 2005.

44. The Role of B Cells in Transplantation. Anti-CD20 Advisory Board. Paris, France. September 2005.

45. Treatment and Long-term Outcome of Antibody-Mediated Rejection. “Transplant Immunosuppression 2005: Improving Recipient Outcome”. University of Minnesota, Minneapolis, Minnesota, September 2005.

46. Optimizing the use of Tacrolimus for Prevention of Antibody Mediated Rejection in Renal Transplantation-Beyond the Barrier. “Highly Sensitized Recipient”. The 41th Annual Meeting of Japan Society for Transplantation. Niigata, Japan, October 2005.

47. New Innovations in Kidney Transplantation. Johns Hopkins Medicine Department of Surgery. Palm Beach, Florida. January 2006.

48. New Frontiers in Transplantation: Paired Kidney Exchange. Johns Hopkins Medicine Department of Surgery. Palm Beach, Florida. January 2006.

49. Options Available for Patients with Incompatible Donors. The Lankenau Hospital Kidney Transplant Program. Philadelphia, PA, May 2006.

50. ABO Incompatible Transplant and the Highly Sensitized Patient. “Transplant Teaching Conference”: Medical Science Building Lecture. Virginia Commonwealth University, Richmond, VA, May 2006.

51. Options Available for Patients with Incompatible Donors. “Free Communication-Clinical Research”. Canadian Society of Nephrology. Quebec City, Quebec Canada. May 2006.

52. Best Strategy for ABO-Incompatible Kidney Transplants – Desensitization. “3rd International Conference on Living Donor Abdominal Organ Transplantation: State of the Art”. Sardegna, Italy. June 2006.

53. How Do I Do It Section II: Desensitization Protocol and the Role of Splenectomy in ABO-Incompatible Kidney Transplantation – “Plasmapheresis”. “3rd International Conference on Living Donor Abdominal Organ Transplantation: State of the Art”. Sardegna, Italy. June 2006.

54. Dealing with Blood Group Incompatibility. “Management of The Sensitized Patient”. The World Transplant Congress 2006. Boston, MA. July 2006.

55. The Best Option for Highly Sensitized Patients is … Desensitization. “Controversies in Renal Transplantation: Defining the Importance of B Cells and Antibody Responses”. The World Transplant Congress 2006. Boston, MA. July 2006.

56. Expanding the Donor Pool in Kidney. “State of the Art Symposia”. The World Transplant Congress 2006. Boston, MA. July 2006.

57. The High PRA Patient. Midwest Kidney/Pancreas Transplant Advisory Board: Medimmune. Kohler, WI. August 2006.

58. “Options Available for Patients With Incompatible Kidney Transplant Donors”. University of Padua – Ospedale Giustinianeo, Clinical and Experimental Transplantation Immunology. Padova, Italy. September 2006.

59. “In vivo delivery of ICAN-1 siRNA reduces ischemia/Reperfusion injury in rodent orthoptic liver transplantation”. American College of Surgeons, 92nd Annual Clinical Congress. Chicago, IL. October 2006.

60. “ABO Incompatible Transplantation: Clinical Observations and Mechanistic Insights”. The Transplantation Society. TTS New Key Opinion Leader Meeting 2006. Buenos Aires, Argentina. October 2006.

61. “Setting up an Incompatible Kidney Transplant Program”. University of Oklahoma City Visiting Professor, Oklahoma City, OK. February 2007.

62. “Advances in Transplantation: Options Available for Patients with Incompatible Donors”. 39th Annual Medical Symposium National Kidney Foundation of Northern California & Northern Nevada. San Francisco, CA. March 2007.

63. “Advances in Transplantation: Options Available for Patients with Incompatible Donors”. 39th Annual Medial Symposium National Kidney Foundation of Northern California & Northern Nevada. San Jose, CA. March 2007.

64. “Options Available to Patients with Incompatible Kidney Donors”. 21st Advanced HLA Technical Workshop. 20th Clinical Histocompatibility Workshop. Cancun, Mexico. March 2007.

65. “Expanded Donor Criteria for Kidney Transplant”. Controversies in Transplantation. University of Colorado School of Medicine. Breckenridge, CO. March 2007.

66. “In vivo Efficacy of siRNA”. 2nd Annual Invitrogen Transplant Advisory Board Meeting. Lake Las Vegas, Nevada. March 2007.

67. “The US Experience”. First International Workshop on ABO-Incompatible Kidney Transplantation. Stockholm, Sweden. March 2007.

68. “Splenectomy or Rituximab or Neither Nor?” First International Workshop on ABO-Incompatible Kidney Transplantation. Stockholm, Sweden. March 2007.

69. “Succeeding in the Highly Sensitized Patient”. Renal Transplantation in the High-Risk Patient: Practical Considerations. Advanced Studies in Medicine (ASiM). New York, NY. April 2007.

70. “Paired Kidney Donation”. Kidney Disease Update 2007. National Kidney Foundation, Covenant Health System. Lubbock, TX. April 2007.

71. “Desensitization: The Johns Hopkins Experience”. Transplantation of the Highly Sensitized Patient. Royal Society of Medicine. London, England. June 2007.

72. “The Good Samaritan and Anonymous Living Organ Donation”. Third International Symposium on Living Donor Organ Transplantation. University Hospital Essen, University Duisburg. Essen, Germany. June 2007.

73. “Long Term Outcomes. The ABO-I and Highly Sensitized Patients” Roche Nephrology Transplant Symposium 2007 (RNTS). Sydney, Australia. July 2007.

74. “Crossmatch Positive Renal Transplantation”. Transplantation in the Positive Crossmatch Recipient. CTS-IPITA-IXA 2007 Joint Conference. Minneapolis, MN. Sept. 2007.

# 75. “Strong Arguments in Favor of the Live Organ Donation”. 5th Edition Short Meeting Kidney Transplantation. “Aula Foscolo” University of Pavia. Pavia, Italy. Sept. 2007.

76. “Strategies for the Sensitized Recipient”. Transplant Summit 2007: Defining the Future. Chicago, IL. Sept. 2007.

# 77. “Living Donor Kidney Transplantation: Opportunities and Challenges”. Transforming Transplantation: Advanced Strategies to Optimize Outcomes. The University of Cincinnati College of Medicine and The University of Tennessee College of Pharmacy. June, July, August, October 2007.

# 78. “Indications and Contraindications: ABO Incompatible, Paired Exchange, Desensitization”. Transplant Immunosuppression 2007 The Ongoing Search for Improvement. University of Minnesota Medical School, Division of Transplantation, Department of Surgery. October 2007.

79. “Treatment of Early C4d Positive AR”. Transplant Immunosuppression 2007 The Ongoing Search for Improvement. University of Minnesota Medical School, Division of Transplantation, Department of Surgery. October 2007.

80. “Kidney Paired Donation”. International Society for Organ Donation and Procurement 2007 Congress. Philadelphia, PA. November 2007.

81. “Crossing ABO and HLA Barriers in Renal Transplantation”. Transplantation Grand Rounds, Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Department of Surgery, Division of Transplantation. Pittsburgh, PA. November 2007.

82. “ABO Incompatible Renal Transplantation”. Keynote Address: Annual Meeting of the Mexican Institute For Nephrological Research. Instituto Nacional de Ciencias Medicas. Puerto Vallarta, Mexico. December 2007.

83. “Options Available for Patients with Incompatible Donor”. Annual Meeting of the Mexican Institute For Nephrological Research. Instituto Nacional de Ciencias Medicas. Puerto Vallarta, Mexico. December 2007.

84. “Positive Crossmatch in Renal Transplant”. Frontiers In Transplantation. University of Utah, Salt Lake City, Utah. February 6, 2008.

85. “The Johns Hopkins Experience”. ABO Incompatible Transplantation in Canada. Canadian Kidney Transplant Working Group. University of British Columbia, Vancouver, British Columbia, Canada. February 28, 2008.

86. “Immune Risk and Desensitizing in Baltimore”. Transplant Histocompatibility Conference. University of Texas Medical School at Houston. Chicago, Illinois. March 3, 2008.

87. “Kidney Paired Donation” Current Controversies in Transplantation. Association of Health Care Journalists. Missouri School of Journalism. Health Journalism 2008 Conference. Washington, DC. March 28, 2008.

88. “Options Available to Incompatible Donors”. Karolinska Institute Karolinska University Hospital Huddinge. Department of Transplantation Surgery. Stockholm, Sweden. April 10, 2008.

89. “ABO Incompatible Renal Transplantation: The Hopkins Experience”. Margot S. Kruskall Lectureship: 2008. Harvard Medical School, Boston, Massachusetts. May 9, 2008.

90. “Transplantation in the Sensitized Recipient”. XXII International Congress of The Transplantation Society, Post Graduate Program. Sydney, Australia. August 9, 2008.

91. “Domino Effect: Understanding the Paired Donation Exchange Program”. American Association of Kidney Patients, 35th Annual National Convention. Washington, DC. August 30, 2008.

92. “Detection of donor-specific Antibodies pre-transplant: Sensitivity: specifically of the available tools”. Highly Sensitized Patients; 2nd International Vicenza Course on Kidney Transplantation” Vincenza, Italy. November 21, 2008.

93. “Antibody, Complement and Accommodation in ABO-Incompatible Transplants” ABO-Incompatible Kidney Transplantation; 2nd International Vicenza Course on Kidney Transplantation” Vincenza, Italy. November 22, 2008.

94. “Immunologically Challenging Live Donor Kidney Transplantation”; 2nd Advanced Transplant Course 2008 Hammersmith Conference Center, Hammersmith Hospital. London. November 25, 2008

95. “Innovations In Live Donor Renal Transplantation”. The University of Arizona, Department of Surgery Grand Rounds. Tucson, AZ. January 7, 2009.

96. “Transplantation of the Highly Sensitized Patient: Unmet Challenges” Management of the Highly Sensitized Patient Clinical Logistical and Financial Consideration; American Society of Transplant Surgeons Pre-Meeting Symposium CTI. Marco Island, Florida. January 15, 2009.

97. “I Won’t Back Down: Options for the Sensitized Kidney Recipient” American Society of Transplant Surgeons 9th Annual State of the Art Winter Symposium; The Right Organ for the Right Recipient. Marco Island, Florida. January 17, 2009.

98. “Paired Kidney Exchange Programs, Hopkins Experience” ABO Incompatible and Paired Kidney Exchange Programs; American Society of Transplantation Annual Winter Symposium. Fairmont Banff Springs Banff, Alberta, Canada. March 4, 2009.

99. “ABO-Incompatible Transplants: Antibodies Complement And Treatment”. Bergamo Meeting on Organ Transplantation, Bergamo, Italy. March 14, 2009.

100. “Kidney Transplantation in Highly Sensitized Patients”. ViroPharma Incorporated Wilmington, Delaware. April 3, 2009.

101. “ABO Incompatible Renal Transplantation: A Paradigm Ready for Broad Implementation”. Kidney Transplantation Symposium Crossing ABO Incompatibility and Crossmatch Positivity. Maryknoll Hospital, Busan City Korea. April 11, 2009.

102. “Options Available to Patients with Incompatible Kidney Donors”. Kidney Transplantation Symposium Crossing ABO Incompatibility and Crossmatch Positivity. Maryknoll Hospital, Busan City Korea. April 11, 2009.

103. “B Cell Depletion in Clinical Trials in Transplantation: Is It All Good?” New Insights into targeting B Cells. American Transplant Congress. Boston, MA. June 1, 2009.

104. “Desensitization with plasmapheresis and low dose immunoglobulins.” Transplantation in the hyperimmunized patient. The Transplant Society Joint Meeting IPITA-IXA 2009. Venice, Italy. October 13, 2009.

105. “New Insights into Humoral Barriers in Renal Transplantation.” Annual Day in Transplantation. University of Toronto Transplant Institute. Toronto, Canada. December 4, 2009.

106. “Innovation in the Current Regulatory Environment.” Clinical Research in Transplantation. American Society of Transplant Surgeons Pre-Meeting Symposium 10th Annual State of the Art Winter Symposium. Fort Lauderdale, Florida. January 14, 2010.

107. “ABO Incompatible Transplantation – The American Experience.” Overcoming Immunologic Barriers in Organ Transplantation. The 7th Annual Winter Meeting of the Israel Transplantation Society. Tel Aviv, Israel. January 28, 2010.

108. “New Insights into Antibody Barriers in Renal Transplantation”. High Risk Crossmatch Positive and BAO Incompatible Transplants. Transplant Rounds, St. Joseph’s Hospital. Hamilton, Ontario, Canada. March 25, 2010.

109. “Long-Term Results of Live Donor Positive-Crossmatch Transplants”. Incompatible Kidney Transplantation: A Long-Term Solution? The American Transplant Congress. San Diego, California. May 3, 2010

110. “Incompatible Kidney Transplantation”. The American Transplant Congress. San Diego, California. May 2, 2010.

111. “Transplantation in the hyperimmunized patient: Role of novel immunomodulatory strategies”. University of Padua, Aula Ramazzini, Policlinico di Padova, Ospedale Giustinianeo, Italy. June 22, 2010.

112. “Living Donor Kidney Transplantation” 5th International Conference: Living Donor Abdominal Organ Transplantation: State of the Art. Cenacolo di Ognissanti, Piazza Ognizzanti, Florence, Italy. June 25, 2010.

113. “Recent Advances in the Treatment of Cross-Match Positive Candidates in Kidney Transplantation” Highly Sensitized/ABO-Incompatible Living Donor Kidney Transplantation. 5th International Conference: Living Donor Abdominal Organ Transplantation: State of the Art. Cenacolo di Ognissanti, Piazza Ognizzanti, Florence, Italy. June 25, 2010.

114. “Paired Exchange”. Ethical Debate: Proposed Models for Increasing Organ Supply. 5th International Conference: Living Donor Abdominal Organ Transplantation: State of the Art. Cenacolo di Ognissanti, Piazza Ognizzanti, Florence, Italy. June 25, 2010.

115. “Single Port Laparoscopic Donor Nephrectomy with Trans-Vaginal Extraction”. Current Technical Issues in Living Donor Kidney Transplantation. 5th International Conference: Living Donor Abdominal Organ Transplantation: State of the Art. Cenacolo di Ognissanti, Piazza Ognizzanti, Florence, Italy. June 25, 2010.

116. “Immunosuppression in Highly Sensitized and ABO Incompatible Transplantation”. Clinical Immunosuppression. XXIII International Congress of The Transplantation Society. Post Graduate Weekend. Vancouver, Canada. August 14, 2010.

117. “Monitoring and Treatment of Antibody-Mediated Rejection”. Detection and monitoring of antibodies after Transplantation. XXXI International Congress of The Transplantation Society. Vancouver, Canada. August 19, 2010.

118. “Arranged Marriages and Trail Separations: Immunologic Acrimony in the Union Between Incompatible Donors and Recipients”. Alberta Transplant Lecture Series. University of Alberta, Edmonton, AB, Canada. September 8, 2010.

119. “Innovation in Kidney Transplantation”. Texas Children’s Hospital Pediatric Surgery Grand Rounds. Texas Children’s Hospital. Houston, Texas. October 1, 2010.

120. “Innovation in Kidney Transplantation”. Surgical Biology Club. Washington Marriott Wardman Park. Washington, DC. October 3, 2010.

121. “Experience from The Johns Hopkins”. Oxford Transplant Forum 2010. Oxford, England. October 13, 2010.

122. “Expanding Living Donor Pools through Paired Transplantation”. Kidney Disease: Best Practices for Prevention, Management and Improving Outcomes. Optum-Health Care Solutions & The National Kidney Foundation. Radisson Plaza-Warwick Hotel. Philadelphia, PA. October 25, 2010.

123. “Paired Exchange vs. Desensitization Protocols”. Expanding the Living Donor Pool: thinking Outside the Box. 11th Annual Canadian Transplant Forum. “Expanding Opportunities for Living Donation”. Ottawa, Canada. November 6, 2010.

124. “Avoiding Alloantibody: ABO Incompatible and Paired/domino kidney exchange protocols”. Antibodies, Dominos and Algorithms: Transplanting the highly sensitized patient. American Society of Nephrology, Renal Week 43rd Annual Meeting. Colorado Convention Center, Denver, CO. November 19, 2010.

125. “The Khyber Pass: the sensitized Candidate”. Times they are a Changing: The Evolving Candidate. ASTS State of the Art Winter Symposium. “Transplantation at the Crossroads”. Westin Diplomat Hotel, Hollywood, FL. January 15, 2011.

126. “Paired Exchange Donation – Kidney and Liver”. Improving Outcomes-Reducing Risks in Solid Organ Transplantation. Asia Pacific Summit, Bexco Center, Busan, Korea. January 22, 2011.

127. “Paired Donation in Kidney Transplantation”. “XXI Latin-American Organ Transplant Congress” Latin American and The Caribbean Transplant Society. Convention Center of Cartagena, Cartagena de Indias, Colombia South America. March 23, 2011.

128. “New Strategies/treatment to facilitate transplantation in the immunized kidney transplant”. “Hot Topics in renal transplantation: The sensitized recipient”. Badia Benedettina dela Castagna, Genova, Italia. April 16, 2011.

129. “Desensitization” Transplantation in Depth: Antibody Mediated Rejection: Pathogenesis, Prevention and Treatment: Debate: Swap or Desensitize? What’s the right way to go? American Transplant Congress 2011. Pennsylvania Convention Center, Philadelphia, PA. May 1, 2011.

130. “Non-HLA vs. HLA or non-HLA and HLA, take-home-messages of the symposium”. Assessing and Adapting to Risk in Kidney Transplantation: HLA and non-HLA. XM-One Transplantation Crossmatch. American Transplant Congress 2011. Marriott Hotel, Philadelphia, PA. May 2, 2011.

131. “Living Donor Transplant Desensitization Protocols”. Pre-Transplant: The Patients, The Tools, The Protocols. Eleventh Banff Conference on Allograft Pathology. Paris, France. June 5, 2011.

132. “Overview of the Sensitized Patient: Treatment Decisions (pre-transplant)”. Kidney Transplantation: Impacting long-term Outcomes. European Society for Organ Transplantation. September 5, 2011. Glasgow, United Kingdom.

133. “Innovation in Transplantation Surgery”. 6th Young European Scientist Meeting (YES). September 17, 2011. Porto, Portugal.

134. “Thymoglobulin in High Immunologic Risk Patients”. Mexican Society of Transplant Meeting. September 22, 2011. Merida City, Yucatan Mexico.

135. “ABO Incompatible Kidney Transplantation”. Indian Society for Organ Transplantation (ISOT). October 7, 2011. New Delhi, India.

136. “Paired Exchange, ABO Incompatible, or Desensitization – When?” Transplant Immunosuppression 2011 – The Difficult Issues. October 15, 2011. Minneapolis, Minnesota.

137. “Innovation In Kidney Transplantation”. The 5th Joseph E. Murray Visiting Professorship in Transplantation. Boston, MA, November 2011.

138. “Kidney Paired Donation: Past, Present, Future”. Massachusetts General Hospital Harvard Medical School Transplant Center. Boston, MA, April 13, 2012.

139. “Incompatible Kidney Transplantation” Goody Endowed Lectureship, Georgetown University Hospital, Washington, DC, April 19, 2012.

140. “The State-of-Art in Management of Antibody-Mediated Rejection”. International Symposium on Antibody-Medicated Rejection in Kidney Transplantation. Veteran General Hospital, Taichun Transplantation Society of Taiwan. May 19, 2012.

141. “Desensitization in the context of Kidney Exchange”. American Transplant Congress, Desensitization: State of the Art. Boston, MA, June 5, 2012.

142. “Desensitization”. 5th Waddensymposium Modulating and Monitoring Alloreactivity. Texel, the Netherlands, June 27, 2012.

143. “Incompatible Kidney Transplantation: State of the Art”. 6th International Conference Living Donor Abdominal Organ Transplantation: State of the Art. Puglia, Italy, October 5, 2012.

144. “Innovations to Expand Live Kidney Donation”. 7th annual Oscar Salvatierra, Jr., MD Lecturer. Stanford University School of Medicine, Menlo Park, CA, November 6, 2012.

145. “Antibody and Cell Mediated Rejection: The Highly Sensitized Transplant Recipient”. American Society for Reconstructive Transplantation. Chicago, Illinois, November 16, 2012.

146. “Kidney Transplantation Across Both ABO & HLA Barriers”. French Speaking Transplant Society, 12th Congress Annual Meeting. Nantes, France. December 13, 2012.

147. “Strategy and Logistics of Combining Desensitization and Kidney Paired Donation”.

French Speaking Transplant Society, 12th Congress Annual Meeting. Nantes, France. December 14, 2012.

148. “Update & Debate on Desensitization: The Role of Plasmapheresis”. ASTS 13th Annual State of the Art Winter Symposium Success at the Margins. Miami, Florida. February 1, 2013.

149. “The Clinical Challenge: The Sensitized Patient”. AST Cutting Edge of Transplantation. Chandler/Phoenix, Arizona. February 14, 2013.

150. “Difficult Issues in the Management of Renal Transplant Patients – Managing Highly Sensitized Patients”. Mini-Summit in Seoul. Seoul, Korea. February 27, 2013.

151. “Managing Highly Sensitized Patients” 8th Asia Pacific Summit on Solid Organ Transplantation. Hong Kong, March 2, 2013.

152. “Issues In Assessing The Living Kidney Donor” 8th Asia Pacific Summit on Solid Organ Transplantation. Hong Kong, March 2, 2013.

153. “A GPS for Finding the Route to Transplantation for the Sensitized Patient”. Saudi International Congress on New Frontiers in Organ Transplantation 2013 (SICOT 2013).

Riyadh, Saudi Arabia. March 4, 2013.

154. “Paired Kidney Donation”. Saudi International Congress on New Frontiers in Organ Transplantation 2013 (SICOT 2013). Riyadh, Saudi Arabia. March 5, 2013.

155. “Overcoming Obstacles: Managing Sensitized Patients”. One Lambda Clinical Histocompatibility Workshop. Orlando, Florida. March 7, 2013.

156. “Desensitization and Kidney Paired Donation” Future Directions in Kidney Paired Exchange. The National Kidney Registry Symposium. New York, NY. April 19, 2013.

157. “Kidney Transplantation: Antibodies are Barrier- or are they?” American Transplant Congress. Seattle, Washington. May 19, 2013.

158. “The Role of Plasmapheresis in Treatment of AMR” American Transplant Congress. Seattle, Washington. May 20, 2013.

159. “Desensitization: What have we Learned” American Transplant Congress. Seattle, Washington. May 21, 2013.

160. “Transplanting the Sensitized Patient” 16th Congress of the European Society of Organ Transplantation. Vienna, Austria. September 8, 2013.

161. “Desensitization vs. Paired Exchange?” Transplant Immunosuppression 2013: An In-Depth Look at Today’s Issues. Minneapolis, Minnesota. October 18, 2013

162. “Incompatible Kidney Transplantation” 8th Annual Interdisciplinary Transplant Symposium. Hartford, Connecticut. November 7, 2013.

163. “Hopkins: A Model of a Specialized Program for Incompatible Transplantation” Terasaki Festschrift. Los Angeles, CA. January 26, 2014.

164. “Highly Sensitized Kidney Recipients” Overcoming Obstacles for Sensitized Recipients. Transplant Grand Rounds, University of Texas-San Antonio. January 31, 2014.

165. “ABO Incompatible”. Controversies In Transplantation. Breckenridge, Colorado. February 21, 2014.

166. “Disruptive Thinking and Innovation” Alpha Omega Alpha Lecture University of Rochester School of Medicine and Dentistry. Rochester, New York. February 27, 2014.

167. “Highly Sensitized Kidney Recipients” Overcoming Obstacles for Sensitized Recipients. Transplant Grand Rounds, University of Iowa Hospital Organ Transplant Center. May 6, 2014.

168. “Innovation In Kidney Transplantation” Irish Nephrology Society Annual Scientific Meeting 2014. Dublin, Ireland. June 6, 2014.

169. “Antibody Mediated Rejection” World Transplant Congress 2014, San Francisco, CA. July 25, 2014.

170. “Minimizing Risk of Sensitization with Paired Donation” World Transplant Congress 2014, San Francisco, CA. July 29, 2014.

171. “New Horizons in Kidney Transplant: Preventing Antibody-Mediated Rejection in Sensitized Patient” University of New Mexico Peer View CME Symposium. San Francisco, CA. July 29, 2014.

172. “Living Donor Tolerance Protocols” 7th International Conference Living Donor Abdominal Organ Transplantation. Padova, Italy. September 26, 2014.

173. “Johns Hopkins Experience” Desensitization and transplant Antibodies Course (DATA) Florida Hospital Transplant Institute. Orlando, Florida. October 2, 2014.

174. “A Surgeon’s Perspective – Eliminating Obstacles to get More Transplants” American Society for Histocompatibility and Immunogenetics 40th Annual Meeting. Denver, Colorado. October 24, 2014.

175. “Living donor Tolerance Protocols” Transplantation Update 2015. Ahmedabad, India. January 9, 2015.

176. “Desensitization versus Kidney Paired Donation for Incompatible Kidney Transplants” Transplantation Update 2015. Ahmedabad, India. January 9, 2015.

177. “The Next Big Thing (s) in Organ Transplantation” Transplant Grand Rounds, Thomas E. Starzl Transplant Institute. University of Pittsburgh, Pennsylvania. January 30, 2015.

178. “Live Donor Kidney Transplant Tolerance Protocols” Controversies in Transplantation. Breckenridge, Colorado. March 6, 2015.

179. “ABO Incompatible Transplantation” IPTA 8th Congress on Pediatric Transplantation San Francisco, California. March 28, 2015.

180. “Transplanting the Highly Sensitized Patient: Trials and Tribulations” IPTA 8th Congress on Pediatric Transplantation San Francisco, California. March 28, 2015.

181. “A Heinous Happening at Hopkins” American Transplant Congress 2015. Philadelphia, Pennsylvania. May 3, 2015.

182. “Incompatible Transplants and Surgical Adventures” 1st “All Ireland” Transplant Forum Dublin, Ireland. September 10, 2015.

183. “High risk donors, results from a valuable resource” 1st “All Ireland” Transplant Forum

Dublin, Ireland. September 11, 2015 – Keynote Speaker.

184. “Innovation in Kidney Transplantation” 89th Annual Halsted Society Meeting Thomas Jefferson University, Philadelphia, PA. September 19, 2015.

185. “Incompatible Kidney Transplants, Tolerance” Mt. Sinai, St. Luke’s Roosevelt Hospital Grand Rounds. New York, NY. September 30, 2015.

186. “Protocols for Preventing/Treating ABMR: Results and Perspectives”

BANFF-CST Joint Scientific Meeting Vancouver, British Columbia. October 8, 2015.

187. “Approach to the highly sensitized Patient – How I Do It:” Transplant Immunosuppression, Minneapolis, Minnesota. October 9, 2015.

188. “Treatment of AbMR” presensitized patient: early, late and Unsensitized patient; early, late” Transplant Immunosuppression, Minneapolis, Minnesota. October 9, 2015.

189. “Approach to de novo DSA: Bx? Treat? How I Do It” Transplant Immunosuppression, Minneapolis, Minnesota. October 9, 2015.

190. ‘ABO Incompatible Transplantation: To Do or Not to DO?” Miami Transplant International Symposium 2015, Miami, Florida. October 23, 2015.

191. “Transplanting the highly sensitized patient” Refresher Course in Renal Transplantation, Nephrology Institute. La Havana, Cuba. November 5, 2015.

192. “Live donor tolerance protocols” Refresher Course in Renal Transplantation, Nephrology Institute. La Havana, Cuba. November 5, 2015.

193. “ABO Incompatible Transplantation” Refresher Course in Renal Transplantation, Nephrology Institute. La Havana, Cuba. November 5, 2015.

194. “Clinical Benefits of Eculizumab” Alexion aHUS Medical Training Meeting Cambridge, Massachusetts. November 19, 2015.

195. “Kidney Transplantation: Technical Challenges” American Transplant Congress 2016. June 12, 2016.

196. “Kidney AMR: Making the Diagnosis” American Transplant Congress 2016. June 12, 2016.

197. “What to Do In Patients with Post-Transplant DSA?” 26th International Congress of The Transplantation Society, Hong Kong. August 18, 2016.

198. “Tocilizumab” 26th International Congress of The Transplantation Society, Hong Kong. August 21, 2016.

199. “What to do in patients with post-transplant DSA?” 26th International Congress of The Transplantation Society, Hong Kong. August 21, 2016.

200. “Triple Black Diamond Kidney Transplants’ 8th Living Donor Abdominal Organ Transplant Conference: State of the Art, Trieste, Italy. Sept 9, 2016.

201. “Latest Transplant Surgical Innovations at JHH & NYULMC and Opportunities for Operations Researchers”, Johns Hopkins Symposium on Healthcare Operations When Organ Transplantation Meets Operations Research, Baltimore, MD. October 1, 2016.

202. “Innovation in Kidney Transplantation” NYU General Surgery Grand Rounds, NYU Langone Health New York, NY. December 21, 2016.

203. “Treatment of Chronic Antibody Mediated Rejection” Cutting Edge of Transplantation (CEOT) Phoenix, AZ. February 23, 2017.

204. “New Developments in Desensitization Protocols; Is there a Standard of Care?”

FDA Public Workshop: Antibody Mediated Rejection in Kidney Transplantation. Silver Spring, MD. April 12, 2017.

205. “AMR: Transplant Glomerulopathy and Emerging Therapies” ATC Symposia on CMV & AMR Infection & Rejection in Solid Organ Transplantation: Improving Outcomes in CMV & AMR Chicago, IL. May 1, 2017.

206. “Hematopoietic Stem Cell Therapy for Live Donor Kidney Transplant Tolerance Protocols” Hematology 2017 8th Cuban Congress on Hematology, 10th Latin-American Meeting on Hematology, Immunology and Transfusion Medicine. Havana, Cuba May 11, 2017.

207. “Antibodies and Transplantation” NYU Medical Grand Rounds NYU Langone Health New York, NY. June 7, 2017.

208. “Options Available to the Hyperimmunized Patient” 14th Congress of the International Xenotransplantation Association (IXA 2017) Baltimore, MD. Sept 20, 2017.

209. “AMR: Transplant Glomerulopathy and Emerging Therapies” ATC Symposia on CMV & AMR Infection & Rejection in Solid Organ Transplantation: Improving Outcomes in CMV & AMR. ESOT 2017 Barcelona Congress. Barcelona, Spain. Sept 26, 2017.

210. “Leadership in Transplantation” ESOT 2017 Barcelona Congress. Barcelona, Spain.

Sept 27, 2017.

211. “ABO Incompatible Transplant” Transplant Immunosuppression 2017: Achieving Long Term Success, University of Minnesota Minneapolis, MN. October 13, 2017.

212. “Treatment of AMR” Transplant Immunosuppression 2017: Achieving Long Term Success, University of Minnesota Minneapolis, MN. October 13, 2017.

213. “Development of New Onset DSA – How I Do It” Transplant Immunosuppression 2017: Achieving Long Term Success, University of Minnesota Minneapolis, MN. October 13, 2017.

214. “The NYU Langone Transplant Institute: A new model for managing end stage organ disease” NYU Winthrop Department of Medicine Annual Forum Garden City, NY. October 19, 2017.

215. “ABO Incompatible Transplantation: Identification of Candidates and Care of the Recipients” Intas India Transplant Conference Webinar, November 21, 2017.

216. “AMR: Diagnosis and Treatment” Tianjin First Transplant Center, Tianjin, China, December 15, 2017.

217. “Overcoming Complement in Transplant Rejection” American Transplant Congress 2018, Seattle, Washington, June 5, 2018.

218. “Complement Inhibition in Transplantation for Prevention and Treatment of AMR” 11th International Conference on Complement Therapeutics, Crete, Greece, June 25, 2018.

219. “Management of the Highly Sensitized Patient” XXVII International Congress of The Transplant Society (TTS) Meeting, Madrid Spain, June 30, 2018.

220. “IdeS: A New Approach to Desensitization” XXVII International Congress of The Transplant Society (TTS) Meeting, Madrid Spain, June 30, 2018.

221. “Is IdeS a Game Changer for Sensitized Patients” 9th Living Donor Abdominal Organ Transplant Conference: State of the Art, Matera, Italy. August 29, 2018.

222. “Pharmacologic Complement Inhibition in the Prevention and Treatment of Antibody Mediated Injury of Transplanted Kidneys”. Cutting Edge of Transplantation (CEOT) Phoenix, AZ. February 2019.

223. “Evidence for IDIS and other biologics” Consensus Guidelines for Diagnosis and Treatment of Anti-Body Mediated Rejection. TTS/CSL Behring Education Grant Beverly Hills, CA March 7, 2019.

224. “Prevention and treatment of clinical antibody-mediated Allograft Rejection” Pathways to Clinical Xenotransplantation. University of Alabama at Birmingham. March 21, 2019.

225. “That the powerful play goes on, and you may contribute a verse” The Howard Fox Lecture Series, The Ronald O. Perelman Department of Dermatology. NYU Post-Graduate Medical School. New York, NY. April 19, 2019.

226. “Debate: clinical trial for xenotransplant: con: I am not sure I will refer my patient to you for this trial” American Transplant Congress. Boston, MA. June 4, 2019.

227. “The Role of Complement in the Pathophysiology, Prevention and Treatment of Antibody Mediated Rejection in Solid Oran Transplants” 12th International Conference on Complement Therapeutics, Rhodes, Greece. June 16, 2019.

228. “Desensitization across HLA in Transplantation”. FOCIS 2019: Regulatory Mechanisms of Innate Immune Responses that Influence Transplantation, Autoimmune Disease and Cancer, Boston, MA. June 18, 2019.

229. “Treating HLA antibodies pre-transplant/desensitization Approaches”. Terasaki Antibody Symposium, Los Angeles, CA. July 20, 2019.

230. “IdeS a new paradigm for Desensitization” 2019 Chilean Transplant Congress, Santiago, Chile. August 22, 2019.

231. “Complement Inhibition in renal transplantation” 2019 Chilean Transplant Congress, Santiago, Chile. August 22, 2019.

232. “The utilization of HCV positive organs in HCV negative recipients” 2019 Chilean Transplant Congress, Santiago Chile. August 22, 2019.

233. “Empathy: Patient Experience Real Time; Now It’s Me” KEYNOTE Address at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting, Philadelphia PA September 14, 2019.

234. “Identify unmet needs/challenges and issues in the management of Antibody Mediated Rejection” ESOT 2019 Symposia Copenhagen, Denmark. September 17, 2019.

235. “Selecting candidates for desensitization/paired exchange and characterizing risk” Transplant Immunosuppression 2019, Minnesota MN. September 20, 2019

236. “What Has Been and What Will Be: A Transplant Odyssey” KEYNOTE Address at ASHI/BANFF Joint Scientific Meeting, Pittsburgh PA. September 24, 2019.

237. “Antibody Medicate Rejection Related Clinical Trials: The Slippery Slope Into Confusion and Prospect for Improvement” ASHI/BANFF Joint Scientific Meeting, Pittsburgh PA. September 25, 2019.

238. “Hep C+ into Hep C- Organ Transplantation”. KEYNOTE speaker 2019 Kidney/Pancreas Transplant & Nephrology Symposium. UC Irvine, CA. October 4, 2019.

239. “The Journey So Far… Immune Interventions”. NYU School of Medicine Student Lecture Transplant Immunology. New York, NY October 8, 2019

240. “State-of-the-Art Desensitization: Increasing Access to Transplantation by Being Willing to Cross Antibodies”. 2019 Canadian Transplant Summit. Banff, Canada. October 17, 2019.

241. “Terminal Complement Inhibition – current experience”. 3rd Biennial DATA Course. Orlando, FL. October 31, 2019.

242. “Your Patient is Suitable! Expanding the Donor Pool”. 6th Synergy for Life Symposium 2019 Washington Regional Transplant Community (WRTC). Falls Church, VA. November 1, 2019.

243. “My Journey as a Transplant Surgeon and Patient” International Transplantation Science Meeting. Transplant Community Roundtable. Clearwater, FL. November 11, 2019.

244. “Exploring the Use of Complement Blockers in Kidney Transplantation”. 3rd Annual Complement-Based Drug Development Summit. Boston, MA. November 13, 2019.

245. “Imlifidase (IdeS) a promising new approach for HLA desensitization’ Workshop on Allosensitiation in Hematopoietic Stem Cell Transplantation. Haploidentical Transplantation 2019. Orlando, FL. December 5, 2019.

246. “The Present and Future of Transplantation” Israeli Transplantation Society. Nazareth, Israeli. December13, 2019.

247. “The Present and Future of Immunosuppression” Israeli Transplantation Society. Nazareth, Israeli. December13, 2019.

248. “Surgeon to Patient Transplant Experience” Patient presentation: Immunology”. Mount Sinai Immunology Lecture Session. New York, NY January 27, 2020.

249. “My Journey as a Transplant Surgeon and Patient” Temple University Hospital General Surgery Grand Rounds. Philadelphia, PA February 12, 2020.

250. “What has been and what will be: A Transplant Odyssey” Advanced HLA Technical Workshop, Paul I. Terasaki Antibody Lecture, One Lambda. Rancho Mirage, CA March 4, 2020

251. “Equity: Kidney Track: Equity in Kidney Transplantation: Past, Present & Future”. CEoT Transplant Summit. Arizona Biltmore, Phoenix, AZ. March 5, 2020.

252. “My Life as a Patient Being a Transplant Surgeon”. Columbian Transplant Center. Webex May 7, 2020.

253. “What has been & what will be: A Transplant Odyssey” John S. Najarian, MD Lecture in Transplantation. The Department of Surgery Grand Rounds, University of Minnesota. Webex May 12, 2020.

254. “Imifidase” CART Transplant Research Meeting. Hematology/Oncology Hospital of the University of Pennsylvania. Webex May 28, 2020

255. “COVID-19 Solid Organ Transplant Registry and new frontiers in transplantation: HCV, HIV, IDES etc.” Medical Webinar COVID-19 Solid Organ Transplant Registry. Sans Couci Conference Szczecin, Poland Webex July 14, 2020,

256. “Assessment and Management of Immunological Risk” International Society of Nephrology (ISN)-The Transplantation Society (TTS) Webinar: “Immunological Risk Assessment and Management” July 29, 2020.

257. “Kidney Paired Donation: How it started and Where it is Going” The Cutting Edge In Transplantation: 21st Cutting Edge in Transplantation Conference in the 21st Century. University of Minnesota Health. Zoom Webinar: August 20, 2020.

258. “Highly Sensitized Waitlist Candidates – IdeS” Charite Kidney Transplant Symposium. Charite University Medicine Berlin, Germany. Virtual webinar: September 11, 2020.

259. “The Journey So Far… Immune Interventions”. NYU School of Medicine Student Lecture Transplant Immunology. New York, NY October 13, 2020

260. “The Transplant Institute: Zero to One” Grand Rounds Department of Surgery NYU Langone Winthrop Hospital. Virtual webinar January 25, 2021.

261. “Transplant Recipient Perspectives” The National Academies of Sciences, Engineering and Medicine; Committee on A Fairer and More Equitable, Cost-Effective, and Transparent System of Donor Organ Procurement, Allocation and Distribution. Virtual Workshop February 5, 2021.

262. “Emerging therapeutic strategies, considerations in study design and new potential endpoints” Focus: Chronic Antibody-Mediated Rejection. CEoT, Transplant Summit 2021 Innovations in Modern Immunosuppression: Ideas and Implications. Virtual webinar February 26, 2021.

263. “Personalizing Post-Transplant Care: Can Precision Diagnostics Improve Patient Outcomes? One Lambda Transplant Diagnostics Thermo Fisher Scientific Symposium. CEoT, Transplant Summit 2021. Virtual webinar February 26, 2021.

264. “Implementation of Paired Liver Donation in a LDLT Program” American Transplant Congress 2021. Virtual talk June 6, 2021.

265. “The Transplant Surgeon Needed a New Heart-Even if It Had Hepatitis C” AAKP Healthline Innovator Series /Delta Virus, Vaccines, & Kidney Patients: Ongoing Threats to Weak Immune Systems and Kidney Transplants. Virtual talk July 8, 2021.

266. “Different approach in Immunosuppress to ABO and HLA-incompatible organ transplantation” The Transplantation Society Masterclass. Virtual talk July 12, 2021.

277. “Transplant Surgeon Becomes Transplant Patient: HepC Heart Transplant”

2021 NATCO Conference “Believe in Yourself: Make a Difference”. Virtual talk August 5, 2021.

278. “Optimizing Volume and Outcomes Using Distressed Organs” The Transplant Surgeon Needed a New Heart-Even if It Had Hepatitis C. LiverCenter Northwest “All Hands Meeting. Virtual talk August 19, 2021.

279. “A 360-degree View of Risk” ESOT 2021 The 20th Congress of The European Society for Organ Transplantation. Virtual talk August 29, 2021.

280. “Ask the Experts: Delta Variant & COVID-19 Boosters for Transplant Patients” CareDx Patient Webinar. Virtual talk September 1, 2021.

281. “Update on Immunosuppressive Strategies for ABO- and HLA-Incompatible Kidney and Non-Kidney Transplantation” 44th Italian Society for Organ and Tissue Transplantation (SITO).

Virtual talk October 4, 2021.

282. “International COVID-19 Solid Organ Transplant Registry” 15th Congress of the Polish Transplantation Society. Virtual talk October 15, 2021.

283. “Connect to Purpose: Transplant Surgeon Becomes Transplant Patient” Organ Donation and Transplantation Summit; A Regional Collaboration Aimed at Improving Outcomes.

Virtual talk October 27, 2021.

284. “Unconventional Renal Allograft Landing Sites (Venous Anastomosis) In the Presence of Near Total Caval Thrombosis” VEITH Symposium, Orlando, FL November 16, 2021.

285. “Innovation in Transplantation: Xenotransplantation” AAKP Healthline Virtual talk November 11, 2021.

286. “Xenotransplantation: A Success Story” 51st Annual Conference of the Indian Society of Nephrology. Virtual talk December 11, 2021.

287. “Xenotransplantation: A Success Story” National Heart, Lung & Blood Institute Workshop “How Can We Use Bio-engineering Approaches to (Re) Build a Lung” Virtual talk December 16, 2021.

288. “Results of the First Successful Pig-To Human Xenotransplantation” George Washington University Surgery Grand Rounds. December 22, 2021 Washington, DC.

289. “Xenotransplantation: Present and Future” Colombiana de Trasplantes, Puerto Colombia. Virtual talk February 17, 2022.

290. “Updates on Xenotransplantation and the Artificial Kidney” OptumHealth Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management. Scottsdale, AZ March 14, 2022.

291. “Xenotransplantation: Have We Turned The Last Corner?” Alberta Transplant Institute Seminar Series, University of Alberta Canada. Virtual talk March 16, 2022.

292. “Review of the World’s first Pig-to-Human Kidney Transplant” CareDx Xenotransplantation Innovation Day. Virtual talk March 22, 2022.

293. “Recent Advances in Xenotransplantation and Changing Societal Norms Around its Acceptability” 2022 STAT Breakthrough Summit. Apella Space NYU Langone Health March 31, 2022.

294. “Xenotransplantation: Present and Future” Master Event of Transplantation 2022 Sanofi

Mexico City, Mexico April 6, 2022.

295. “Introduction to Current Level of Interest and Excitement” Enhancing Kidney Transplantation: The Role of Xenografts. National Kidney Foundation Washington, DC April 11, 2022.

296. “Resilience – Journey of the Transplant Surgeon as a Transplant Recipient” 2022 Joint International Congress of ILTS, ELITA & LICAGE Virtual talk May 5, 2022.

297. “Xenotransplantation – Implications for VCA” 15th Meeting of the International Society of Vascularized Composite Allotransplantation 2022 Virtual talk June 6, 2022.

298. “Innovation in Transplantation Session: The NYU Xenotransplant Experience, the ethics, next steps, etc.” American Transplant Congress 2022 Boston, MA June 6, 2022.

299. “Pro-The Opportunities are Limitless and the Benefits Unrealized” Kidney Paired Donation First & Foremost: Decoupling All Donor and Recipient Pairs Should Become Standard of Care. American Transplant Congress 2022 Boston, MD June 7, 2022.

300. “Clinical Xenotransplantation Updates” Grand International Forum of Transplantation (GIFT) Chana-ShenZhen China. Virtual talk July 5, 2022

ENDOWED LECTURESHIPS

1. “Innovation in Kidney Transplantation”. The 5th Joseph E. Murray Visiting Professorship in Transplantation. Boston, MA, November 2011.

2. “Complement Inhibition in Kidney Transplantation”. The Andrew Lazarovits Memorial Lectureship. Quebec City, Canada, 2012.

3. “Incompatible Kidney Transplantation” Goody Endowed Lectureship, Georgetown University Hospital, Washington, DC, April 19, 2012.

4. “Innovations to Expand Live Kidney Donation”. 7th annual Oscar Salvatierra, Jr., MD Lecturer. Stanford University School of Medicine, Menlo Park, CA, November 6, 2012.

5. “Assessment and Management of Post-Transplant Donor Specific Antibodies”. The Terasaki Lecture. BSHI. Oxford, England. September 14, 2016.

6. “Options Available to the Hyperimmunized Patient”. The Goran Klintmalm Lecture. Texas Transplant Society Meeting. San Antonio Texas. July 27, 2018.

7. “What has been & what will be: A Transplant Odyssey” John S. Najarian, MD Lecture in Transplantation. The Department of Surgery Grand Rounds, University of Minnesota. Webex May 12, 2020.

8. “New Innovations in Transplantation Driven By My Own Transplant Journey”. The 50th Annual Benjamin S. Park, Jr., MD Visiting Professor Lectureship. Virtual Lecture via Zoom Weill Cornell Medicine New York Presbyterian. December 14, 2020.

9. “The Story of an Unlikely Personal and Professional Transplant Odyssey” The 2022 Anthony B. Rishwain Lecturer. Virtual Lecture via Zoom University of California, San Francisco. February 9, 2022.

10. “The Story of an Unlikely Personal and Professional Transplant Odyssey” The Henry Ford Transplant Institute Grand Rounds 2022 Lecturer. Virtual Lecture via Zoom May 2, 2022.

11. “Xenotransplantation: First in man pig-human Kidney Transplantation” 2022 Michael van Vloten Keynote Lecture Annual Meeting of the Dutch Surgical Society Amsterdam the Netherlands May 20, 2022.

12. “Recent Advances in Clinical Xenotransplantation” 2022 Whitehead Visiting Professor of Surgery, Department of Surgery Grand Rounds Emory University Atlanta, GA May 25, 2022.